


PCT/IB 03/06477



PA 1122291

# THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

February 04, 2004

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE UNDER 35 USC 111.

APPLICATION NUMBER: 60/435,827

FILING DATE: December 19, 2002

PRIORITY DOCUMENT  
SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH  
RULE 17.1(a) OR (b)



By Authority of the  
COMMISSIONER OF PATENTS AND TRADEMARKS

*T. Wallace*  
T. WALLACE  
Certifying Officer

12/19/02  
JCS86 U.S. PTO

12-26-02 60435827-121902  
**PROVISIONAL APPLICATION FOR PATENT  
COVER SHEET**

Case No. BIOBANK.011PR  
Date: December 19, 2002  
Page 1

A/PR  
Box  
J1011 U.S. PTO  
60/435827

United States Patent and Trademark Office  
P.O. Box 2327  
Arlington, VA 22202

ATTENTION: PROVISIONAL PATENT APPLICATION

Sir:

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR § 1.53(c).

For: **NF-HEV GENE, PROTEIN, ASSAYS FOR INHIBITORS OF HEV-LIKE VESSEL  
DEVELOPMENT IN CHRONIC INFLAMMATION**

Name of First Inventor: Jean-Philippe Girard  
Residence Address: 9 chemin du Vieux Moulin, 31320 Rebique, France

Name of Second Inventor: François Amalric  
Residence Address: 26 rue Bessières, 31500 Toulouse, France

Enclosed are:

- ☒ Specification in 102 pages.
- ☒ Attachment A in 30 pages.
- ☒ 4 sheets of drawings.
- ☒ Sequence Submission Statement.
- ☒ Sequence Listing in 12 pages.
- ☒ Sequence Listing in computer readable format.
- ☒ A check in the amount of \$160 to cover the filing fee is enclosed.
- ☒ A return prepaid postcard.
- ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, now or in the future, or credit any overpayment to Account No. 11-1410.

Was this invention made by an agency of the United States Government or under a contract with an agency of the United States Government?

☒ No.

60435827 .121902

**PROVISIONAL APPLICATION FOR PATENT  
COVER SHEET**

Case No. BIOBANK.011PR


Date: December 19, 2002

Page 2

(X) Please send correspondence to:

Daniel Hart  
Knobbe, Martens, Olson & Bear, LLP  
2040 Main Street, 14th Floor  
Irvine, CA 92614

Respectfully submitted,



Daniel Hart

Registration No. 40,637

Customer No. 20,995

(619) 235-8550

S:\DOCS\VLH\H-1708.DOC\121902

# **Knobbe Martens Olson & Bear LLP**

Intellectual Property Law


2040 Main Street  
Fourteenth Floor  
Irvine, CA 92614  
Tel 949-760-0404  
Fax 949-760-9502  
www.knob.com

BOX PROVISIONAL PATENT APPLICATION  
United States Patent and Trademark Office  
P.O. Box 2327  
Arlington, VA 22202

## **CERTIFICATE OF MAILING BY "EXPRESS MAIL"**

Attorney Docket No. : BIOBANK.011PR  
Applicant(s) : Girard et al.  
For : NF-HEV GENE, PROTEIN, ASSAYS FOR  
INHIBITORS OF HEV-LIKE VESSEL  
DEVELOPMENT IN CHRONIC  
INFLAMMATION  
Attorney : Daniel Hart  
"Express Mail"  
Mailing Label No. : EV 077979938 US  
Date of Deposit : December 19, 2002

I hereby certify that the accompanying transmittal letter; specification in 102 pages; attachment A in 30 pages; 4 sheets of drawings; sequence submission statement; sequence listing in 12 pages; sequence listing in computer readable format; check for filing fee; Return Prepaid Postcard are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and are addressed to the United States Patent and Trademark Office, P.O. Box 2327, Arlington, VA 22202.

  
Craig Smelter

S:\DOCS\VLH\1709.DOC\121902

San Diego  
619-235-8550

San Francisco  
415-954-4114

Los Angeles  
310-551-3450

Riverside  
909-781-9231

San Luis Obispo  
805-547-5580



BIOBANK.011PR

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Girard et al.  
 Appl. No. : Unknown  
 Filed : December 19, 2002  
 For : NF-HEV GENE, PROTEIN, ASSAYS FOR INHIBITORS OF  
 HEV-LIKE VESSEL DEVELOPMENT IN CHRONIC  
 INFLAMMATION

SEQUENCE SUBMISSION STATEMENT

Assistant Commissioner for Patents  
 Washington, D.C. 20231

Dear Sir:

A copy of the Sequence Listing in computer readable form as required by 37 C.F.R. § 1.821(e) is submitted herewith.

As required by 37 C.F.R. § 1.821(f), the data on the enclosed diskette is identical to the Sequence Listing in the application filed herewith.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: December 19, 2002

By: Daniel Hart  
 Daniel Hart  
 Registration No. 40,637  
 Attorney of Record  
 2040 Main Street, 14<sup>th</sup> Floor  
 Irvine, CA 92614  
 (619) 235-8550

S:\DOCS\ULHVLH-1710.DOC\121902

BIOBANK.011PR

PROVISIONAL

**NF-HEV GENE, PROTEIN, ASSAYS FOR INHIBITORS OF HEV-LIKE VESSEL  
DEVELOPMENT IN CHRONIC INFLAMMATION**

Background of the Invention

5    Field of the Invention

          The present invention is directed to uses of NF-HEV nuclear factor polynucleotides and polypeptides expressed in endothelial cells from chronically inflamed tissues, particularly in high endothelial venules endothelial cells (HEVECs) and endothelial cells from HEV-like vessels and small blood vessels in rheumatoid arthritis and Crohn's disease. The invention also relates to drug screening assays for identifying compounds capable of modulating NF-HEV activity, which compounds may be used in inhibiting or preventing chronic inflammation.

Description of the Related Art

15           Although all vascular endothelial cells (ECs) share certain common functions, it has become clear that considerable heterogeneity exists both structurally and functionally along the length of the vascular tree and in the microvascular beds of various organs.(Cines et al. (1998) Blood 91:3527-61; Garlanda and Dejana (1997) Arterioscler Thromb Vasc Biol 17:1193-202; Risau (1995) Faseb J 9:926-33; Simionescu et al. (1975) J Cell Biol 67:863-85)

20   The structural heterogeneity of ECs is a perfect example of their adaptation to the unique demands of the actual tissue. ECs can either form a tight continuous monolayer in organs such as the brain or the lungs, where they perform important barrier functions. Alternatively, they can form a discontinuous layer with intercellular gaps or fenestrae in organs such as kidney, spleen or bone marrow, where rapid exchange of fluid, particles and cells takes

25   place.(Risau (1995) Faseb J 9:926-33) The heterogeneity of ECs is also apparent at other levels.(Augustin et al. (1994) Bioessays 16:901-6; Garlanda and Dejana (1997) Arterioscler Thromb Vasc Biol 17:1193-202) For instance, several monoclonal antibodies (mAbs) and phage displayed-peptide sequences that distinguish among different types of ECs are available,(Augustin et al. (1994) Bioessays 16:901-6; Garlanda and Dejana (1997)

30   Arterioscler Thromb Vasc Biol 17:1193-202; Pasqualini and Ruoslahti (1996) Nature

380:364-6; Rajotte et al. (1998) J Clin Invest 102:430-7) revealing antigenic differences between continuous and sinusoidal ECs, microvascular and large vessel ECs, as well as brain and lung ECs.(Page et al. (1992) Am J Pathol 141:673-83; Turner et al. (1987) Am J Clin Pathol 87:569-75) However, EC heterogeneity remains largely ill-defined at the molecular level and very few organ-specific EC markers have been described.(Cines et al. (1998) Blood 91:3527-61; Rişau (1995) Faseb J 9:926-33)

One of the most striking examples of EC differentiation is the postcapillary high endothelial venules (HEVs) found in secondary organized lymphoid tissue (Girard and Springer (1995) Immunol Today 16:449-457; Kraal and Mebius (1997) Adv Immunol 65:347-95). Such vessels are particularly abundant in the T-cell zones that surround the B-cell follicles, and serve as entry sites for extravasating T and B lymphocytes. In contrast to the ECs from other vessels, the HEV endothelial cells or HEVECs have a plump almost cuboidal appearance, express specialized ligands for the lymphocyte homing receptor L-selectin, and are able to support extensive lymphocyte extravasion from blood.(Anderson and Anderson (1976) Immunology 31:731-48; Butcher and Picker (1996) Science 272:60-66; Girard and Springer (1995) Immunol Today 16:449-457; Kraal and Mebius (1997) Adv Immunol 65:347-95; Marchesi and Gowans (1964) Proc. R. Soc. Lond. B 159:283-290) At the ultrastructural level, HEVECs exhibit a prominent Golgi complex and glycocalix, abundant mitochondria closely associated with rough endoplasmic reticulum, and many ribosomes frequently found in polyribosomes clusters, revealing an intense biosynthetic activity generally not observed in ECs from other vessels.(Anderson et al. (1976) Immunology 31:455-73; Freemont and Jones (1983) J Anat 136:349-362; Wenk et al. (1974) J Ultrastruct Res 47:214-41) The specialized HEVECs also contain many membrane-bound vesicular structures, multivesicular bodies, Weibel-Palade bodies and a variety of dense bodies, indicating that they are involved in secretion.(Anderson et al. (1976) Immunology 31:455-73; Freemont and Jones (1983) J Anat 136:349-362; Wenk et al. (1974) J Ultrastruct Res 47:214-41) One of the major metabolic activity of HEVECs is the sulfation of L-selectin countereceptors. Sulfate residues have been shown to be the key for recognition of HEV sialomucins GlyCAM-1 and CD34 by L-selectin (Rosen (1999) Am J Pathol 155:1013-20) and MECA-79, an HEV-specific adhesion-blocking mAb (Michie et al. (1993) Am J Pathol

143:1688-1698; Streeter et al. (1988) *J Cell Biol* 107:1853-1862). Genes important for sulfation of L-selectin ligands in HEVs include the genes encoding PAPS synthetase, (Girard et al. (1998) *Faseb J* 12:603-12) a bifunctional enzyme which catalyzes synthesis of PAPS (3'-phosphoadenosine-5'-phosphosulfate), the activated sulfate donor used by all sulfotransferases, and L-selectin ligand N-acetyl-glucosamine-6-O-sulfotransferase (LSST) (Bistrup et al. (1999) *J Cell Biol* 145:899-910; Hemmerich et al. (2001) *Immunity* 15:237-47.; Hiraoka et al. (1999) *Immunity* 11:79-89), which transfers sulfate from PAPS to HEV sialomucins. In addition to sulfated cell adhesion molecules (Rosen (1999) *Am J Pathol* 155:1013-20), HEVECs express high levels of secreted molecules such as the chemokine SLC/6CKine, (Gunn et al. (1998) *Proc Natl Acad Sci U S A* 95:258-63) which activates lymphocyte adhesiveness, and the SPARC-like antiadhesive extracellular matrix protein hevin, (Girard and Springer (1995) *Immunity* 2:113-123) which may facilitate lymphocyte emigration by modulating EC-to-EC and EC-to-matrix adhesion. (Girard and Springer (1996) *J Biol Chem* 271:4511-4517)

15        Lymphocyte recruitment in HEVs depends on sequential multistep interactions between lymphocytes and HEVECs (von Andrian and Mackay (2000) *N Engl J Med* 343:1020-34.), and is initiated by transient interactions between L-selectin on the lymphocyte microvilli and glycosylated and sulfated ligands on the HEV surface. This step is followed by chemokine activation of lymphocyte integrins via G protein-coupled chemokine receptors, resulting in firm adhesion mediated through interactions with their HEV ligands intercellular adhesion molecule (ICAM)-1/ICAM-2. Much progress has recently been made in the molecular understanding of this adhesion cascade, including the identification of the unique HEV-expressed sulfated carbohydrate ligands for L-selectin (Rosen (1999) *Am J Pathol* 155:1013-20) and the contribution by HEVECs to lymphocyte integrin activation by luminal presentation of endogenous or perivascularly derived chemokines (Baekkevold et al. (2001) *J Exp Med* 193:1105-12.; Stein et al. (2000) *J Exp Med* 191:61-76.).

HEV-like vessels also occur in chronically inflamed non-lymphoid tissue and may mediate aberrant lymphocyte influx at such sites. In rheumatoid arthritis, HEV-like vessels are seen close to the joint cavity, surrounded by dense lymphoid infiltrates (Freemont (1987) *Ann Rheum Dis* 46:924-928). Furthermore, in Crohn's disease and ulcerative colitis,

collectively called inflammatory bowel disease (IBD), HEVs are found associated with extensive accumulations of lymphocytes (Salmi et al. (1994) *Gastroenterology* 106:596-605.). Recently, HEV-like vessels were also found in nasal allergy and various chronic skin diseases, including lesions of cutaneous T-cell lymphomas (Farkas et al. (2001) *Am J Pathol* 159:237-43.; Jahnsen et al. (2000) *J Immunol* 165:4062-8.; Lechleitner et al. (1999) *J Invest Dermatol* 113:410-4.). Finally, endothelium in rejecting heart transplants also exhibit HEV-like characteristics that correlate with the severity of the rejection (Toppila et al. (1999) *Am J Pathol* 155:1303-10). All these observations suggest that aberrant development of HEV-like vessels might mediate abnormal lymphocyte recruitment to the target tissue, thereby contributing to intensification and maintenance of chronic inflammation.

There is therefore a need for the identification of biological targets for the development of therapeutic molecules for the treatment of inflammation, particularly for inhibiting an inflammatory response in endothelial cells.

**Summary of the Invention**

The present invention relates to use of a nuclear factor gene and protein specifically expressed in HEVEC and endothelial cells from chronically inflamed tissues. NF-HEV polypeptides can be used as targets for therapeutic intervention based on their role in promoting inflammation in endothelial cells. NF-HEV may also be involved in endothelial cell and more particularly HEVEC differentiation, as well as HEV-like vessel development. Provided herein is the characterization of NF-HEV, a nuclear factor expressed specifically in human endothelial cells from chronically inflamed tissues. Functional assays based on NF-HEV activity may allow inflammation and HEV-like vessel formation to be examined. NF-HEV provides a valuable tool for modulating an endothelial cell's role in chronic inflammation as well as endothelial cell gene expression. NF-HEV may also provide a means for modulating endothelial cell, or preferably HEVEC, differentiation as well as HEV-like vessel development. NF-HEV therefore provides a valuable biological target for the inhibition of HEV-like vessel development or reducing HEV-like vessels already formed, thereby providing decreased adhesion of lymphocytes to HEVs, decreased lymphocyte

extravasation to tissues and finally ameliorating or preventing inflammation, particularly chronic inflammation.

The present invention concerns the role of NF-HEV polypeptides in modulating endothelial cell gene expression as well as in modulating endothelial cell phenotype, particularly phenotypic characteristics of HEVEC cells. As is further discussed herein, the NF-HEV polypeptides for use according to the present invention comprise NF-HEV peptides as well as biologically active fragments and variants thereof.

A further object of the invention relates to recombinant vectors comprising any of the nucleic acid sequences described above, and in particular to recombinant vectors comprising a NF-HEV regulatory sequence or a sequence encoding a NF-HEV protein, as well as to cell hosts and transgenic non-human animals comprising said nucleic acid sequences or recombinant vectors.

The invention is also directed to methods for the screening of substances or molecules that inhibit the expression of the NF-HEV gene, as well as with methods for the screening of substances or molecules that interact with and/or inhibit the activity of a NF-HEV polypeptide.

In one aspect there is provided an expression cassette comprising a polynucleotide encoding a NF-HEV polypeptide. Preferably, such expression cassettes further comprise one or more regulatory sequences operably linked to said polynucleotide, capable of enhancing or otherwise modulating transcription and/or translation of said polynucleotide in a target cell, for example a mammalian cell. By way of illustration, in one embodiment, an expression cassette comprising a polynucleotide encoding a NF-HEV polypeptide operably linked to a promoter is provided. The promoter may be an inducible promoter or a constitutive promoter. The promoter may be heterologous to the NF-HEV coding sequence. Further, the promoter may be a ubiquitous promoter, for example a cytomegalovirus (CMV) promoter, rous sarcoma virus (RSV) promoter or human elongation factor (e.g., hEF-1a) promoter, or it may be active only in certain tissues/cells. The expression cassette may be a viral expression construct for example; a retroviral vector, an adenoviral vector, an adeno-associated viral vector, a vaccinia viral vector, a herpesviral vector, a polyoma viral construct, lentiviral vector or a Sindbis viral vector. The expression cassette may further comprise a second

polynucleotide encoding a second polypeptide. The second, polypeptide may be, for example, a transcription factor, preferably an endothelial cell transcription factor.

In still a further aspect of the invention, there is provided a transformed host cell comprising a polynucleotide encoding a NF-HEV polypeptide and a promoter heterologous to the NF-HEV-encoding polynucleotide which promoter directs the expression of the NF-HEV polypeptide. The host cell may be prokaryotic or eukaryotic. In a related aspect of the invention, there is provided a method of using the transformed host cell and culturing it under conditions suitable for the expression of the NF-HEV polypeptide. In yet another aspect, there is provided a fusion protein comprising a NF-HEV protein or peptide fused to a second protein or peptide.

In yet a further and related aspect of the present invention, there is provided a method of modulating (e.g. stimulating or inhibiting) the expression of a gene in an endothelial cell. Modulating the expression of a gene in an endothelial cell may modulate an endothelial cell proinflammatory signaling pathway. In another aspect, the invention provides a method of converting a non-endothelial cell or non-HEVEC target cell, into an endothelial cell or a HEVEC, respectively, comprising introducing into the target cell an expression cassette. The expression cassette comprises a polynucleotide encoding a NF-HEV polypeptide as well as one or more regulatory sequences, for example, a promoter with or without enhancer sequences, which regulatory sequences are active in the target cell and direct the expression of the polypeptide. The method may further comprise measuring endothelial cell or HEVEC lineage markers. In another aspect, the method involves introducing into the target cell a nucleic acid comprising a NF-HEV recognition element (e.g. a nucleotide sequence to which NF-HEV binds), said nucleic acid preferably being operably linked to a detectable polypeptide. In yet another aspect, the expression cassette may comprise one or more additional polynucleotides encoding one or more polypeptides, such as additional nuclear factors. By way of illustration, a second polypeptide may be a transcription factor, for example, an endothelial cell or HEVEC transcription factor. In a related aspect, expression of the additional polynucleotides may be under the control of the same regulatory sequences as the first polynucleotide or may be separately controlled by additional regulatory sequences. In another aspect of the present invention, the method further comprises introducing one or

more additional expression cassettes into target cells separately from introduction of the NF-HEV expression cassette. By way of illustration, a second expression cassette comprising a polynucleotide encoding a second polypeptide and including a second promoter able to direct expression of the second polypeptide in the target cells may be delivered to the target cell using a separate gene delivering means from that used to introduce the NF-HEV expression cassette. Thus, for example, a first gene delivery vector comprising a NF-HEV expression cassette may be delivered simultaneously or contemporaneously with a second gene delivery vector comprising a second expression cassette. If desired, polypeptide expression may be measured, for example, by measuring transcription by RNA hybridization, RT-PCR or Western analysis.

In yet another aspect, there is provided a method of generating a modified endothelial cell, or more preferably a method of generating a modified HEVEC comprising introducing into a cell, preferably an endothelial cell, an expression cassette. The expression cassette comprises, for example, a polynucleotide encoding a NF-HEV polypeptide operatively linked to a promoter capable of directing of expression of the polypeptide. The promoter may be heterologous to the coding sequence and may be a ubiquitous (e.g., CMV) or a specific promoter (e.g., an alpha collagen promoter). The expression cassette may be introduced into the cell by any of a variety of means known to those of skill in the art. By way of illustration, lipid-based vectors (e.g., liposomes), viral vectors (e.g., retroviral vectors, vaccinia viral vectors, herpesviral vectors, polyoma viral constructs, lentiviral vectors or Sindbis viral vectors), or other macromolecular complexes capable of mediating delivery of the polynucleotide to the target cell, may be employed.

In a further aspect the gene delivery vector may be modified, for example by means known to those of skill in the art, to target one or more specific cell types. The expression cassette may also comprise a selectable marker, e.g., an immunologic marker. The expression cassette may further comprise a second polynucleotide encoding a second polypeptide, such as endothelial cell or HEVEC-active transcription factor. Such a second polynucleotide may be under control of a second promoter or the same promoter as the first polynucleotide. Alternatively, an internal ribosomal entry site (IRES) may be employed between the two transgenes to permit expression of the second transgene.



In a further aspect of the present invention, there is provided a method of modulating the expression of a gene in an endothelial cell comprising inhibiting the function or expression of NF-HEV. Preferably said method causes the decreased expression of a proinflammatory protein in an endothelial cell. In another aspect the invention provides a method for modulating endothelial cell phenotype, preferably HEVEC cell phenotype, or preferably reducing or preventing the development of HEV-like vessels, comprising inhibiting the function of NF-HEV. In one aspect, NF-HEV function may be reduced in a post-mitotic endothelial cell or HEVEC. Inhibiting may comprise providing antisense nucleic acid that inhibits transcription or translation of a NF-HEV mRNA, or small interfering RNAs that induces degradation of a NF-HEV mRNA. The antisense nucleic acid or small interfering RNAs may be provided by introducing an expression cassette encoding NF-HEV antisense RNA or small interfering RNAs.

As further discussed herein, chronic inflammatory disorders typically involves development of HEV-like vessels. This development can be the result of the activities of cells, especially non-HEVEC cells which differentiate into HEVEC or HEV-like vessel cells in the region of disease. In preferred aspects of the present invention, compositions and methods are provided that alleviate the deleterious inflammation potentiating activities of such HEVEC cells or cells from HEV-like vessels by modulating the phenotype of said cells.

In preferred embodiments, the compositions and methods can be used not only to alleviate or prevent the deleterious proinflammatory activities of the target cell population (in this case endothelial cells such as HEVECs or cells from HEV-like vessels) but also to stimulate the target cells to engage in one or more functions typical of endothelial cells not involved in inflammation, thereby reducing inflammation or inflammatory potential in the diseased region. By way of illustration, lymphocyte cells typically bind and extravasate from HEV or HEV-like vessels, thereby resulting in chronic inflammation and possibly related tissue damage. Introduction of a composition in accordance herewith into such HEV-like vessels or small blood vessels capable of differentiating thereinto can prevent those cells from engaging in such deleterious activity.

In a preferred aspect, modulating inflammation comprises modulating, preferably inhibiting, the transcription of a gene in an endothelial cell. Preferably said gene encodes a

polypeptide involved in a proinflammatory pathway. In a preferred aspect, modulating HEVEC phenotype comprises modulating transcription of a gene involved in determining (e.g. inducing differentiation of or maintaining) the HEVEC phenotype. The invention involves methods of detecting or assessing NF-HEV activity comprising detecting the expression or transcription of one or a plurality of endothelial markers or HEVEC lineage markers. Detecting the expression or transcription of one or a plurality of endothelial markers or HEVEC lineage markers may comprise detecting an mRNA or protein known to be expressed in an endothelial cell, or may comprise detecting a polypeptide encoded by a polynucleotide operably linked to a transcriptional regulatory sequence known to be active in an endothelial cell.

In one aspect the method comprises (a) introducing to a cell an expression cassette comprising a polynucleotide encoding a NF-HEV polypeptide operatively linked to a promoter capable of directing of expression of the polypeptide; and (b) detecting expression or transcription from an endothelial cell regulatory sequence (e.g. detecting a polypeptide under the regulatory control of a regulatory sequence active in an endothelial cell). The method may also comprises (a) introducing to a cell an expression cassette comprising a polynucleotide encoding a NF-HEV polypeptide operatively linked to a promoter capable of directing of expression of the polypeptide; and (b) detecting expression or transcription of an endothelial cell marker, preferably a HEVEC marker. In other aspects, as further described in the section titled "Drug Screening Assays", the invention comprises: (a) introducing to the cell an inhibitor of an NF-HEV polypeptide; (b) optionally, providing to the cell a NF-HEV polypeptide; (c) optionally, providing to the cell a polynucleotide encoding an additional polypeptide factor, preferably a transcription factor; and (d) detecting expression or transcription of an endothelial cell marker, preferably a HEVEC marker. Again, in preferred aspects, detecting the expression or transcription of an endothelial cell marker comprises detecting expression or transcription from an endothelial cell regulatory sequence.

Preferably, the screening method comprises: (a) introducing to the cell an inhibitor of an NF-HEV polypeptide; (b) optionally, introducing to a cell an expression cassette comprising a polynucleotide encoding a NF-HEV polypeptide operatively linked to a promoter capable of directing of expression of the polypeptide; (c) optionally, introducing to

a cell an expression cassette comprising a polynucleotide encoding an additional polypeptide factor, preferably a transcription factor, said polynucleotide operatively linked to a promoter capable of directing of expression of the polypeptide; and (d) detecting expression or transcription of an endothelial cell marker, or preferably a HEVEC marker. Preferably the  
5 endothelial cell or HEVEC marker is a lineage marker. In one aspect of the methods, the expression of a endothelial cell or HEVEC marker mRNA or polypeptide is detected. In another example, the method comprises introducing to the cell an expression cassette comprising a polynucleotide encoding a detectable polypeptide operatively linked to a transcriptional regulatory sequence of a gene encoding an endothelial cell or HEVEC marker.

10 In still another aspect, there is provided a non-human transgenic animal, e.g., a mouse, comprising an expression cassette. The expression cassette comprises a polynucleotide encoding a NF-HEV peptide or protein and a promoter operably linked thereto which promoter may be heterologous to the NF-HEV peptide or protein encoding region. The promoter may be a constitutive or an inducible promoter. The expression cassette  
15 may further comprise selectable marker(s). In a related aspect of the present invention, the non-human transgenic animal may comprise a defective germ-line NF-HEV allele or two defective germ-line NF-HEV alleles.

In a further aspect of the invention, there is provided a method of treating an inflammatory disorder, such as rheumatoid arthritis, Crohn's disease or inflammatory bowel  
20 disorder. The method comprises administering to an animal suffering from an inflammatory disorder a compound capable of inhibiting NF-HEV activity. In preferred aspects there is provided a method of alleviating one or more symptoms of an inflammatory disorder comprising inhibiting the function of NF-HEV in postmitotic endothelial cells or HEVECs in the subject.

25 An additional aspect of the present invention is to provide compositions and methods for the identification of downstream target genes of NF-HEV polypeptides.

A gene delivery vector, for example an adenoviral vector, can be employed to deliver a NF-HEV gene to isolated endothelial cells thereby permitting over-expression of the NF-HEV polypeptide. Differences in gene profiling between control (i.e., nontransfected)  
30 endothelial cells and transfected (i.e., NF-HEV-overexpressing) endothelial cells can then be

assessed by standard methods, such as differential display and microarray (e.g., gene chip) technology. Genes that are activated by NF-HEV in endothelial cells can subsequently be evaluated as potential therapeutics, for example, using bioinformatics techniques.

In yet another aspect of the present invention, there is provided a method of screening  
 5 for a candidate substance for an effect on NF-HEV regulation of endothelial cell or HEVEC gene expression or endothelial cell or HEVEC development, said method comprising: (a) providing NF-HEV and optionally one or more further HEVEC factors (e.g. transcription factor) to a cell; (b) admixing NF-HEV and optionally said further HEVEC factor(s) in the presence of the candidate substance; and (c) measuring the effect of the candidate substance  
 10 on the expression of an endothelial cell or HEVEC marker, wherein a difference in the expression of the endothelial cell or HEVEC marker, as compared to an untreated cell, indicates that the candidate substance effects NF-HEV regulation of endothelial cell or HEVEC gene expression or development.

Exemplary cells include endothelial cells such as HEVECs, which may be located in an  
 15 animal. The modulator may increase or decrease the expression of the HEVEC lineage marker. Any suitable lineage marker may be used. Examples of HEVEC lineage marker include the L-selectin ligand N-acetyl-glucosamine-6-O-sulfotransferase (LSST) (Bistrup et al. (1999) J Cell Biol 145:899-910; Hemmerich et al. (2001) Immunity 15:237-47.; Hiraoka et al. (1999) Immunity 11:79-89), and the HEV-specific MECA-79 sulfated epitope (Michie  
 20 et al. (1993) Am J Pathol 143:1688-1698; Streeter et al. (1988) J Cell Biol 107:1853-1862), the fucosyltransferase FucTVII (Maly et al. (1996) Cell 86:643-653; Smith et al. (1996) J Biol Chem 271:8250-8259) and the HECA-452-fucosylated epitope (Duijvestijn et al. (1988) Am J Path 130:147-155), the chemokine CCL21 (SLC/6CKine/TCA-4/exodus-2) (Gunn et al. (1998) Proc Natl Acad Sci U S A 95:258-63) and the SPARC-like antiadhesive matricellular  
 25 protein hevin (Girard and Springer (1995) Immunity 2:113-123; Girard and Springer (1996) J Biol Chem 271:4511-4517). The measuring of the expression of the endothelial cell or HEVEC markers may comprise RNA hybridization, RT-PCR, immunologic detection, ELISA or immunohistochemistry, for example.

In still yet another aspect of the invention, there is provided a method of screening for  
 30 a modulator of NF-HEV expression comprising: (a) providing a cell that expresses a NF-

HEV polypeptide; (b) contacting the NF-HEV polypeptide with a candidate substance; and (c) measuring the expression of NF-HEV, wherein a difference in NF-HEV expression, indicates that the candidate substance is a modulator of NF-HEV expression. The modulator may be a pharmaceutical composition. The modulator may enhance or inhibit NF-HEV expression.

Other aspects of the present invention are described with reference to the numbered paragraphs below:

1. A method of reducing the symptoms of a condition associated with inflammation, said method comprising modulating the level of transcription of at least one promoter responsive to an NF-HEV polypeptide or biologically active fragment thereof.

2. The method of Claim 1, wherein said NF-HEV polypeptide or biologically active fragment thereof comprises an amino acid sequence selected from the group consisting of amino acids 1-65 of SEQ ID NOs: 4-6.

Other aspects of the present invention are described in Attachment A.

#### Brief Description of the Sequence Listing

SEQ ID No 1 is a cDNA sequence encoding a human NF-HEV protein.

SEQ ID No 2 is a cDNA sequence encoding a murine NF-HEV protein.

SEQ ID No 3 is a cDNA sequence encoding a canine NF-HEV protein.

SEQ ID No 4 is a polypeptide sequence of the human NF-HEV protein.

SEQ ID No 5 is a polypeptide sequence of the murine NF-HEV protein.

SEQ ID No 6 is a polypeptide sequence of the canine NF-HEV protein.

SEQ ID No 7 is a genomic DNA sequence encoding the human NF-HEV protein.

SEQ ID No 8 is a genomic DNA sequence encoding the murine NF-HEV protein.

#### Brief Description of the Drawings

**Figure 1.** Amino acid sequence alignment of human NF-HEV (hNF-HEV) with its mouse (mNF-HEV) and canine (caDVS27) orthologs. Conserved residues are boxed. Black boxes indicate identical residues, whereas shaded boxes show similar amino acids. Dashed lines represent gaps introduced to align sequences. Sequence alignment was performed with

ClustalW (<http://www2.ebi.ac.uk/clustalw>) and colored with Boxshade ([http://www.ch.embnet.org/software/BOX\\_form.html](http://www.ch.embnet.org/software/BOX_form.html)). The bipartite NLS and the three helices of the homeodomain-like Helix-Turn-Helix (HTH) putative DNA-binding motif are indicated.

5        **Figure 2.** NF-HEV contains a homeodomain-like HTH motif. Model of the three-dimensional structure of the homeodomain-like HTH motif of human NF-HEV (aa 1-65), based on its threading-derived homology with the crystallographic structure of the homeodomain DBD from drosophila transcription factor *engrailed* (PDB code : 1DU0). The  $\alpha$ -helices have been numbered in order and color-coded in brown. The potential DNA  
10      recognition helix ( $\alpha$ -helix 3) is marked by a red arrow. The turn of the HTH motif is coded in blue. Molecular modeling was performed as described in Example 8.

**Figure 3.** Genomic structure of the human and mouse *NF-HEV* genes. Open boxes indicate non-translated exon sequence and black boxes coding exon sequence. The two genes share a similar organization with seven exons. A major difference is the size of the first  
15      intron, which is > 9 kb in the human gene but only ~ 2 kb in its mouse ortholog.

**Figure 4.** *NF-HEV* mRNA expression in HEVs of human tonsil, Peyer's patch and mesenteric lymph node. *In situ* hybridization was performed on paraformaldehyde-fixed sections with an RNA probe complementary to NF-HEV mRNA (antisense), and hybridization signal (red) occurs in HEVs of the T-cell zone around lymphoid follicles in (A)  
20      tonsil, (B) Peyer's patch, and (C) mesenteric lymph node. Higher magnification (x 600, right panels) reveals that the signal is confined to HEVECs and scattered surrounding cells. Hybridization with a sense probe produced no signal (left panels).

**Figure 5.** Virtual northern and western blot analyses demonstrating preferential expression of NF-HEV in HEVECs. (A) Virtual northern blot analysis of NF-HEV  
25      expression in HEVECs, PMECs, HUVECs or placenta tissue. PCR-generated full-length cDNAs from the various types of ECs were electrophoresed on a 1% agarose gel, transferred to nylon filters, and hybridized under high-stringency conditions with a <sup>32</sup>P-labeled human *NF-HEV* cDNA probe. (B) Western blot analysis of extracts of tonsillar stroma, HEVECs, PMECs or HUVECs with rabbit antibodies to NF-HEV. A single band of ~30 kDa was  
30      detected in extracts of tonsillar stroma and HEVECs.

**Figure 6.** RT-PCR analysis of NF-HEV expression in human HEVEC, Rheumatoid arthritis endothelial cells (ECs) and Crohn's disease ECs. RT-PCR was performed as described in Example 9. Colon Tumor ECs and Hela samples, and amplification of G3PDH were used as controls. All PCR reactions were done at the same time and the identity of the PCR products was confirmed by restriction mapping or sequencing.

**Figure 7.** *NF-HEV* encodes a nuclear protein. (A-B) Nuclear localization of epitope-tagged NF-HEV ectopically expressed in primary HUVECs or immortalized HeLa epithelial cells. (A) HUVECs and (B) HeLa cells transfected with myc-tagged NF-HEV expression vector were stained by indirect immunofluorescence with antibodies to myc and analyzed by confocal laser scanning microscopy. Original magnification: x 1000.

**Figure 8.** *In situ* expression of NF-HEV protein in the nucleus of tonsillar HEVECs. Cryosections of human tonsils (4  $\mu$ m, acetone-fixed) were double-stained with (A) HEV-specific rat mAb MECA-79 or (B) antibodies to NF-HEV peptides. (C) Two-color overlays reveal that NF-HEV immunoreactivity is associated with MECA-79-positive HEVECs. Counterstaining with the nuclear dye DAPI showed a clear nuclear localization of NF-HEV in MECA-79-positive HEVECs (right panels). No nuclear staining was observed with preimmune rabbit serum (not shown). Original magnification: x 600.

#### Detailed Description

Aspects of the present invention is based on the characterization of the NF-HEV protein, a nuclear factor protein expressed in endothelial cells from chronically inflamed tissues, and particularly HEVECs in individuals suffering from chronic inflammation.

NF-HEV has been identified based on its expression in HEVs, specialized postcapillary venules found in lymphoid tissues and nonlymphoid tissues during chronic inflammatory diseases that support a high level of lymphocyte extravasation from the blood. Lymphocyte migration to secondary lymphoid tissue and lesions of chronic inflammation is directed by multistep interactions between the circulating cells and the specialized endothelium of high endothelial venules (HEVs) and HEV-like vessels. To identify novel HEV genes, freshly purified HEV endothelial cells (HEVECs) and nasal polyp-derived microvascular endothelial cells (PMECs) were compared using the PCR-based method of

suppression subtractive hybridization (SSH). This approach resulted in the cloning of NF-HEV (nuclear factor from HEVs), the first nuclear factor preferentially expressed in HEVECs. Virtual northern and western blot analyses showed strong expression of NF-HEV in HEVECs, compared to human umbilical vein endothelial cells (HUVECs) and PMECs. In situ hybridization and immunohistochemistry revealed that NF-HEV mRNA and protein are expressed at high levels and rather selectively by HEVECs in human tonsils, Peyer's patches and lymph nodes. The NF-HEV protein was found to contain a bipartite nuclear localization signal, and was targeted to the nucleus when ectopically expressed in HUVECs and HeLa cells. Furthermore, endogenous NF-HEV was found *in situ* to be confined to the nucleus of tonsillar HEVECs. Finally, threading and molecular modeling studies indicated that the amino-terminal part of NF-HEV (aa 1-60) corresponds to a novel homeodomain-like Helix-Turn-Helix (HTH) DNA-binding domain. Similarly to the atypical homeodomain transcription factor Prox-1, which plays a critical role in the induction of the lymphatic endothelium phenotype, NF-HEV may be one of the key nuclear factors that controls the specialized HEV phenotype.

An important element in the cloning of the NF-HEV cDNA from HEVECs was the development of protocols for obtaining HEVECs RNA, since HEVECs are not capable of maintaining their phenotype outside of their native environment for more than a few days. Total RNA was obtained from HEVECs freshly purified from human tonsils. Highly purified HEVECs were obtained by a combination of mechanical and enzymatic procedures, immunomagnetic depletion and positive selection (Girard and Springer (1995) *Immunity* 2:113-123)(Baekkevold et al. (1999) *Lab Invest* 79:327-36). Tonsils were minced finely with scissors on a steel screen, digested with collagenase/dispase enzyme mix and unwanted contaminating cells were then depleted using immunomagnetic depletion. HEVECs were then selected by immunomagnetic positive selection with magnetic beads conjugated to the HEV-specific antibody MECA-79 (Girard and Springer (1995) *Immunity* 2:113-123)(Baekkevold et al. (1999) *Lab Invest* 79:327-36).

Despite these methods, extensive molecular characterization of the HEVEC phenotype is still hampered by the low number of cells available after purification, thereby ruling out traditional subtraction cloning techniques, which typically require several



micrograms of mRNA (Byers et al. (2000) *Int J Exp Pathol* 81:391-404.). To circumvent this problem, we previously adapted the PCR-based method of suppression subtractive hybridization (SSH)(Diatchenko et al. (1996) *Proc Natl Acad Sci U S A* 93:6025-30) to identify genes preferentially expressed in human tonsillar HEVECs compared with human  
 5 umbilical vein endothelial cells (HUVECs) (Girard et al. (1999) *Am J Pathol* 155:2043-55.). With this method we generated a subtracted HEVEC cDNA library from 1 µg of total RNA, and were able to clone several HEV-expressed cDNAs, including the promiscuous chemokine receptor DARC, mitochondrial genes, and secreted extracellular matrix (ECM) proteins, such as mac25/IGFBP7/angiomodulin (Girard et al. (1999) *Am J Pathol* 155:2043-  
 10 55.). Thus we showed that SSH could be applied for cloning of differentiation-specific genes from a very limited starting material. This strategy has since been applied for characterization of ECs from several other vascular beds (Kirsch et al. (2001) *Brain Res* 910:106-15.; Stier et al. (2000) *FEBS Lett* 467:299-304.; Wang et al. (2001) *Stroke* 32:1020-7.). SSH was also recently utilized to clone the novel vascular endothelial junction-associated molecule (VE-  
 15 JAM) from an HEVEC cDNA library (Palmeri et al. (2000) *J Biol Chem* 275:19139-45.).

To be reliable, SSH requires a low but significant enrichment of genes in the cells of interest compared with those used for subtraction. Therefore, to identify differentiation-specific genes from HEVECs, subtraction was not performed with HUVECs but with the more closely related and truly microvascular nasal polyp-derived microvascular endothelial  
 20 cells (PMECs) (Jahnsen et al. (1997) *Am J Pathol* 150:2113-23.). This strategy allowed us to identify, in addition to the matricellular protein hevin (which validated our approach), a nuclear factor preferentially expressed in HEVECs, designated nuclear factor from HEV (NF-HEV). NF-HEV mRNA was detected by in situ hybridization in HEVs from several human lymphoid tissues, including tonsils, Peyer's patches and mesenteric lymph nodes. Virtual  
 25 northern and western blot analysis revealed preferential expression of NF-HEV in HEVECs, compared to two other types of ECs, namely microvascular PMECs and macrovascular HUVECs. NF-HEV exhibits a consensus bipartite nuclear localization sequence and localized to the nucleus when ectopically expressed in HUVECs. Immunohistochemistry performed on human tonsil sections showed a similar in situ nuclear localization of NF-HEV  
 30 in HEVECs. Finally, threading and molecular modeling analyses suggested that NF-HEV

contains an homeodomain-like HTH DNA-binding domain (DBD) in its amino-terminal part. Together, our results characterized the first nuclear factor preferentially expressed in HEVECs that may play a key role in the control of the specialized HEV phenotype.

5 *Identification of the NF-HEV cDNA as a cDNA preferentially expressed in HEVECs*

was generated from HEVEC cDNA subtracted against PMEC cDNA (HEVEC-<sub>PMEC</sub>) (Girard et al. (1999) Am J Pathol 155:2043-55.). MECA-79-positive HEVECs were purified from human tonsils (Bækkevold et al. (1999) Lab Invest 79:327-36) and PMECs were isolated from nasal polyps as described (Jahnsen et al. (1997) Am J Pathol 150:2113-23.). A total of 960 clones were obtained in the PCR-select HEVEC-<sub>PMEC</sub> cDNA library. Differential screening of these 960 clones with radioactive probes generated from HEVEC or PMEC cDNAs, revealed 49 cDNAs preferentially expressed in HEVECs. Sequencing of these cDNAs showed that the most abundant family of genes was mitochondrial enzymes (12 clones), particularly transcripts for cytochrome c oxidase 1. This was in line with our previous report (Girard et al. (1999) Am J Pathol 155:2043-55.) that HEVECs express higher levels of these enzymes than other ECs. Our screen also identified three independent clones corresponding to the secreted matricellular protein hevin, one of the known markers of tonsillar HEVECs (Girard et al. (1999) Am J Pathol 155:2043-55.; Girard and Springer (1995) Immunity 2:113-123). Using two distinct polyclonal antisera, we confirmed preferential expression of hevin in MECA-79-positive-HEVECs from human tonsils, as well as MadCAM-1-positive-HEVECs from human Peyer's patches. In addition to the hevin clones, which validated our HEVEC-<sub>PMEC</sub> SSH approach, we identified several other cDNAs corresponding to previously characterized genes, including endothelial multimerin (4 clones), which is a secreted homomultimeric factor V-binding protein (Hayward et al. (1998) Blood 91:1304-17.), the complement inhibitor CD59 (2 clones), and the Nck adaptor protein NCK1 (2 clones). Abundant expression of multimerin and CD59 in HEVECs was confirmed by immunohistochemistry on human tonsil sections.

30 In summary, to identify cDNAs preferentially expressed in HEVEC, a PCR Select library of the sequences corresponding to human genes not yet characterized, we focused on one that was represented by four distinct cDNA clones within the HEVEC-<sub>PMEC</sub>

library. To assess the tissue distribution of this gene, we prepared riboprobes corresponding to the open reading frame, which were applied for *in situ* mRNA hybridization (Figure 4). Strikingly, the antisense riboprobe hybridized strongly to HEVs in the T-cell zones of human tonsil (Figure 4A), Peyer's patch (Figure 4B), and mesenteric lymph node (Figure 4C).

5 Indeed, higher magnification clearly revealed hybridization signals within HEVECs as well as in scattered cells in the T-cell zone (arrow heads). Hybridization with a sense probe produced no signal (Figure 4A, B, C). Based on these *in situ* results, which confirmed preferential expression of this gene in human HEVs *in vivo*, and the localization of the corresponding protein in the cell nucleus (see below), we designated this gene nuclear factor  
10 from HEV (NF-HEV).

#### *Sequence of the NF-HEV cDNA*

Sequencing of the four NF-HEV cDNA clones isolated from the PCR-select HEVEC.  
PMEC cDNA library revealed a sequence identical to that of a human cDNA deposited in  
Genbank with the annotation "Homo sapiens mRNA for DVS27-related protein" (GenBank  
15 Acc. AB024518). This cDNA appears to encode a putative human ortholog of the canine  
DVS27 protein, previously identified in a screen for genes differentially expressed in canine  
vasospastic cerebral arteries after subarachnoid hemorrhage (Onda et al. (1999) J Cereb  
Blood Flow Metab 19:1279-88.). Databases searches with both the nucleotide and amino acid  
sequences of canine DVS27 (Genbank Acc. AB024517), using the programs BLASTN,  
20 TBLASTN and BLASTP (GenBank non-redundant, human htgs and human EST databases at  
National Center for Biotechnology Information, www.ncbi.nlm.nih.gov), failed to reveal any  
other human cDNA or protein more closely related to DVS27 than NF-HEV. This further  
suggested that human NF-HEV is an ortholog of canine DVS27. Two murine cDNAs  
encoding a putative mouse ortholog of human NF-HEV (GenBank Acc. XM\_123362 and  
25 NM\_133775) were also identified by searching GenBank databases with the human NF-HEV  
sequence. Alignment of the human and mouse NF-HEV proteins (48% identity over 270  
residues) with the canine DVS27 sequence (56% identity between hNF-HEV and canine  
DVS27) revealed that the NF-HEV/DVS27 protein is composed of two evolutionary  
conserved regions separated by a highly divergent linker region in the central part (Figure 1).

30

### *Genomic structure of the NF-HEV gene*

A BLAST search of the NR sequence database at NCBI with human *NF-HEV* cDNA or protein sequences as baits, revealed a genomic hit from the *Homo Sapiens* chromosome 9 sequence (GenBank Acc. NT\_008413) that covered the whole *NF-HEV* cDNA. This genomic  
 5 contig contains three independent UniSTS (UniSTS entries: SHGC-15129, stSG27179, RH101248) that have been previously mapped at 9p24.1, between microsatellite markers D9S178 and D9S168. This suggested that the human *NF-HEV* gene is located on the short arm of chromosome 9 at 9p24.1. Alignment between the *NF-HEV* cDNA and genomic  
 10 sequences revealed that there are 7 exons that span more than 16 kb of genomic DNA (Figure 3). All the exon-intron boundaries followed the GT-AG rule. The human *NF-HEV* gene shared a similar organization with its mouse ortholog (Figure 3), that we identified in a *Mus musculus* genomic contig (GenBank Acc. NW\_000143). The size of exons were found to be strictly conserved between the two species, with the exception of exon 3 that contains 15  
 15 additional nucleotides in the human sequence, corresponding to an insertion of 5 residues in the middle of the human NF-HEV protein (Figure 1).

### *NF-HEV is a nuclear protein*

Because the predicted NF-HEV amino acid sequence contains a consensus bipartite nuclear localization sequence (NLS, Prosite PS00015), near the linker region (Figure 1), we  
 20 decided to investigate whether NF-HEV could localize to the nucleus of ECs. For that purpose, we designed an expression construct with NF-HEV fused to the c-myc epitope tag, which was transfected into primary HUVECs and detected by indirect immunofluorescence staining with antibodies to myc. Confocal immunofluorescence microscopy revealed a strict  
 intranuclear localization of the epitope-tagged NF-HEV (Figure 7). The myc-tagged-NF-HEV  
 25 protein also localized to the nucleus when ectopically expressed in HeLa cells (Figure 7), suggesting that the nuclear localization of NF-HEV is not a specific property of ECs.

### *Preferential Expression of NF-Hev in Hevecs Compared with Other Ec Types*

Preferential expression of NF-HEV in human HEVECs was confirmed by virtual  
 30 northern and western blot analyses. Virtual northern blot analysis of PCR-generated full-length cDNA from human HEVECs, PMECs, HUVECs, and placenta with a cDNA probe

corresponding to the NF-HEV open reading frame, revealed a prominent band of ~2.6 kb in HEVECs (Figure 5A); it agreed well with the size of NF-HEV mRNA. Conversely, this 2.6-kb signal was detected at only very low levels in PMECs and HUVECs and was almost undetectable in placenta (Figure 5A). To confirm such preferential expression of NF-HEV in HEVECs at the protein level, we raised rabbit antibodies against NF-HEV peptides. By immunoblotting, these antibodies recognized a ~30 kD protein in lysates from tonsil stroma and purified HEVECs, but not in PMECs or HUVECs (Figure 5B). The apparent molecular weight of ~30 kD for endogenous NF-HEV was in agreement with the predicted  $M_w$  of 31 kD and the size of a recombinant NF-HEV protein produced in *Escherichia coli*.

#### Endogenous NF-HEV localizes to the nucleus of HEVECs *in situ*

To determine the subcellular localization of NF-HEV in HEVECs *in situ*, we performed immunohistochemistry with the rabbit antibodies raised against NF-HEV peptides. Immunostaining of human tonsil sections with these reagents demonstrated strong NF-HEV expression in MECA-79-positive HEVs (Figure 8A-C). Costaining of nuclear DNA with DAPI further showed that NF-HEV was concentrated in the nucleus of HEVECs (Figure 8, right panels). Lower magnification also revealed that the antibodies to NF-HEV decorated, scattered single cells (the identity of which remains unknown) in the T cell zone (data not shown), in addition to the MECA-79-positive-HEVs. This result was consistent with the *in situ* hybridization results described above (Figure 4). In conclusion, although NF-HEV expression did not appear to be strictly HEV-specific, our immunohistochemistry data clearly revealed abundant *in vivo* expression of NF-HEV in the nucleus of HEVECs.

#### NF-HEV contains a putative homeodomain-like Helix-Turn-Helix DNA-binding domain

Searches in Prosite and Pfam databases with the NF-HEV sequence failed to reveal significant similarities to previously characterized protein sequence motifs, excepted for a low level of homology of the NF-HEV amino-acids 28 to 68 with prokaryotic Helix-Turn-Helix (HTH) DBDs (HTH\_ARAC, Prosite PS00041). Because detection of sequence homology is more sensitive and selective when aided by secondary structure information, structural homologs of human NF-HEV in the PDB crystallographic database, were searched with the SeqFold threading program (Olszewski (1999) Theor. Chem. Acc. 101:57-61) which

combines sequence and secondary structure alignment. This search revealed significant structural homologies between the first 65 amino-terminal residues of NF-HEV and the DNA-binding homeodomains of several drosophila (*engrailed*, *fushi-tarazu*, ...) and vertebrate (POU, ...) transcription factors. The crystallographic structure (PDB # 1DU0) of the drosophila transcription factor *engrailed* homeodomain (Grant et al. (2000) Biochemistry 39:8187-8192) provided the best score of the search. The resulting threading-derived secondary structure alignment, was used to generate a homology-based model for the amino-terminal domain of human NF-HEV (Figure 2; see Example 8 for a detailed account of the model-building and structural check protocols). Similarly to the homeodomain (Kissinger et al. (1990) Cell 63:579-90) and various other eukaryotic HTH DBDs (human centromere protein CENP-B, human Myb transcription factor, yeast telomere binding protein RAP1), (Iwahara et al. (1998) EMBO J 17:827-37) NF-HEV was predicted to contain a homeodomain-like HHTH motif that could be described as a right-handed three-helical bundle, (Grant et al. (2000) Biochemistry 39:8187-8192; Kissinger et al. (1990) Cell 63:579-90) composed of an hydrophobic core of two  $\alpha$ -helices (helices 2 and 3 corresponding to the HTH motif) completed by another N-terminal  $\alpha$ -helix (helix 1). A conserved characteristic of this HHTH motif is the packing of  $\alpha$ -helices 2 and 3 at nearly a right angle to each other (Figure 2); the turn between  $\alpha$ -helices 2 and 3 offsets  $\alpha$ -helix 3 so that the N-terminal part of  $\alpha$ -helix 3, which is predicted to bind to the target DNA major groove, is packed against the middle of  $\alpha$ -helix 2. Together, our threading and modeling results suggested that the amino-terminal part of NF-HEV (aa 1-65) corresponds to a novel homeodomain-like HTH DBD.

#### *The NF-HEV protein*

In preferred embodiments, a NF-HEV family member comprises an amino acid sequence of at least about 15, 20, 30, 40, 50, 70, 100, 150, 200, 250 or 270 amino acid residues in length, of which amino acid sequence at least about 99%, 98%, 95%, 90%, 50-80%, preferably at least about 60-70%, more preferably at least about 65% of the amino acid residues are identical or similar to the amino acid sequences shown in SEQ ID NOS [4, 5 or 6]. NF-HEV proteins have an amino acid sequence sufficiently homologous to an amino acid sequence presented in SEQ ID NOS 4, 5 or 6 or are encoded by a nucleotide sequence

sufficiently homologous to a sequence presented in SEQ ID NOS 1,2 or 3. As used herein, the term "sufficiently homologous" refers to a first amino acid or nucleotide sequence which contains a sufficient or minimum number of identical or equivalent (e.g., an amino acid residue which has a similar side chain) amino acid residues or nucleotides to a second amino acid or nucleotide sequence such that the first and second amino acid or nucleotide sequences share common structural domains or motifs and/or a common functional activity. For example, amino acid or nucleotide sequences which share common structural domains have at least about 30-40% identity, preferably at least about 40-50% identity, more preferably at least about 50-60%, and even more preferably at least about 60-70%, 70-80%, 80%, 90%, 95%, 97%, 98%, 99% or 99.8% identity across the amino acid sequences of the domains and contain at least one and preferably two structural domains or motifs, are defined herein as sufficiently homologous. Furthermore, amino acid or nucleotide sequences which share at least about 30%, preferably at least about 40%, more preferably at least about 60%, 70%, 80%, 90%, 95%, 97%, 98%, 99% or 99.8% identity and share a common functional activity are defined herein as sufficiently homologous.

#### *NF-HEV activity*

As used interchangeably herein, a "NF-HEV activity", "biological activity of NF-HEV" or "functional activity of NF-HEV", refers to an activity exerted by a NF-HEV protein, polypeptide or nucleic acid molecule as determined in vivo, or in vitro, according to standard techniques. In one embodiment, a NF-HEV activity is a direct activity, such as an association with a NF-HEV-target molecule. As used herein, a "target molecule" is a molecule with which a NF-HEV protein binds or interacts in nature, such that NF-HEV-mediated function is achieved. A NF-HEV target molecule can be a NF-HEV protein or polypeptide of the present invention or a non-NF-HEV molecule. For example, a NF-HEV target molecule can be a non-NF-HEV protein molecule such as a transcription factor, or may be a non-NF-HEV molecule such as a nucleic acid molecule, preferably a regulatory sequence (e.g. promoter). Alternatively, a NF-HEV activity is an indirect activity, such as an activity mediated by interaction of the NF-HEV protein with a NF-HEV target molecule such that the target molecule modulates a downstream cellular activity (e.g., interaction of a NF-HEV molecule

with a NF-HEV target molecule can modulate the activity of that target molecule on an intracellular signalling pathway, preferably a proinflammatory signaling pathway). In a preferred embodiment, a NF-HEV activity is selected from the group consisting of: (a) modulating gene expression in an endothelial cell, preferably in a HEVEC cell or in a cell  
 5 from a HEV-like vessel; (b) modulating the inflammatory potential of an endothelial cell; (c) regulating endothelial cell, preferably HEVEC phenotype; (d) regulating (e.g. inducing or inhibiting) HEV-like vessel development or maintainance; and (e) modulating (e.g. inducing or inhibiting) the differentiation and/or proliferation of endothelial cell, preferably HEVEC cells, or in cells from HEV-like vessels.

10 NF-HEV activity may be assessed either in vitro or in vivo depending on the assay type and format.

#### *NF-HEV Nucleic Acids*

The present invention relates to the use of the human (SEQ ID NO 1) NF-HEV  
 15 cDNAs as well as the murine NF-HEV coding sequence (SEQ ID NO 2) and the canine NF-HEV coding sequence (SEQ ID NO 3). The human NF-HEV cDNA, which is approximately 2628 nucleotides in length encodes a protein which is approximately 270 amino acid residues in length. The mouse NF-HEV coding sequence, approximately 2486 nucleotides in length, encodes a protein which is approximately 266 amino acid residues in length.

20 One aspect of the invention pertains to the use of purified or isolated nucleic acid molecules that encode NF-HEV proteins or biologically active portions thereof, as well as nucleic acid fragments thereof, in therapeutic methods, in diagnostic and drug screening assays. Fragments may be used for example as hybridization probes to identify NF-HEV-encoding nucleic acids (e.g., NF-HEV mRNA) and fragments for use as probes (e.g. for  
 25 detection of NF-HEV nucleic acid molecules) or primers (e.g. for sequencing, genotyping, amplification or mutation of NF-HEV nucleic acid molecules). As used herein, the term "nucleic acids" and "nucleic acid molecule" is intended to include DNA molecules (e.g., cDNA or genomic DNA) and RNA molecules (e.g., mRNA) and analogs of the DNA or RNA generated using nucleotide analogs. The nucleic acid molecule can be single-stranded  
 30 or double-stranded, but preferably is double-stranded DNA. Throughout the present



specification, the expression "nucleotide sequence" may be employed to designate indifferently a polynucleotide or a nucleic acid. More precisely, the expression "nucleotide sequence" encompasses the nucleic material itself and is thus not restricted to the sequence information (i.e. the succession of letters chosen among the four base letters) that  
5 biochemically characterizes a specific DNA or RNA molecule. Also, used interchangeably herein are terms "nucleic acids", "oligonucleotides", and "polynucleotides".

An "isolated" nucleic acid molecule is one which is separated from other nucleic acid molecules which are present in the natural source of the nucleic acid. Preferably, an "isolated" nucleic acid is free of sequences which naturally flank the nucleic acid (i.e.,  
10 sequences located at the 5' and 3' ends of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived. For example, in various embodiments, the isolated NF-HEV nucleic acid molecule can contain less than about 5 kb, 4 kb, 3 kb, 2 kb, 1 kb, 0.5 kb or 0.1 kb of nucleotide sequences which naturally flank the nucleic acid molecule in genomic DNA of the cell from which the nucleic acid is derived. Moreover, an "isolated"  
15 nucleic acid molecule, such as a cDNA molecule, can be substantially free of other cellular material, or culture medium when produced by recombinant techniques, or substantially free of chemical precursors or other chemicals when chemically synthesized.

A nucleic acid molecule of the present invention, e.g., a nucleic acid molecule having the nucleotide sequences as given in SEQ ID NOS 1,2 or 3, or a portion thereof, can be  
20 isolated using standard molecular biology techniques and the sequence information provided herein. Using all or portion of the nucleic acid sequences in SEQ ID NOS 1,2 or 3 as a hybridization probe, NF-HEV nucleic acid molecules can be isolated using standard hybridization and cloning techniques (e.g., as described in Sambrook, J., Fritsh, E. F., and Maniatis, T. Molecular Cloning, A Laboratory Manual. 2nd, ed., Cold Spring Harbor  
25 Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989).

Moreover, a nucleic acid molecule encompassing all or a portion of the sequences given in SEQ ID NOS 1,2 or 3 can be isolated by the polymerase chain reaction (PCR) using synthetic oligonucleotide primers designed based upon the same sequences.

A nucleic acid of the invention can be amplified using cDNA, mRNA or alternatively,  
30 genomic DNA, as a template and appropriate oligonucleotide primers according to standard

PCR amplification techniques. The nucleic acid so amplified can be cloned into an appropriate vector and characterized by DNA sequence analysis. Furthermore, oligonucleotides corresponding to NF-HEV nucleotide sequences can be prepared by standard synthetic techniques, e.g., using an automated DNA synthesizer.

5 In a preferred embodiment, an isolated nucleic acid molecule for use in methods of the invention comprises, consists essentially of, or consists of a nucleotide sequences shown in SEQ ID NOS 1,2 or 3, or fragments thereof. These cDNAs comprise sequences encoding the human NF-HEV protein (i.e., "the coding region", as well as 5' untranslated sequences and 3' untranslated sequences. Alternatively, the nucleic acid molecule can comprise, consist  
10 essentially of, or consist of only the coding region as given in SEQ ID NOS 4, 5 or 6.

Also encompassed by the NF-HEV nucleic acids of the invention are nucleic acid molecules which are complementary to NF-HEV nucleic acids described herein. Preferably, a complementary nucleic acid is sufficiently complementary to the nucleotide sequence shown in SEQ ID NOS 1,2 or 3, such that it can hybridize to the nucleotide sequence shown  
15 in SEQ ID NOS 1,2 or 3, thereby forming a stable duplex.

The preferred purified, isolated, or recombinant NF-HEV nucleic acids encode a NF-HEV polypeptide comprising, consisting essentially of, or consisting of the amino acid sequences given in SEQ ID NOS 4, 5 or 6, or fragments thereof. For example, the purified, isolated or recombinant nucleic acid may comprise a genomic DNA or fragment thereof  
20 which encode the polypeptides in SEQ ID NOS 4, 5 or 6 or a fragment thereof. Preferred polynucleotides of the invention also include purified, isolated, or recombinant NF-HEV cDNAs consisting of, consisting essentially of, or comprising the sequences shown in SEQ ID NOS 1,2 or 3 or fragments thereof. Particularly preferred nucleic acids of the invention include isolated, purified, or recombinant fragments of NF-HEV nucleic acids comprising a  
25 contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, 1000 or 2000 nucleotides of the sequences in SEQ ID NOS 1,2 or 3 or the complements thereof.

Moreover, an NF-HEV nucleic acid molecule can comprise only a portion of the nucleic acid sequences in SEQ ID NOS 1,2 or 3, for example a fragment which can be used  
30 as a probe or primer or a fragment encoding a biologically active portion of a NF-HEV

protein. The probe/primer typically comprises substantially purified oligonucleotide. The oligonucleotide typically comprises a region of nucleotide sequence that hybridizes under stringent conditions to at least about 12, preferably about 25, more preferably about 40, 50, more than 75 consecutive nucleotides of a sequence in SEQ ID NOS 1,2 or 3, or a sequence complementary thereto. In an exemplary embodiment, a nucleic acid molecule of the present invention comprises a nucleotide sequence which is at least about 400, 500, 1000, preferably at least about 1000-1250, more preferably at least about 1250-1500, more preferably at least about 1500-1750 in length and hybridizes under stringent hybridization conditions to a nucleic acid molecule in SEQ ID NOS 1,2 or 3.

10 A nucleic acid fragment encoding a "biologically active portion of a NF-HEV protein" can be prepared by isolating a portion of the nucleotide sequence in SEQ ID NOS 1, 2 or 3 which encodes a polypeptide having a NF-HEV biological activity (the biological activities of the NF-HEV proteins described herein), expressing the encoded portion of the NF-HEV protein (e.g., by recombinant expression in vitro or in vivo) and assessing the activity of the  
15 encoded portion of the NF-HEV protein.

NF-HEV nucleic acid molecules that differ from the nucleotide sequence shown in SEQ ID NOS 1,2 or 3 due to degeneracy of the genetic code and thus encode the same NF-HEV proteins as those encoded by the nucleotide sequence shown in SEQ ID NOS 1,2 or 3 can also be used. In another embodiment, such an isolated nucleic acid molecule comprises a  
20 nucleotide sequence encoding a protein comprising an amino acid sequence shown in SEQ ID NOS 4, 5 or 6 or a fragment thereof.

In addition to the NF-HEV nucleotide sequences shown in SEQ ID NOS 1,2 or 3, it will be appreciated by those skilled in the art that DNA sequence polymorphisms that lead to changes in the amino acid sequences of the NF-HEV proteins may exist within a population (e.g., the human population). Such genetic polymorphism in the NF-HEV genes may exist  
25 among individuals within a population due to natural allelic variation. As used herein, the terms "gene" and "recombinant gene" refer to nucleic acid molecules comprising an open reading frame encoding a NF-HEV protein, preferably a mammalian NF-HEV protein. Such natural allelic variations can typically result in 1-5% variance in the nucleotide sequence of a  
30 NF-HEV gene. Thus, also to be used according to the invention are any and all such

nucleotide variations and resulting amino acid polymorphisms in NF-HEV genes that are the result of natural allelic variation and, most preferably, that do not alter the functional activity of a NF-HEV protein.

Also useful are nucleic acid molecules encoding other NF-HEV family members, and thus which have a nucleotide sequence which differs from the NF-HEV sequences of SEQ ID NOS 1, 2 or 3. For example, a cDNA encoding a NF-HEV family member can be identified based on the nucleotide sequence of human NF-HEV. Moreover, nucleic acid molecules encoding NF-HEV proteins from different species, and thus which have a nucleotide sequence which differs from the NF-HEV sequences of SEQ ID NOS 1, 2 or 3 are intended to be within the scope of the invention. For example, a mouse NF-HEV cDNA can be identified based on the nucleotide sequence of a human NF-HEV. Such NF-HEV family members may be identified by hybridization to a NF-HEV nucleic acid or fragment thereof, amplification with primers derived from a NF-HEV nucleic acid or fragment thereof, or bioinformatic comparison with a NF-HEV nucleic acid or fragment thereof or a NF-HEV polypeptide or fragment thereof.

Nucleic acid molecules corresponding to natural allelic variants and homologues of the NF-HEV cDNAs of the invention can be isolated based on their homology to the NF-HEV nucleic acids disclosed herein using the cDNAs disclosed herein, or a portion thereof, as a hybridization probe according to standard hybridization techniques under stringent hybridization conditions.

As used herein, the term "hybridizes under stringent conditions" is intended to describe conditions for hybridization and washing under which nucleotide sequences at least 60% homologous to each other typically remain hybridized to each other. Preferably, the conditions are such that sequences at least about 70%, more preferably at least about 80%, even more preferably at least about 85%, 90%, 95% or 98% homologous to each other typically remain hybridized to each other. Stringent conditions are known to those skilled in the art and can be found in Current Protocols in Molecular Biology, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6. A preferred, non-limiting example of stringent hybridization conditions are hybridization in 6 sodium chloride/sodium citrate (SSC) at about 45° C., followed by one or more washes in 0.2 SSC, 0.1% SDS at 50-65° C. Preferably, an isolated

nucleic acid molecule of the invention that hybridizes under stringent conditions to the sequences in SEQ ID NOS 1, 2 or 3 corresponds to a naturally-occurring nucleic acid molecule. As used herein, a "naturally-occurring" nucleic acid molecule refers to an RNA or DNA molecule having a nucleotide sequence that occurs in nature (e.g., encodes a natural protein).

In addition to naturally-occurring allelic variants of the NF-HEV sequences that may exist in the population, the skilled artisan will further appreciate that changes can be introduced by mutation into the nucleotide sequences in SEQ ID NOS 1, 2 or 3 thereby leading to changes in the amino acid sequence of the encoded NF-HEV proteins, without altering the functional ability of the NF-HEV proteins. For example, nucleotide substitutions leading to amino acid substitutions at "non-essential" amino acid residues can be made in the sequences in SEQ ID NOS 1, 2 or 3. A "non-essential" amino acid residue is a residue that can be altered from the wild-type sequence of NF-HEV (e.g., the sequences of SEQ ID NOS 4, 5 or 6) without altering the biological activity, whereas an "essential" amino acid residue is required for biological activity. For example, amino acid residues that are conserved among the NF-HEV proteins of the present invention, are predicted to be less un-amenable to alteration.

Accordingly, nucleic acid molecules encoding NF-HEV proteins may contain changes in amino acid residues that are not essential for activity. Such NF-HEV proteins differ in amino acid sequence from sequences in SEQ ID NOS 4, 5 or 6 yet retain biological activity. In one embodiment, the isolated nucleic acid molecule comprises a nucleotide sequence encoding a protein, wherein the protein comprises an amino acid sequence at least about 60% homologous to an amino acid sequences of SEQ ID NOS 4, 5 or 6. Preferably, the protein encoded by the nucleic acid molecule is at least about 65-70% homologous to a sequence of SEQ ID NOS 1, 2 or 3, more preferably sharing at least about 75-80% identity with a sequences in SEQ ID NOS 1, 2 or 3, even more preferably sharing at least about 85%, 90%, 92%, 95%, 97%, 98%, 99% or 99.8% identity with a sequence of SEQ ID NOS 1, 2 or 3.

An isolated nucleic acid molecule encoding a NF-HEV protein homologous to the proteins in SEQ ID NOS 4, 5 or 6 can be created by introducing one or more nucleotide substitutions, additions or deletions into a nucleotide sequences in SEQ ID NOS 1, 2 or 3

such that one or more amino acid substitutions, additions or deletions are introduced into the encoded protein. Mutations can be introduced into the sequences in SEQ ID NOS 1, 2 or 3 by standard techniques, such as site-directed mutagenesis and PCR-mediated mutagenesis. Preferably, conservative amino acid substitutions are made at one or more predicted non-essential amino acid residues. A "conservative amino acid substitution" is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Thus, a predicted nonessential amino acid residue in a NF-HEV protein is preferably replaced with another amino acid residue from the same side chain family. Alternatively, in another embodiment, mutations can be introduced randomly along all or part of a NF-HEV coding sequence, such as by saturation mutagenesis, and the resultant mutants can be screened for NF-HEV biological activity to identify mutants that retain activity. Following mutagenesis of a sequence given in SEQ ID NOS 1, 2 or 3, the encoded protein can be expressed recombinantly and the activity of the protein can be determined.

In a preferred embodiment, a mutant NF-HEV protein encoded by a NF-HEV nucleic acid of the invention can be assayed for NF-HEV-activity in any suitable assay, examples of which are provided herein.

Primers and probes of the invention can be prepared by any suitable method, including, for example, cloning and restriction of appropriate sequences and direct chemical synthesis by a method such as the phosphodiester method of Narang et al. (1979), the phosphodiester method of [Brown et al. (1979)], the diethylphosphoramidite method of Beaucage et al. (1981) and the solid support method described in EP 0 707 592, the disclosures of which are incorporated herein by reference in their entireties.

Detection probes are generally nucleic acid sequences or uncharged nucleic acid analogs such as, for example peptide nucleic acids which are disclosed in International Patent Application WO 92/20702, morpholino analogs which are described in U.S. Patents Numbered 5,185,444; 5,034,506 and 5,142,047. The probe may have to be rendered "non-extendable" in that additional dNTPs cannot be added to the probe. In and of themselves analogs usually are non-extendable and nucleic acid probes can be rendered non-extendable by modifying the 3' end of the probe such that the hydroxyl group is no longer capable of participating in elongation. For example, the 3' end of the probe can be functionalized with the capture or detection label to thereby consume or otherwise block the hydroxyl group.

Any of the polynucleotides of the present invention can be labeled, if desired, by incorporating any label known in the art to be detectable by spectroscopic, photochemical, biochemical, immunochemical, or chemical means. For example, useful labels include radioactive substances (including,  $^{32}\text{P}$ ,  $^{35}\text{S}$ ,  $^3\text{H}$ ,  $^{125}\text{I}$ ), fluorescent dyes (including, 5-bromodesoxyuridin, fluorescein, acetylaminofluorene, digoxigenin) or biotin. Preferably, polynucleotides are labeled at their 3' and 5' ends. Examples of non-radioactive labeling of nucleic acid fragments are described in the French patent No. FR-7810975 or by Urdea et al. (1988) or Sanchez-Pescador et al. (1988). In addition, the probes according to the present invention may have structural characteristics such that they allow the signal amplification, such structural characteristics being, for example, branched DNA probes as those described by Urdea et al. in 1991 or in the European patent No. EP 0 225 807 (Chiron).

A label can also be used to capture the primer, so as to facilitate the immobilization of either the primer or a primer extension product, such as amplified DNA, on a solid support. A capture label is attached to the primers or probes and can be a specific binding member which forms a binding pair with the solid's phase reagent's specific binding member (e.g. biotin and streptavidin). Therefore depending upon the type of label carried by a polynucleotide or a probe, it may be employed to capture or to detect the target DNA. Further, it will be understood that the polynucleotides, primers or probes provided herein, may, themselves, serve as the capture label. For example, in the case where a solid phase reagent's binding member is a nucleic acid sequence, it may be selected such that it binds a complementary portion of a primer or probe to thereby immobilize the primer or probe to the

solid phase. In cases where a polynucleotide probe itself serves as the binding member, those skilled in the art will recognize that the probe will contain a sequence or "tail" that is not complementary to the target. In the case where a polynucleotide primer itself serves as the capture label, at least a portion of the primer will be free to hybridize with a nucleic acid on a solid phase. DNA Labeling techniques are well known to the skilled technician.

The probes of the present invention are useful for a number of purposes. They can be notably used in Southern hybridization to genomic DNA. The probes can also be used to detect PCR amplification products. They may also be used to detect mismatches in the NF-HEV gene or mRNA using other techniques.

Any of the nucleic acids, polynucleotides, primers and probes of the present invention can be conveniently immobilized on a solid support. Solid supports are known to those skilled in the art and include the walls of wells of a reaction tray, test tubes, polystyrene beads, magnetic beads, nitrocellulose strips, membranes, microparticles such as latex particles, sheep (or other animal) red blood cells, duracytes and others. The solid support is not critical and can be selected by one skilled in the art. Thus, latex particles, microparticles, magnetic or non-magnetic beads, membranes, plastic tubes, walls of microtiter wells, glass or silicon chips, sheep (or other suitable animal's) red blood cells and duracytes are all suitable examples. Suitable methods for immobilizing nucleic acids on solid phases include ionic, hydrophobic, covalent interactions and the like. A solid support, as used herein, refers to any material which is insoluble, or can be made insoluble by a subsequent reaction. The solid support can be chosen for its intrinsic ability to attract and immobilize the capture reagent. Alternatively, the solid phase can retain an additional receptor which has the ability to attract and immobilize the capture reagent. The additional receptor can include a charged substance that is oppositely charged with respect to the capture reagent itself or to a charged substance conjugated to the capture reagent. As yet another alternative, the receptor molecule can be any specific binding member which is immobilized upon (attached to) the solid support and which has the ability to immobilize the capture reagent through a specific binding reaction. The receptor molecule enables the indirect binding of the capture reagent to a solid support material before the performance of the assay or during the performance of the assay. The solid phase thus can be a plastic, derivatized plastic, magnetic or non-magnetic metal, glass



or silicon surface of a test tube, microtiter well, sheet, bead, microparticle, chip, sheep (or other suitable animal's) red blood cells, duracytes and other configurations known to those of ordinary skill in the art. The nucleic acids, polynucleotides, primers and probes of the invention can be attached to or immobilized on a solid support individually or in groups of at  
5 least 2, 5, 8, 10, 12, 15, 20, or 25 distinct polynucleotides of the invention to a single solid support. In addition, polynucleotides other than those of the invention may be attached to the same solid support as one or more polynucleotides of the invention.

The invention also comprises methods for detecting or identifying an endothelial cell, a HEVEC cell or a cell from a HEV or HEV-like vessel, and methods for detecting or  
10 identifying a HEV-like vessel. More preferably, the invention also comprises methods for detecting or identifying an endothelial cell, a HEVEC cell or a cell from a HEV-like vessel which is involved in chronic inflammation.

These methods are useful for in research protocols where it is desirable to identify such cells or vessels as well as in diagnostic procedures as discussed herein (e.g.  
15 inflammatory conditions).

Detecting the presence of an NF-HEV nucleic acid comprising a nucleotide sequence selected from a group consisting of a sequences of SEQ ID NOS 1, 2 or 3, a fragment or a variant thereof and a complementary sequence thereto in a sample, said method comprising the following steps of: (a) bringing into contact a nucleic acid probe or a plurality of nucleic  
20 acid probes which can hybridize with a nucleotide sequence included in a nucleic acid selected from the group consisting of a nucleotide sequences of SEQ ID NOS 1, 2 or 3, a fragment or a variant thereof and a complementary sequence thereto and the sample to be assayed; and (b) detecting the hybrid complex formed between the probe and a nucleic acid in the sample. Preferably, detecting the presence of a hybrid formed indicates that the sample is  
25 derived from an endothelial cell, a HEVEC cell or a cell from a HEV-like vessel. Preferably, detecting the presence of a hybrid formed indicates that the sample derived from a cell involved in chronic inflammation.

The invention further concerns a kit for detecting the presence of an NF-HEV nucleic acid comprising a nucleotide sequence selected from a group consisting of a nucleotide  
30 sequences of SEQ ID NOS 1, 2 or 3, a fragment or a variant thereof and a complementary

sequence thereto in a sample, said kit comprising: (a) a nucleic acid probe or a plurality of nucleic acid probes which can hybridize with a nucleotide sequence included in a nucleic acid selected from the group consisting of the nucleotide sequences of SEQ ID NOS 1, 2 or 3, a fragment or a variant thereof and a complementary sequence thereto; and (b) optionally, the reagents necessary for performing the hybridization reaction.

In a first preferred embodiment of this detection method and kit, said nucleic acid probe or the plurality of nucleic acid probes are labeled with a detectable molecule. In a second preferred embodiment of said method and kit, said nucleic acid probe or the plurality of nucleic acid probes has been immobilized on a substrate.

Any polynucleotide provided herein may be attached in overlapping areas or at random locations on a solid support. Alternatively the polynucleotides of the invention may be attached in an ordered array wherein each polynucleotide is attached to a distinct region of the solid support which does not overlap with the attachment site of any other polynucleotide. Preferably, such an ordered array of polynucleotides is designed to be "addressable" where the distinct locations are recorded and can be accessed as part of an assay procedure. Addressable polynucleotide arrays typically comprise a plurality of different oligonucleotide probes that are coupled to a surface of a substrate in different known locations. The knowledge of the precise location of each polynucleotides location makes these "addressable" arrays particularly useful in hybridization assays. Any addressable array technology known in the art can be employed with the polynucleotides of the invention. One particular embodiment of these polynucleotide arrays is known as the Genechips, and has been generally described in US Patent 5,143,854; PCT publications WO 90/15070 and 92/10092.

Probes based on the NF-HEV nucleotide sequences can be used to detect transcripts or genomic sequences encoding the same or homologous proteins. In preferred embodiments, the probe further comprises a label group attached thereto, e.g., the label group can be a radioisotope, a fluorescent compound, an enzyme, or an enzyme co-factor. Such probes can be used as a part of a diagnostic test kit for identifying cells or tissue which misexpress a NF-HEV protein, such as by measuring a level of a NF-HEV-encoding nucleic acid in a sample

of cells from a subject e.g., detecting NF-HEV mRNA levels or determining whether a genomic NF-HEV gene has been mutated or deleted.

*NF-HEV Polypeptides and Anti-NF-HEV Antibodies*

5       The invention also relates to the use of isolated NF-HEV proteins, and biologically active portions thereof, as well as polypeptide fragments suitable for use as immunogens to raise anti-NF-HEV antibodies. In one embodiment, native NF-HEV proteins can be isolated from cells or tissue sources by an appropriate purification scheme using standard protein purification techniques. In another embodiment, NF-HEV proteins are produced by  
10 recombinant DNA techniques. Alternative to recombinant expression, a NF-HEV protein or polypeptide can be synthesized chemically using standard peptide synthesis techniques.

SEQ ID NOS 4, 5 and 6 show the amino acid sequences human, mouse and canine NF-HEV polypeptides, respectively.

An "isolated" or "purified" protein or biologically active portion thereof is  
15 substantially free of cellular material or other contaminating proteins from the cell or tissue source from which the NF-HEV protein is derived, or substantially free from chemical precursors or other chemicals when chemically synthesized. The language "substantially free of cellular material" includes preparations of NF-HEV protein in which the protein is separated from cellular components of the cells from which it is isolated or recombinantly  
20 produced. In one embodiment, the language "substantially free of cellular material" includes preparations of NF-HEV protein having less than about 30% (by dry weight) of non-NF-HEV protein (also referred to herein as a "contaminating protein"), more preferably less than about 20% of non-NF-HEV protein, still more preferably less than about 10% of non-NF-HEV protein, and most preferably less than about 5% non-NF-HEV protein. When the NF-HEV  
25 protein or biologically active portion thereof is recombinantly produced, it is also preferably substantially free of culture medium, i.e., culture medium represents less than about 20%, more preferably less than about 10%, and most preferably less than about 5% of the volume of the protein preparation.

The language "substantially free of chemical precursors or other chemicals" includes  
30 preparations of NF-HEV protein in which the protein is separated from chemical precursors

or other chemicals which are involved in the synthesis of the protein. In one embodiment, the language "substantially free of chemical precursors or other chemicals" includes preparations of NF-HEV protein having less than about 30% (by dry weight) of chemical precursors or non-NF-HEV chemicals, more preferably less than about 20% chemical precursors or non-  
5 NF-HEV chemicals, still more preferably less than about 10% chemical precursors or non-NF-HEV chemicals, and most preferably less than about 5% chemical precursors or non-NF-HEV chemicals.

The term "polypeptide" refers to a polymer of amino acids without regard to the length of the polymer; thus, peptides, oligopeptides, and proteins are included within the  
10 definition of polypeptide. This term also does not specify or exclude post-expression modifications of polypeptides, for example, polypeptides which include the covalent attachment of glycosyl groups, acetyl groups, phosphate groups, lipid groups and the like are expressly encompassed by the term polypeptide. Also included within the definition are polypeptides which contain one or more analogs of an amino acid (including, for example,  
15 non-naturally occurring amino acids, amino acids which only occur naturally in an unrelated biological system, modified amino acids from mammalian systems etc.), polypeptides with substituted linkages, as well as other modifications known in the art, both naturally occurring and non-naturally occurring.

The term "recombinant polypeptide" is used herein to refer to polypeptides that have  
20 been artificially designed and which comprise at least two polypeptide sequences that are not found as contiguous polypeptide sequences in their initial natural environment, or to refer to polypeptides which have been expressed from a recombinant polynucleotide.

Biologically active portions of a NF-HEV protein include peptides comprising amino acid sequences sufficiently homologous to or derived from the amino acid sequence of the  
25 NF-HEV protein, e.g., an amino acid sequence shown in SEQ ID NOS 4, 5 or 6, which include less amino acids than the full length NF-HEV proteins, and exhibit at least one activity of a NF-HEV protein. Typically, biologically active portions comprise a domain or motif with at least one activity of the NF-HEV proteins. A biologically active portion of a NF-HEV protein can be a polypeptide which is, for example at least 15, 25, 40, 50, 75, 100,  
30 150, 200, 250 or 270 amino acids in length.

In a preferred embodiment, the NF-HEV protein comprises, consists essentially of, or consists of the amino acid sequence shown in SEQ ID NOS 4, 5 or 6. The invention also concerns the polypeptide encoded by a nucleotide sequences selected from the group consisting of the sequences in SEQ ID NOS 1, 2 or 3, a complementary sequence thereof or a fragment thereto. The present invention embodies isolated, purified, and recombinant fragments of one NF-HEV polypeptide comprising a contiguous span of at least 6 amino acids, preferably at least 8 to 10 amino acids, more preferably at least 12, 15, 20, 25, 30, 40, 50, 100, 150, 200, 250 or 270 amino acids of a sequence of SEQ ID NOS 4, 5 or 6. In other preferred embodiments the contiguous stretch of amino acids comprises the site of a mutation or functional mutation, including a deletion, addition, swap or truncation of the amino acids in the NF-HEV protein sequence.

In other embodiments, the NF-HEV protein is substantially homologous to a sequence of SEQ ID NOS 4, 5 or 6, and retains the functional activity of a protein of SEQ ID NOS 4, 5 or 6, yet differs in amino acid sequence due to natural allelic variation or mutagenesis, as described in detail in subsection I above. Accordingly, in another embodiment, the NF-HEV proteins are proteins which comprise an amino acid sequence at least about 60% homologous to an amino acid sequence of SEQ ID NOS 4, 5 or 6 and retain the functional activity of the NF-HEV proteins of SEQ ID NOS 4, 5 or 6. Preferably, the proteins are at least about 30%, 40%, 50%, 60%, 70%, 80%, 85%, 90%, 92%, 95%, 97%, 98%, 99% or 99.8% homologous to a protein of SEQ ID NOS 4, 5 or 6.

To determine the percent homology of two amino acid sequences or of two nucleic acids, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in the sequence of a first amino acid or nucleic acid sequence for optimal alignment with a second amino or nucleic acid sequence and non-homologous sequences can be disregarded for comparison purposes). In a preferred embodiment, the length of a reference sequence aligned for comparison purposes is at least 30%, preferably at least 40%, more preferably at least 50%, even more preferably at least 60%, and even more preferably at least 70%, 80%, 90% or 95% of the length of the reference sequence (e.g., when aligning a second sequence to a NF-HEV amino acid sequences of SEQ ID NOS 4 having 270 amino acid residues, at least 100, preferably at least 200, more preferably at least 250, even more

preferably 270 amino acid residues are aligned or when aligning a second sequence to a NF-HEV nucleic acid sequence of SEQ ID NOS 1, preferably a human NF-HEV sequence comprising, consisting essentially of or consisting of 2628 nucleotides which encode the amino acids of the NF-HEV protein, preferably at least 100, preferably at least 200, more preferably at least 300, even more preferably at least 400, and even more preferably at least 500, 600, at least 700, at least 800, at least 900, or more than 1000 nucleotides are aligned. The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are homologous at that position (i.e., as used herein amino acid or nucleic acid "identity" is equivalent to amino acid or nucleic acid "homology"). The percent homology between the two sequences is a function of the number of identical positions shared by the sequences (i.e.,  $\% \text{ homology} = \text{number (\#) of identical positions} / \text{total number (\#) of positions} \times 100$ ).

The comparison of sequences and determination of percent homology between two sequences can be accomplished using a mathematical algorithm. A preferred, non-limiting example of a mathematical algorithm utilized for the comparison of sequences is the algorithm of Karlin and Altschul (1990) Proc. Natl. Acad. Sci. USA 87:2264-68, modified as in Karlin and Altschul (1993) Proc. Natl. Acad. Sci. USA 90:5873-77, the disclosures of which are incorporated herein by reference in their entireties. Such an algorithm is incorporated into the NBLAST and XBLAST programs (version 2.0) of Altschul, et al. (1990) J. Mol. Biol. 215:403-10. BLAST nucleotide searches can be performed with the NBLAST program, score=100, wordlength=12 to obtain nucleotide sequences homologous to NF-HEV nucleic acid molecules of the invention. BLAST protein searches can be performed with the XBLAST program, score=50, wordlength=3 to obtain amino acid sequences homologous to NF-HEV protein molecules of the invention. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul et al., (1997) Nucleic Acids Research 25(17):3389-3402. When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used. See <http://www.ncbi.nlm.nih.gov>, the disclosures of which are incorporated

herein by reference in their entireties. Another preferred, non-limiting example of a mathematical algorithm utilized for the comparison of sequences is the algorithm of Myers and Miller, CABIOS (1989), the disclosures of which are incorporated herein by reference in their entireties. Such an algorithm is incorporated into the ALIGN program (version 2.0) which is part of the GCG sequence alignment software package. When utilizing the ALIGN program for comparing amino acid sequences, a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4 can be used.

It is proposed that the monoclonal antibodies of the present invention will find useful application in standard immunochemical procedures, such as ELISA and Western blot methods and in immunohistochemical procedures such as tissue staining, as well as in other procedures which may utilize antibodies specific to NF-HEV antigen epitopes. Additionally, it is proposed that monoclonal antibodies specific to the particular NF-HEV of different species may be utilized in other useful applications. In general, both polyclonal and monoclonal antibodies against NF-HEV may be used in a variety of embodiments. For example, they may be employed in antibody cloning protocols to obtain cDNAs or genes encoding other NF-HEV. They may also be used in inhibition studies to analyze the effects of NF-HEV-related peptides in cells or animals. NF-HEV antibodies will also be useful in immunolocalization studies to analyze the distribution of NF-HEV during various cellular events, for example, to determine the cellular or tissue-specific distribution of NF-HEV polypeptides at different points in the cell cycle. A particularly useful application of such antibodies is in purifying native or recombinant NF-HEV, for example, using an antibody affinity column. The operation of such immunological techniques will be known to those of skill in the art in light of the present disclosure.

The invention also provides NF-HEV chimeric or fusion proteins. As used herein, a NF-HEV "chimeric protein" or "fusion protein" comprises a NF-HEV polypeptide operatively linked, preferably fused in-frame, to a non-NF-HEV polypeptide. In a preferred embodiment, a NF-HEV fusion protein comprises at least one biologically active portion of a NF-HEV protein. In another preferred embodiment, a NF-HEV fusion protein comprises at least two biologically active portions of a NF-HEV protein. For example, in one embodiment, the fusion protein is a GST-NF-HEV fusion protein in which the NF-HEV

sequences are fused to the C-terminus of the GST sequences. Such fusion proteins can facilitate the purification of recombinant NF-HEV. In another embodiment, the fusion protein is a NF-HEV protein containing a heterologous signal sequence at its N-terminus, such as for example to allow for a desired cellular localization in a certain host cell. The NF-HEV-fusion proteins of the invention can be used for example as immunogens to produce anti-NF-HEV antibodies in a subject, to purify NF-HEV ligands and in screening assays to identify molecules which inhibit the interaction of NF-HEV with a NF-HEV target molecule.

The present invention also pertains to use of variants of the NF-HEV proteins which function as either NF-HEV mimetics or as NF-HEV inhibitors. Variants of the NF-HEV proteins can be generated by mutagenesis, e.g., discrete point mutation or truncation of a NF-HEV protein. An agonist of the NF-HEV proteins can retain substantially the same, or a subset, of the biological activities of the naturally occurring form of a NF-HEV protein. An antagonist of a NF-HEV protein can inhibit one or more of the activities of the naturally occurring form of the NF-HEV protein by, for example, competitively inhibiting the sulfate transport activity of a NF-HEV protein. Thus, specific biological effects can be elicited by treatment with a variant of limited function. In one embodiment, variants of a NF-HEV protein which function as either NF-HEV agonists (mimetics) or as NF-HEV antagonists can be identified by screening combinatorial libraries of mutants, e.g., truncation mutants, of a NF-HEV protein for NF-HEV protein agonist or antagonist activity. In one embodiment, a variegated library of NF-HEV variants is generated by combinatorial mutagenesis at the nucleic acid level and is encoded by a variegated gene library. A variegated library of NF-HEV variants can be produced by, for example, enzymatically ligating a mixture of synthetic oligonucleotides into gene sequences such that a degenerate set of potential NF-HEV sequences is expressible as individual polypeptides, or alternatively, as a set of larger fusion proteins (e.g., for phage display) containing the set of NF-HEV sequences therein. There are a variety of methods which can be used to produce libraries of potential NF-HEV variants from a degenerate oligonucleotide sequence. Chemical synthesis of a degenerate gene sequence can be performed in an automatic DNA synthesizer, and the synthetic gene then ligated into an appropriate expression vector. Use of a degenerate set of genes allows for the provision, in one mixture, of all of the sequences encoding the desired set of potential NF-HEV sequences.



In addition, libraries of fragments of a NF-HEV protein coding sequence can be used to generate a variegated population of NF-HEV fragments for screening and subsequent selection of variants of a NF-HEV protein. In one embodiment, a library of coding sequence fragments can be generated by treating a double stranded PCR fragment of a NF-HEV coding sequence with a nuclease under conditions wherein nicking occurs only about once per molecule, denaturing the double stranded DNA, renaturing the DNA to form double stranded DNA which can include sense/antisense pairs from different nicked products, removing single stranded portions from reformed duplexes by treatment with S1 nuclease, and ligating the resulting fragment library into an expression vector. By this method, an expression library can be derived which encodes N-terminal, C-terminal and internal fragments of various sizes of the NF-HEV protein.

Several techniques are known in the art for screening gene products of combinatorial libraries made by point mutations or truncation, and for screening cDNA libraries for gene products having a selected property. Such techniques are adaptable for rapid screening of the gene libraries generated by the combinatorial mutagenesis of NF-HEV proteins. The most widely used techniques, which are amenable to high through-put analysis, for screening large gene libraries typically include cloning the gene library into replicable expression vectors, transforming appropriate cells with the resulting library of vectors, and expressing the combinatorial genes under conditions in which detection of a desired activity facilitates isolation of the vector encoding the gene whose product was detected.

An isolated NF-HEV protein, or a portion or fragment thereof, can be used as an immunogen to generate antibodies that bind NF-HEV using standard techniques for polyclonal and monoclonal antibody preparation. A full-length NF-HEV protein can be used or, alternatively, the invention provides antigenic peptide fragments of NF-HEV for use as immunogens. Any fragment of the NF-HEV protein which contains at least one antigenic determinant may be used to generate antibodies. The antigenic peptide of NF-HEV comprises at least 8 amino acid residues of the amino acid sequences shown in SEQ ID NOS 4, 5 or 6 and encompasses an epitope of NF-HEV such that an antibody raised against the peptide forms a specific immune complex with NF-HEV. Preferably, the antigenic peptide comprises at least 10 amino acid residues, more preferably at least 15 amino acid residues,

even more preferably at least 20 amino acid residues, and most preferably at least 30 amino acid residues.

Preferred epitopes encompassed by the antigenic peptide are regions of NF-HEV that are located on the surface of the protein, e.g., hydrophilic regions.

5 A NF-HEV immunogen typically is used to prepare antibodies by immunizing a suitable subject, (e.g., rabbit, goat, mouse or other mammal) with the immunogen. An appropriate immunogenic preparation can contain, for example, recombinantly expressed NF-HEV protein or a chemically synthesized NF-HEV polypeptide. The preparation can further include an adjuvant, such as Freund's complete or incomplete adjuvant, or similar  
10 immunostimulatory agent. Immunization of a suitable subject with an immunogenic NF-HEV preparation induces a polyclonal anti-NF-HEV antibody response.

Accordingly, another aspect of the invention pertains to anti-NF-HEV antibodies. The term "antibody" as used herein refers to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., molecules that contain an antigen binding  
15 site which specifically binds (immunoreacts with) an antigen, such as NF-HEV. Examples of immunologically active portions of immunoglobulin molecules include F(ab) and F(ab')<sub>2</sub> fragments which can be generated by treating the antibody with an enzyme such as pepsin. The invention provides polyclonal and monoclonal antibodies that bind NF-HEV. The term "monoclonal antibody" or "monoclonal antibody composition", as used herein, refers to a  
20 population of antibody molecules that contain only one species of an antigen binding site capable of immunoreacting with a particular epitope of NF-HEV. A monoclonal antibody composition thus typically displays a single binding affinity for a particular NF-HEV protein with which it immunoreacts.

The invention concerns antibody compositions, either polyclonal or monoclonal,  
25 capable of selectively binding, or selectively bind to an epitope-containing a polypeptide comprising a contiguous span of at least 6 amino acids, preferably at least 8 to 10 amino acids, more preferably at least 12, 15, 20, 25, 30, 40, 50, 100, or more than 100 amino acids in a sequence of SEQ ID NOS 4, 5 or 6. The invention also concerns a purified or isolated antibody capable of specifically binding to a mutated NF-HEV proteins or to a fragment or  
30 variant thereof comprising an epitope of the mutated NF-HEV proteins.

Polyclonal anti-NF-HEV antibodies can be prepared as described above by immunizing a suitable subject with a NF-HEV immunogen. The anti-NF-HEV antibody titer in the immunized subject can be monitored over time by standard techniques, such as with an enzyme linked immunosorbent assay (ELISA) using immobilized NF-HEV. If desired, the antibody molecules directed against NF-HEV can be isolated from the mammal (e.g., from the blood) and further purified by well known techniques, such as protein A chromatography to obtain the IgG fraction. At an appropriate time after immunization, e.g., when the anti-NF-HEV antibody titers are highest, antibody-producing cells can be obtained from the subject and used to prepare monoclonal antibodies by standard techniques, such as those described in the following references, the disclosures of which are incorporated herein by reference in their entireties: the hybridoma technique originally described by Kohler and Milstein (1975) *Nature* 256:495-497) (see also, Brown et al. (1981) *J. Immunol.* 127:539-46; Brown et al. (1980) *J. Biol. Chem.* 255:4980-83 ; Yeh et al. (1976) *PNAS* 76:2927-31; and Yeh et al. (1982) *Int. J. Cancer* 29:269-75), the more recent human B cell hybridoma technique (Kozbor et al. (1983) *Immunol Today* 4:72), the EBV-hybridoma technique (Cole et al. (1985), *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, Inc., pp. 77-96) or trioma techniques. The technology for producing monoclonal antibody hybridomas is well known (see generally R. H. Kenneth, in *Monoclonal Antibodies: A New Dimension In Biological Analyses*, Plenum Publishing Corp., New York, N.Y. (1980); E. A. Lerner (1981) *Yale J. Biol. Med.*, 54:387-402; M. L. Geffer et al. (1977) *Somatic Cell Genet.* 3:231-36), the disclosures of which are incorporated herein by reference in their entireties. Briefly, an immortal cell line (typically a myeloma) is fused to lymphocytes (typically splenocytes) from a mammal immunized with a NF-HEV immunogen as described above, and the culture supernatants of the resulting hybridoma cells are screened to identify a hybridoma producing a monoclonal antibody that binds NF-HEV.

Any of the many well known protocols used for fusing lymphocytes and immortalized cell lines can be applied for the purpose of generating an anti-NF-HEV monoclonal antibody (see, e.g., G. Galfre et al. (1977) *Nature* 266:55052; Geffer et al. *Somatic Cell Genet.*, cited supra; Lerner, *Yale J Biol. Med*, cited supra; Kenneth, *Monoclonal Antibodies*, cited supra), the disclosures of which are incorporated herein by reference in their entireties. Moreover, the

ordinarily skilled worker will appreciate that there are many variations of such methods which also would be useful. Typically, the immortal cell line (e.g., a myeloma cell line) is derived from the same mammalian species as the lymphocytes. For example, murine hybridomas can be made by fusing lymphocytes from a mouse immunized with an immunogenic preparation of the present invention with an immortalized mouse cell line. Preferred immortal cell lines are mouse myeloma cell lines that are sensitive to culture medium containing hypoxanthine, aminopterin and thymidine ("HAT medium"). Any of a number of myeloma cell lines can be used as a fusion partner according to standard techniques, e.g., the P3-NS1/1-Ag4-1, P3-x63-Ag8.653 or Sp2/O-Ag14 myeloma lines. These myeloma lines are available from ATCC. Typically, HAT-sensitive mouse myeloma cells are fused to mouse splenocytes using polyethylene glycol ("PEG"). Hybridoma cells resulting from the fusion are then selected using HAT medium, which kills unfused and unproductively fused myeloma cells (unfused splenocytes die after several days because they are not transformed). Hybridoma cells producing a monoclonal antibody of the invention are detected by screening the hybridoma culture supernatants for antibodies that bind NF-HEV, e.g., using a standard ELISA assay.

Alternative to preparing monoclonal antibody-secreting hybridomas, a monoclonal anti-NF-HEV antibody can be identified and isolated by screening a recombinant combinatorial immunoglobulin library (e.g., an antibody phage display library) with NF-HEV to thereby isolate immunoglobulin library members that bind NF-HEV. Kits for generating and screening phage display libraries are commercially available (e.g., the Pharmacia Recombinant Phage Antibody System, Catalog No. 27-9400-01; and the Stratagene SurfZAP.TM. Phage Display Kit, Catalog No. 240612), the disclosures of which are incorporated herein by reference in their entireties. Additionally, examples of methods and reagents particularly amenable for use in generating and screening antibody display library can be found in, for example, Ladner et al. U.S. Pat. No. 5,223,409; Kang et al. PCT International Publication No. WO 92/18619; Dower et al. PCT International Publication No. WO 91/17271; Winter et al. PCT International Publication WO 92/20791; Markland et al. PCT International Publication No. WO 92/15679; Breitling et al. PCT International Publication WO 93/01288; McCafferty et al. PCT International Publication No. WO

92/01047; Garrard et al. PCT International Publication No. WO 92/09690; Ladner et al. PCT International Publication No. WO 90/02809; Fuchs et al. (1991) *Bio/Technology* 9:1370-1372; Hay et al. (1992) *Hum. Antibod. Hybridomas* 3:81-85; Huse et al. (1989) *Science* 246:1275-1281; Griffiths et al. (1993) *EMBO J* 12:725-734; Hawkins et al. (1992) *J. Mol. Biol.* 226:889-896; Clarkson et al. (1991) *Nature* 352:624-628; Gram et al. (1992) *PNAS* 89:3576-3580; Garrard et al. (1991) *Bio/Technology* 9:1373-1377; Hoogenboom et al. (1991) *Nuc. Acid. Res.* 19:4133-4137; Barbas et al. (1991) *PNAS* 88:7978-7982; and McCafferty et al. *Nature* (1990) 348:552-554.

Additionally, recombinant anti-NF-HEV antibodies, such as chimeric and humanized monoclonal antibodies, comprising both human and non-human portions, which can be made using standard recombinant DNA techniques, are within the scope of the invention. Such chimeric and humanized monoclonal antibodies can be produced by recombinant DNA techniques known in the art, for example using methods described in Robinson et al. International Application No. PCT/US86/02269; Akira, et al. European Patent Application 184,187; Taniguchi, M., European Patent Application 171,496; Morrison et al. European Patent Application 173,494; Neuberger et al. PCT International Publication No. WO 86/01533; Cabilly et al. U.S. Pat. No. 4,816,567; Cabilly et al. European Patent Application 125,023; Better et al. (1988) *Science* 240:1041-1043; Liu et al. (1987) *PNAS* 84:3439-3443; Liu et al. (1987) *J. Immunol.* 139:3521-3526; Sun et al. (1987) *PNAS* 84:214-218; Nishimura et al. (1987) *Canc. Res.* 47:999-1005; Wood et al. (1985) *Nature* 314:446-449; and Shaw et al. (1988) *J. Natl. Cancer Inst.* 80:1553-1559; Morrison, S. L. (1985) *Science* 229:1202-1207; Oi et al. (1986) *BioTechniques* 4:214; Winter U.S. Pat. No. 5,225,539; Jones et al. (1986) *Nature* 321:552-525; Verhoeyan et al. (1988) *Science* 239:1534; and Beidler et al. (1988) *J. Immunol.* 141:4053-4060, the disclosures of which are incorporated herein by reference in their entireties.

An anti-NF-HEV antibody (e.g., monoclonal antibody) can be used to isolate NF-HEV by standard techniques, such as affinity chromatography or immunoprecipitation. An anti-NF-HEV antibody can facilitate the purification of natural NF-HEV from cells and of recombinantly produced NF-HEV expressed in host cells. Moreover, an anti-NF-HEV antibody can be used to detect NF-HEV protein (e.g., in a cellular lysate or cell supernatant)

in order to evaluate the abundance and pattern of expression of the NF-HEV protein. Anti-NF-HEV antibodies can be used diagnostically to monitor protein levels in tissue as part of a clinical testing procedure, e.g., to, for example, determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling (i.e., physically linking) the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, -galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin; and examples of suitable radioactive material include  $^{125}\text{I}$ ,  $^{131}\text{I}$ ,  $^{35}\text{S}$  or  $^3\text{H}$ .

15

#### *Recombinant Expression Vectors and Host Cells*

Another aspect of the invention pertains to vectors, preferably expression vectors, containing a nucleic acid encoding a NF-HEV protein (or a portion thereof). As used herein, the term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a "plasmid", which refers to a circular double stranded DNA loop into which additional DNA segments can be ligated. Another type of vector is a viral vector, wherein additional DNA segments can be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively linked. Such vectors are referred to herein as "expression vectors". In general, expression vectors of utility in recombinant DNA techniques are often in the form of plasmids. In the present specification, "plasmid" and "vector" can be

30

used interchangeably as the plasmid is the most commonly used form of vector. However, the invention is intended to include such other forms of expression vectors, such as viral vectors (e.g., replication defective retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent functions.

5       The recombinant expression vectors of the invention comprise a NF-HEV nucleic acid of the invention in a form suitable for expression of the nucleic acid in a host cell, which means that the recombinant expression vectors include one or more regulatory sequences, selected on the basis of the host cells to be used for expression, which is operatively linked to the nucleic acid sequence to be expressed. Within a recombinant expression vector, "operably  
10   linked" is intended to mean that the nucleotide sequence of interest is linked to the regulatory sequence(s) in a manner which allows for expression of the nucleotide sequence (e.g., in an in vitro transcription/translation system or in a host cell when the vector is introduced into the host cell). The term "regulatory sequence" is intended to include promoters, enhancers and other expression control elements (e.g., polyadenylation signals). Such regulatory sequences  
15   are described, for example, in Goeddel; Gene Expression Technology: Methods in Enzymology, 185, Academic Press, San Diego, Calif. (1990), the disclosure of which is incorporated herein by reference in its entirety. Regulatory sequences include those which direct constitutive expression of a nucleotide sequence in many types of host cell and those which direct expression of the nucleotide sequence only in certain host cells (e.g., tissue-  
20   specific regulatory sequences). It will be appreciated by those skilled in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, etc. The expression vectors of the invention can be introduced into host cells to thereby produce proteins or peptides, including fusion proteins or peptides, encoded by nucleic acids as described herein (e.g., NF-HEV  
25   proteins, mutant forms of NF-HEV proteins, fusion proteins, or fragments of any of the preceding proteins, etc.).

      The recombinant expression vectors of the invention can be designed for expression of NF-HEV proteins in prokaryotic or eukaryotic cells. For example, NF-HEV proteins can be expressed in bacterial cells such as E. coli, insect cells (using baculovirus expression  
30   vectors) yeast cells, or mammalian cells. Suitable host cells are discussed further in Goeddel,

Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, Calif. (1990), the disclosure of which is incorporated herein by reference in its entirety. Alternatively, the recombinant expression vector can be transcribed and translated in vitro, for example using T7 promoter regulatory sequences and T7 polymerase.

5        Expression of proteins in prokaryotes is most often carried out in *E. coli* with vectors containing constitutive or inducible promoters directing the expression of either fusion or non-fusion proteins. Fusion vectors add a number of amino acids to a protein encoded therein, usually to the amino terminus of the recombinant protein. Such fusion vectors typically serve three purposes: 1) to increase expression of recombinant protein; 2) to increase  
10 the solubility of the recombinant protein; and 3) to aid in the purification of the recombinant protein by acting as a ligand in affinity purification. Often, in fusion expression vectors, a proteolytic cleavage site is introduced at the junction of the fusion moiety and the recombinant protein to enable separation of the recombinant protein from the fusion moiety subsequent to purification of the fusion protein. Such enzymes, and their cognate recognition  
15 sequences, include Factor Xa, thrombin and enterokinase. Typical fusion expression vectors include pGEX (Pharmacia Biotech Inc; Smith, D. B. and Johnson, K. S. (1988) *Gene* 67:31-40), pMAL (New England Biolabs, Beverly, Mass.) and pRIT5 (Pharmacia, Piscataway, N.J.), the disclosures of which are incorporated herein by reference in their entireties, which fuse glutathione S-transferase (GST), maltose E binding protein, or protein A, respectively, to  
20 the target recombinant protein.

Purified fusion proteins can be utilized in NF-HEV activity assays, (e.g., direct assays or competitive assays described in detail below), or to generate antibodies specific for NF-HEV proteins, for example. In a preferred embodiment, a NF-HEV fusion protein expressed in a retroviral expression vector of the present invention can be utilized to infect bone  
25 marrow cells which are subsequently transplanted into irradiated recipients. The pathology of the subject recipient is then examined after sufficient time has passed (e.g six (6) weeks).

Examples of suitable inducible non-fusion *E. coli* expression vectors include pTrc (Amann et al., (1988) *Gene* 69:301-315) and pET 11d (Studier et al., *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, Calif. (1990) 60-89),  
30 the disclosures of which are incorporated herein by reference in their entireties. Target gene



expression from the pTrc vector relies on host RNA polymerase transcription from a hybrid trp-lac fusion promoter. Target gene expression from the pET 11d vector relies on transcription from a T7 gn10-lac fusion promoter mediated by a coexpressed viral RNA polymerase (T7 gn 1). This viral polymerase is supplied by host strains BL21 (DE3) or HMS174(DE3) from a resident prophage harboring a T7 gn1 gene under the transcriptional control of the lacUV 5 promoter.

One strategy to maximize recombinant protein expression in *E. coli* is to express the protein in a host bacteria with an impaired capacity to proteolytically cleave the recombinant protein (Gottesman, S., *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, Calif. (1990) 119-128, the disclosure of which is incorporated herein by reference in its entirety). Another strategy is to alter the nucleic acid sequence of the nucleic acid to be inserted into an expression vector so that the individual codons for each amino acid are those preferentially utilized in *E. coli* (Wada et al., (1992) *Nucleic Acids Res.* 20:2111-2118, the disclosure of which is incorporated herein by reference in its entirety). Such alteration of nucleic acid sequences of the invention can be carried out by standard DNA synthesis techniques.

In another embodiment, the NF-HEV expression vector is a yeast expression vector. Examples of vectors for expression in yeast *S. cerevisiae* include pYepSec I (Baldari, et al., (1987) *Embo J.* 6:229-234), pMFa (Kurjan and Herskowitz, (1982) *Cell* 30:933-943), pJRY88 (Schultz et al., (1987) *Gene* 54:113-123), pYES2 (Invitrogen Corporation, San Diego, Calif.), and picZ (Invitrogen Corp, San Diego, Calif.), the disclosures of which are incorporated herein by reference in their entireties.

Alternatively, NF-HEV proteins can be expressed in insect cells using baculovirus expression vectors. Baculovirus vectors available for expression of proteins in cultured insect cells (e.g., Sf 9 cells) include the pAc series (Smith et al. (1983) *Mol. Cell Biol.* 3:2156-2165) and the pVL series (Lucklow and Summers (1989) *Virology* 170:31-39), the disclosures of which are incorporated herein by reference in their entireties. In particularly preferred embodiments, NF-HEV proteins are expressed according to Karniski et al, *Am. J. Physiol.* (1998) 275: F79-87, the disclosure of which is incorporated herein by reference in its entirety.

In yet another embodiment, a nucleic acid of the invention is expressed in mammalian cells using a mammalian expression vector. Examples of mammalian expression vectors include pCDM8 (Seed, B. (1987) Nature 329:840) and pMT2PC (Kaufman et al. (1987) EMBO J. 6:187-195), the disclosures of which are incorporated herein by reference in their  
5 entirety. When used in mammalian cells, the expression vector's control functions are often provided by viral regulatory elements. For example, commonly used promoters are derived from polyoma, Adenovirus 2, cytomegalovirus and Simian Virus 40. For other suitable expression systems for both prokaryotic and eukaryotic cells see chapters 16 and 17 of Sambrook, J., Fritsh, E. F., and Maniatis, T. Molecular Cloning: A Laboratory Manual. 2nd,  
10 ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989, the disclosure of which is incorporated herein by reference in its entirety.

In another embodiment, the recombinant mammalian expression vector is capable of directing expression of the nucleic acid preferentially in a particular cell type (e.g., tissue-specific regulatory elements are used to express the nucleic acid). Tissue-specific regulatory  
15 elements are known in the art. Non-limiting examples of suitable tissue-specific promoters include the albumin promoter (liver-specific; Pinkert et al. (1987) Genes Dev. 1:268-277, the disclosure of which is incorporated herein by reference in its entirety), lymphoid-specific promoters (Calame and Eaton (1988) Adv. Immunol. 43:235-275), in particular promoters of T cell receptors (Winoto and Baltimore (1989) EMBO J. 8:729-733) and immunoglobulins  
20 (Banerji et al. (1983) Cell 33:729-740; Queen and Baltimore (1983) Cell 33:741-748), neuron-specific promoters (e.g., the neurofilament promoter; Byrne and Ruddle (1989) PNAS 86:5473-5477), pancreas-specific promoters (Edlund et al. (1985) Science 230:912-916), and mammary gland-specific promoters (e.g., milk whey promoter; U.S. Pat. No. 4,873,316 and European Application Publication No. 264,166). Developmentally-regulated promoters are  
25 also encompassed, for example the murine hox promoters (Kessel and Gruss (1990) Science 249:374-379) and the alpha-fetoprotein promoter (Campes and Tilghman (1989) Genes Dev. 3:537-546), the disclosures of which are incorporated herein by reference in their entirety.

The invention further provides a recombinant expression vector comprising a DNA molecule of the invention cloned into the expression vector in an antisense orientation. That  
30 is, the DNA molecule is operatively linked to a regulatory sequence in a manner which

allows for expression (by transcription of the DNA molecule) of an RNA molecule which is antisense to NF-HEV mRNA. Regulatory sequences operatively linked to a nucleic acid cloned in the antisense orientation can be chosen which direct the continuous expression of the antisense RNA molecule in a variety of cell types, for instance viral promoters and/or enhancers, or regulatory sequences can be chosen which direct constitutive, tissue specific or cell type specific expression of antisense RNA. The antisense expression vector can be in the form of a recombinant plasmid, phagemid or attenuated virus in which antisense nucleic acids are produced under the control of a high efficiency regulatory region, the activity of which can be determined by the cell type into which the vector is introduced. For a discussion of the regulation of gene expression using antisense genes see Weintraub, H. et al., Antisense RNA as a molecular tool for genetic analysis, Reviews--Trends in Genetics, Vol. 1(1) 1986, the disclosure of which is incorporated herein by reference in its entirety.

Another aspect of the invention pertains to host cells into which a recombinant expression vector of the invention has been introduced. The terms "host cell" and "recombinant host cell" are used interchangeably herein. It is understood that such term refer not only to the particular subject cell but to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein.

A host cell can be any prokaryotic or eukaryotic cell. For example, a NF-HEV protein can be expressed in bacterial cells such as E. coli, insect cells, yeast or mammalian cells (such as Chinese hamster ovary cells (CHO) or COS cells or human cells). Other suitable host cells are known to those skilled in the art, including *Xenopus laevis* oocytes as further described in the Examples.

Vector DNA can be introduced into prokaryotic or eukaryotic cells via conventional transformation or transfection techniques. As used herein, the terms "transformation" and "transfection" are intended to refer to a variety of art-recognized techniques for introducing foreign nucleic acid (e.g., DNA) into a host cell, including calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, lipofection, or electroporation. Suitable methods for transforming or transfecting host cells can be found in

Sambrook, et al. (Molecular Cloning: A Laboratory Manual. 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989, the disclosure of which is incorporated herein by reference in its entirety), and other laboratory manuals.

5        For stable transfection of mammalian cells, it is known that, depending upon the expression vector and transfection technique used, only a small fraction of cells may integrate the foreign DNA into their genome. In order to identify and select these integrants, a gene that encodes a selectable marker (e.g., resistance to antibiotics) is generally introduced into the host cells along with the gene of interest. Preferred selectable markers include those  
10        which confer resistance to drugs, such as G418, hygromycin and methotrexate. Nucleic acid encoding a selectable marker can be introduced into a host cell on the same vector as that encoding a NF-HEV protein or can be introduced on a separate vector. Cells stably transfected with the introduced nucleic acid can be identified by drug selection (e.g., cells that have incorporated the selectable marker gene will survive, while the other cells die).

15        A host cell of the invention, such as a prokaryotic or eukaryotic host cell in culture, can be used to produce (i.e., express) a NF-HEV protein. Accordingly, the invention further provides methods for producing a NF-HEV protein using the host cells of the invention. In one embodiment, the method comprises culturing the host cell of invention (into which a recombinant expression vector encoding a NF-HEV protein has been introduced) in a suitable  
20        medium such that a NF-HEV protein is produced. In another embodiment, the method further comprises isolating a NF-HEV protein from the medium or the host cell.

      In another embodiment, the invention encompasses providing a cell capable of expressing a NF-HEV protein, culturing said cell in a suitable medium such that a NF-HEV protein is produced, and isolating or purifying the NF-HEV protein from the medium or cell.

25        The host cells of the invention can also be used to produce nonhuman transgenic animals. Transgenic animals (for example an animal having a disrupted NF-HEV gene) may be useful for examining the development of HEV-like vessels. For example, in one embodiment, a host cell of the invention is a fertilized oocyte or an embryonic stem cell into which NF-HEV-coding sequences have been introduced. Such host cells can then be used to  
30        create non-human transgenic animals in which exogenous NF-HEV sequences have been

introduced into their genome or homologous recombinant animals in which endogenous NF-HEV sequences have been altered. Such animals are useful for studying the function and/or activity of a NF-HEV polypeptide or fragment thereof and for identifying and/or evaluating modulators of NF-HEV activity. As used herein, a "transgenic animal" is a non-human animal, preferably a mammal, more preferably a rodent such as a rat or mouse, in which one or more of the cells of the animal includes a transgene. Other examples of transgenic animals include non-human primates, sheep, dogs, cows, goats, chickens, amphibians, etc. A transgene is exogenous DNA which is integrated into the genome of a cell from which a transgenic animal develops and which remains in the genome of the mature animal, thereby directing the expression of an encoded gene product in one or more cell types or tissues of the transgenic animal. As used herein, a "homologous recombinant animal" is a non-human animal, preferably a mammal, more preferably a mouse, in which an endogenous NF-HEV gene has been altered by homologous recombination between the endogenous gene and an exogenous DNA molecule introduced into a cell of the animal, e.g., an embryonic cell of the animal, prior to development of the animal.

A transgenic animal of the invention can be created by introducing a NF-HEV-encoding nucleic acid into the male pronuclei of a fertilized oocyte, e.g., by microinjection or retroviral infection, and allowing the oocyte to develop in a pseudopregnant female foster animal. The NF-HEV cDNA sequence or a fragment thereof such as a sequence of SEQ ID NO 1 can be introduced as a transgene into the genome of a non-human animal. Alternatively, a nonhuman homologue of a human NF-HEV gene, such as a mouse or rat NF-HEV gene of SEQ ID NO 2, can be used as a transgene. Intronic sequences and polyadenylation signals can also be included in the transgene to increase the efficiency of expression of the transgene. A tissue-specific regulatory sequence(s) can be operably linked to a NF-HEV transgene to direct expression of a NF-HEV protein to particular cells. Methods for generating transgenic animals via embryo manipulation and microinjection, particularly animals such as mice, have become conventional in the art and are described, for example, in U.S. Pat. Nos. 4,736,866 and 4,870,009, both by Leder et al., U.S. Pat. No. 4,873,191 by Wagner et al. and in Hogan, B., Manipulating the Mouse Embryo, (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1986, the disclosure of which is incorporated

herein by reference in its entirety). Similar methods are used for production of other transgenic animals. A transgenic founder animal can be identified based upon the presence of a NF-HEV transgene in its genome and/or expression of NF-HEV mRNA in tissues or cells of the animals. A transgenic founder animal can then be used to breed additional animals carrying the transgene. Moreover, transgenic animals carrying a transgene encoding a NF-HEV protein can further be bred to other transgenic animals carrying other transgenes.

To create an animal in which a desired nucleic acid has been introduced into the genome via homologous recombination, a vector is prepared which contains at least a portion of a NF-HEV gene into which a deletion, addition or substitution has been introduced to thereby alter, e.g., functionally disrupt, the NF-HEV gene. The NF-HEV gene can be a human gene (e.g., the cDNA of SEQ ID NO 1), but more preferably, is a non-human homologue of a human NF-HEV gene (e.g., a cDNA isolated by stringent hybridization with a nucleotide sequence of SEQ ID NO 1). For example, a mouse NF-HEV gene of SEQ ID NO 2 can be used to construct a homologous recombination vector suitable for altering an endogenous NF-HEV gene in the mouse genome. In a preferred embodiment, the vector is designed such that, upon homologous recombination, the endogenous NF-HEV gene is functionally disrupted (i.e., no longer encodes a functional protein; also referred to as a "knock out" vector). Alternatively, the vector can be designed such that, upon homologous recombination, the endogenous NF-HEV gene is mutated or otherwise altered but still encodes functional protein (e.g., the upstream regulatory region can be altered to thereby alter the expression of the endogenous NF-HEV protein). In the homologous recombination vector, the altered portion of the NF-HEV gene is flanked at its 5' and 3' ends by additional nucleic acid sequence of the NF-HEV gene to allow for homologous recombination to occur between the exogenous NF-HEV gene carried by the vector and an endogenous NF-HEV gene in an embryonic stem cell. The additional flanking NF-HEV nucleic acid sequence is of sufficient length for successful homologous recombination with the endogenous gene. Typically, several kilobases of flanking DNA (both at the 5' and 3' ends) are included in the vector (see e.g., Thomas, K. R. and Capecchi, M. R. (1987) Cell 51:503, the disclosure of which is incorporated herein by reference in its entirety, for a description of homologous recombination vectors). The vector is introduced into an embryonic stem cell line (e.g., by

electroporation) and cells in which the introduced NF-HEV gene has homologously recombined with the endogenous NF-HEV gene are selected (see e.g., Li, E. et al. (1992) Cell 69:915, the disclosure of which is incorporated herein by reference in its entirety). The selected cells are then injected into a blastocyst of an animal (e.g., a mouse) to form aggregation chimeras (see e.g., Bradley, A. in Teratocarcinomas and Embryonic Stem Cells. A Practical Approach, E. J. Robertson, ed. (IRL, Oxford, 1987) pp. 113-152, the disclosure of which is incorporated herein by reference in its entirety). A chimeric embryo can then be implanted into a suitable pseudopregnant female foster animal and the embryo brought to term. Progeny harboring the homologously recombined DNA in their germ cells can be used to breed animals in which all cells of the animal contain the homologously recombined DNA by germline transmission of the transgene. Methods for constructing homologous recombination vectors and homologous recombinant animals are described further in Bradley, A. (1991) Current Opinion in Biotechnology 2:823-829 and in PCT International Publication Nos.: WO 90/11354 by Le Mouellec et al.; WO 91/01140 by Smithies et al.; WO 92/0968 by Zijlstra et al.; and WO 93/04169 by Berns et al., the disclosures of which are incorporated herein by reference in their entireties.

In another embodiment, transgenic non-human animals can be produced which contain selected systems which allow for regulated expression of the transgene. One example of such a system is the cre/loxP recombinase system of bacteriophage P1. For a description of the cre/loxP recombinase system, see, e.g., Lakso et al. (1992) PNAS 89:6232-6236, the disclosure of which is incorporated herein by reference in its entirety. Another example of a recombinase system is the FLP recombinase system of *Saccharomyces cerevisiae* (O'Gorman et al. (1991) Science 251:1351-1355, the disclosure of which is incorporated herein by reference in its entirety). If a cre/loxP recombinase system is used to regulate expression of the transgene, animals containing transgenes encoding both the Cre recombinase and a selected protein are required. Such animals can be provided through the construction of "double" transgenic animals, e.g., by mating two transgenic animals, one containing a transgene encoding a selected protein and the other containing a transgene encoding a recombinase.

30

### *Drug Screening Assays*

The invention provides a method (also referred to herein as a "screening assay") for identifying inhibitors, i.e., candidate or test compounds or agents (e.g., preferably small molecules, but also peptides, peptidomimetics or other drugs) which bind to NF-HEV proteins, have an inhibitory or activating effect on, for example, NF-HEV expression or preferably NF-HEV activity, or have an inhibitory or activating effect on, for example, the activity of an NF-HEV target molecule. In some embodiments small molecules can be generated using combinatorial chemistry or can be obtained from a natural products library. Assays may be cell based or non-cell based assays. Drug screening assays may be binding assays or more preferentially functional assays, as further described.

Particularly preferred compounds will be those useful in inhibiting or promoting the actions of NF-HEV in regulating chronic inflammation, particularly in regulating the proinflammatory potential of an endothelial cell. Compounds may be useful in inhibiting or promoting the actions of NF-HEV in regulating the expression of proteins involved in inflammation. Compounds may also be useful in inhibiting or promoting the actions of NF-HEV in regulating the development and differentiation of endothelial cells or HEVECs. In the screening assays of the present invention, the candidate substance may first be screened for basic biochemical activity - e.g., binding to a target molecule - and then tested for its ability to modulate activity, at the cellular, tissue or whole animal level. The invention thus encompasses compounds capable of inhibiting or activating activity of the NF-HEV protein. Preferably, a NF-HEV inhibitor or activator is a selective NF-HEV inhibitor or activator.

In one aspect, a test compound may be identified based on binding to NF-HEV. One technique for high throughput screening of compounds is described in WO 84/03564. Large numbers of small peptide test compounds are synthesized on a solid substrate, such as plastic pins or some other surface. The peptide test compounds are reacted with, for example, NF-HEV and washed. Bound polypeptide is detected by various methods. Purified polypeptide, such as NF-HEV, can be coated directly onto plates for use in the aforementioned drug screening techniques. Alternatively, non-neutralizing antibodies to the polypeptide can be used to immobilize the polypeptide to a solid phase. Also, fusion proteins containing a reactive region (preferably a terminal region) may be used to link an active region (e.g., the



C-terminus of NF-HEV) to a solid phase. Thus, in one embodiment, the present invention is directed to a method comprising: (a) providing a NF-HEV polypeptide; (b) contacting the NF-HEV polypeptide with a candidate substance; and (c) determining the binding of the candidate substance to NF-HEV polypeptide.

5 In preferred embodiments, an assay is a cell-based assay in which a cell which expresses a NF-HEV protein or biologically active portion thereof is contacted with a test compound and the ability of the test compound to inhibit, activate, or increase NF-HEV activity determined. Determining the ability of the test compound to inhibit, activate, or increase NF-HEV activity can be accomplished by monitoring the bioactivity of the NF-HEV  
10 protein or biologically active portion thereof. The cell, for example, can be of mammalian origin, bacterial origin or a yeast cell.

In one aspect, modulating inflammation comprises modulating transcription of genes involved in a pro-inflammatory pathway. In another aspect, modulating inflammation and/or modulating the endothelial cell or HEVEC phenotype comprises modulating transcription of  
15 genes involved in regulation (e.g. preferably involved in differentiation, proliferation or maintainance) of the endothelial cell, or preferably HEVEC, phenotype. Thus, in preferred aspects, the invention involves methods of screening that comprise measuring the effect of the candidate substance on the expression of an endothelial cell or HEVEC marker or any marker generally characterized as related to cells from HEV-like vessels. In one aspect, the  
20 invention comprises: (a) introducing to the cell an inhibitor of an NF-HEV polypeptide; (b) optionally, providing to the cell a NF-HEV polypeptide; (c) optionally, providing to the cell a polynucleotide encoding an additional polypeptide factor, preferably a transcription factor; and (d) detecting expression or transcription of an endothelial cell or HEVEC marker. More preferably, the screening method comprises: (a) introducing to the cell an inhibitor of an NF-  
25 HEV polypeptide; (b) optionally, introducing to a cell an expression cassette comprising a polynucleotide encoding a NF-HEV polypeptide operatively linked to a promoter capable of directing of expression of the polypeptide; (c) optionally, introducing to a cell an expression cassette comprising a polynucleotide encoding an additional polypeptide factor, preferably a transcription factor, said polynucleotide operatively linked to a promoter capable of directing

of expression of the polypeptide; and (d) detecting expression or transcription of an endothelial cell or HEVEC marker.

In one aspect of the methods, the expression of an endothelial cell or HEVEC mRNA or polypeptide is detected. For example, staining by the HEV-specific MECA-79 sulfated epitope (Michie et al. (1993) *Am J Pathol* 143:1688-1698; Streeter et al. (1988) *J Cell Biol* 107:1853-1862) or the HECA-452-fucosylated epitope (Duijvestijn et al. (1988) *Am J Pathol* 130:147-155) can be used to detect HEVECs. In another example, hybridization of a nucleic acid probe having a sequence complementary to the L-selectin ligand N-acetyl-glucosamine-6-O-sulfotransferase (LSST) (Bistrup et al. (1999) *J Cell Biol* 145:899-910; Hemmerich et al. (2001) *Immunity* 15:237-47.; Hiraoka et al. (1999) *Immunity* 11:79-89), the fucosyltransferase FucTVII (Maly et al. (1996) *Cell* 86:643-653; Smith et al. (1996) *J Biol Chem* 271:8250-8259), the chemokine CCL21 (SLC/6CKine/TCA-4/exodus-2) (Gunn et al. (1998) *Proc Natl Acad Sci U S A* 95:258-63) or the SPARC-like antiadhesive matricellular protein hevin (Girard and Springer (1995) *Immunity* 2:113-123; Girard and Springer (1996) *J Biol Chem* 271:4511-4517) mRNA can be detected. In another example, the method comprises introducing to the cell an expression cassette comprising a polynucleotide encoding a detectable polypeptide operatively linked to a transcriptional regulatory sequence of a gene encoding an endothelial cell or HEVEC marker. The effects of an inhibitor of NF-HEV on transcription of an endothelial cell or HEVEC marker can then be determined by assessing expression of the detectable polypeptide.

In one example, determining the ability of the test compound to inhibit or increase NF-HEV activity can be accomplished, by coupling the NF-HEV protein or biologically active portion thereof with a radioisotope or enzymatic label such that binding of the NF-HEV protein or biologically active portion thereof to its cognate target molecule can be determined by detecting the labeled NF-HEV protein or biologically active portion thereof in a complex. For example, compounds (e.g., NF-HEV protein or biologically active portion thereof) can be labeled with  $^{125}\text{I}$ ,  $^{35}\text{S}$ ,  $^{14}\text{C}$ , or  $^3\text{H}$ , either directly or indirectly, and the radioisotope detected by direct counting of radioemission or by scintillation counting. Alternatively, compounds can be enzymatically labeled with, for example, horseradish peroxidase, alkaline phosphatase, or luciferase, and the enzymatic label detected by

determination of conversion of an appropriate substrate to product. The labeled molecule is placed in contact with its cognate molecule and the extent of complex formation is measured. For example, the extent of complex formation may be measured by immunoprecipitating the complex or by performing gel electrophoresis.

5           It is also within the scope of this invention to determine the ability of a compound (e.g., NF-HEV protein or biologically active portion thereof) to interact with its cognate target molecule without the labeling of any of the interactants. For example, a microphysiometer can be used to detect the interaction of a compound with its cognate target molecule without the labeling of either the compound or the target molecule. McConnell, H.  
10 M. et al. (1992) Science 257:1906-1912, the disclosure of which is incorporated herein by reference in its entirety. A microphysiometer such as a cytosensor is an analytical instrument that measures the rate at which a cell acidifies its environment using a light-addressable potentiometric sensor (LAPS). Changes in this acidification rate can be used as an indicator of the interaction between compound and receptor.

15           In a preferred embodiment, the assay comprises contacting a cell which expresses a NF-HEV protein or biologically active portion thereof, with a target molecule to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to inhibit or increase the activity of the NF-HEV protein or biologically active portion thereof, wherein determining the ability of the test compound to inhibit or  
20 increase the activity of the NF-HEV protein or biologically active portion thereof, comprises determining the ability of the test compound to inhibit or increase a biological activity of the NF-HEV expressing cell (e.g., determining the ability of the test compound to inhibit or increase transcription of a target nucleic acid, protein:protein interaction, nucleic acid binding).

25           In another preferred embodiment, the assay comprises contacting a cell which is responsive to a NF-HEV protein or biologically active portion thereof, with a NF-HEV protein or biologically-active portion thereof, to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to modulate the activity of the NF-HEV protein or biologically active portion thereof, wherein  
30 determining the ability of the test compound to modulate the activity of the NF-HEV protein

or biologically active portion thereof comprises determining the ability of the test compound to modulate a biological activity of the NF-HEV-responsive cell.

In another embodiment, an assay is a cell-based assay comprising contacting a cell expressing a NF-HEV target molecule (i.e. a molecule with which NF-HEV interacts) with a test compound and determining the ability of the test compound to modulate (e.g. stimulate or inhibit) the activity of the NF-HEV target molecule. Determining the ability of the test compound to modulate the activity of a NF-HEV target molecule can be accomplished, for example, by determining the ability of the NF-HEV protein to bind to or interact with the NF-HEV target molecule. An NF-HEV inhibitor may be capable of inhibiting or increasing the activity of or binding to more than one (e.g. at least two, three, four) nuclear factor proteins.

Determining the ability of the NF-HEV protein to bind to or interact with a NF-HEV target molecule can be accomplished by one of the methods described above for determining direct binding. In a preferred embodiment, determining the ability of the NF-HEV protein to bind to or interact with a NF-HEV target molecule can be accomplished by determining the activity of the target molecule. For example, the activity of the target molecule can be determined by contacting the target molecule with the NF-HEV protein or a fragment thereof and measuring induction of a cellular second messenger of the target (i.e. intracellular  $Ca^{2+}$ , diacylglycerol, IP3, etc.), detecting catalytic/enzymatic activity of the target on an appropriate substrate, detecting the induction of a reporter gene (comprising a target-responsive regulatory element operatively linked to a nucleic acid encoding a detectable marker, e.g., luciferase), or detecting a target-regulated cellular response, for example, signal transduction or protein:protein interactions.

In yet another embodiment, an assay of the present invention is a cell-free assay in which a NF-HEV protein or biologically active portion thereof is contacted with a test compound and the ability of the test compound to bind to the NF-HEV protein or biologically active portion thereof is determined. Binding of the test compound to the NF-HEV protein can be determined either directly or indirectly as described above. In a preferred embodiment, the assay includes contacting the NF-HEV protein or biologically active portion thereof with a known compound which binds NF-HEV (e.g., a NF-HEV target molecule) to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of

the test compound to interact with a NF-HEV protein, wherein determining the ability of the test compound to interact with a NF-HEV protein comprises determining the ability of the test compound to preferentially bind to NF-HEV or biologically active portion thereof as compared to the known compound.

5           In another embodiment, the assay is a cell-free assay in which a NF-HEV protein or biologically active portion thereof is contacted with a test compound and the ability of the test compound to modulate (e.g., stimulate or inhibit) the activity of the NF-HEV protein or biologically active portion thereof is determined. Determining the ability of the test compound to modulate the activity of a NF-HEV protein can be accomplished, for example,  
10 by determining the ability of the NF-HEV protein to bind to a NF-HEV target molecule by one of the methods described above for determining direct binding. Determining the ability of the NF-HEV protein to bind to a NF-HEV target molecule can also be accomplished using a technology such as real-time Biomolecular Interaction Analysis (BIA). Sjolander, S. and Urbaniczky, C. (1991) Anal. Chem. 63:2338-2345 and Szabo et al. (1995) Curr. Opin. Struct.  
15 Biol. 5:699-705, the disclosures of which are incorporated herein by reference in their entireties. As used herein, "BIA" is a technology for studying biospecific interactions in real time, without labeling any of the interactants (e.g., BIAcore). Changes in the optical phenomenon of surface plasmon resonance (SPR) can be used as an indication of real-time reactions between biological molecules.

20           In an alternative embodiment, determining the ability of the test compound to modulate the activity of a NF-HEV protein can be accomplished by determining the ability of the NF-HEV protein to further modulate the activity of a downstream effector (e.g., a component of a transcription regulation pathway) of a NF-HEV target molecule. For example, the activity of the effector molecule on an appropriate target can be determined or  
25 the binding of the effector to an appropriate target can be determined as previously described.

          In yet another embodiment, the cell-free assay involves contacting a NF-HEV protein or biologically active portion thereof with a known compound which binds the NF-HEV protein to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with the NF-HEV protein, wherein  
30 determining the ability of the test compound to interact with the NF-HEV protein comprises

determining the ability of the NF-HEV protein to preferentially bind to or modulate the activity of a NF-HEV target molecule.

The cell-free assays of the present invention are amenable to use of both soluble and/or membrane-bound forms of isolated proteins (e.g. NF-HEV proteins or biologically active portions thereof or molecules to which NF-HEV targets bind). In the case of cell-free assays in which a membrane-bound form of an isolated protein is used it may be desirable to utilize a solubilizing agent such that the membrane-bound form of the isolated protein is maintained in solution. Examples of such solubilizing agents include non-ionic detergents such as n-octylglucoside, n-dodecylglucoside, n-dodecylmaltoside, octanoyl-N-methylglucamide, decanoyl-N-methylglucamide, Triton™ X-100, Triton™ X-114, Thesit™, Isotridecypoly(ethylene glycol ether)n, 3-[(3-cholamidopropyl)dimethylamminio]-1-propane sulfonate (CHAPS), 3-[(3-cholamidopropyl)dimethylamminio]-2-hydroxy-1-propane sulfonate (CHAPSO), or N-dodecyl-N,N-dimethyl-3-ammonio-1-propane sulfonate.

In more than one embodiment of the above assay methods of the present invention, it may be desirable to immobilize either NF-HEV or its target molecule to facilitate separation of complexed from uncomplexed forms of one or both of the proteins, as well as to accommodate automation of the assay. Binding of a test compound to a NF-HEV protein, or interaction of a NF-HEV protein with a target molecule in the presence and absence of a candidate compound, can be accomplished in any vessel suitable for containing the reactants. Examples of such vessels include microtitre plates, test tubes, and micro-centrifuge tubes. In one embodiment, a fusion protein can be provided which adds a domain that allows one or both of the proteins to be bound to a matrix. For example, glutathione-S-transferase/NF-HEV fusion proteins or glutathione-S-transferase/target fusion proteins can be adsorbed onto glutathione sepharose beads (Sigma Chemical, St. Louis, Mo.) or glutathione derivatized microtitre plates, which are then combined with the test compound or the test compound and either the non-adsorbed target protein or NF-HEV protein, and the mixture incubated under conditions conducive to complex formation (e.g., at physiological conditions for salt and pH). Following incubation, the beads or microtitre plate wells are washed to remove any unbound components, the matrix immobilized in the case of beads, complex determined either directly or indirectly, for example, as described above. Alternatively, the complexes can be

dissociated from the matrix, and the level of NF-HEV binding or activity determined using standard techniques.

Other techniques for immobilizing proteins on matrices can also be used in the screening assays of the invention. For example, either a NF-HEV protein or a NF-HEV target molecule can be immobilized utilizing conjugation of biotin and streptavidin. Biotinylated NF-HEV protein or target molecules can be prepared from biotin-NHS (N-hydroxy-succinimide) using techniques well known in the art (e.g., biotinylation kit, Pierce Chemicals, Rockford, Ill.), and immobilized in the wells of streptavidin-coated 96 well plates (Pierce Chemical). Alternatively, antibodies reactive with NF-HEV protein or target molecules but which do not interfere with binding of the NF-HEV protein to its target molecule can be derivatized to the wells of the plate, and unbound target or NF-HEV protein trapped in the wells by antibody conjugation. Methods for detecting such complexes, in addition to those described above for the GST-immobilized complexes, include immunodetection of complexes using antibodies reactive with the NF-HEV protein or target molecule, as well as enzyme-linked assays which rely on detecting an enzymatic activity associated with the NF-HEV protein or target molecule.

In yet another aspect of the invention, the NF-HEV proteins can be used as "bait proteins" in a two-hybrid assay or three-hybrid assay (see, e.g., U.S. Pat. No. 5,283,317; Zervos et al. (1993) *Cell* 72:223-232; Madura et al. (1993) *J. Biol. Chem.* 268:12046-12054; Bartel et al. (1993) *Biotéchniques* 14:920-924; Iwabuchi et al. (1993) *Oncogene* 8:1693-1696; and Brent WO94/10300, the disclosures of which are incorporated herein by reference in their entireties), to identify other proteins, which bind to or interact with NF-HEV ("NF-HEV-binding proteins" or "NF-HEV-bp") and are involved in NF-HEV activity. Such NF-HEV-binding proteins are also likely to be involved in the propagation of signals by the NF-HEV proteins or NF-HEV targets as, for example, downstream elements of a NF-HEV-mediated signalling pathway or transcription system. Alternatively, such NF-HEV-binding proteins are likely to be NF-HEV inhibitors.

The two-hybrid system is based on the modular nature of most transcription factors, which consist of separable DNA-binding and activation domains. Briefly, the assay utilizes two different DNA constructs. In one construct, the gene that codes for a NF-HEV protein or

a fragment thereof is fused to a gene encoding the DNA binding domain of a known transcription factor (e.g., GAL-4). In the other construct, a DNA sequence, from a library of DNA sequences, that encodes an unidentified protein ("prey" or "sample") is fused to a gene that codes for the activation domain of the known transcription factor. If the "bait" and the "prey" proteins are able to interact, in vivo, forming a NF-HEV-dependent complex, the DNA-binding and activation domains of the transcription factor are brought into close proximity. This proximity allows transcription of a reporter gene (e.g., LacZ) which is operably linked to a transcriptional regulatory site responsive to the transcription factor. Expression of the reporter gene can be detected and cell colonies containing the functional transcription factor can be isolated and used to obtain the cloned gene which encodes the protein which interacts with the NF-HEV protein.

In another embodiment, a NF-HEV target molecule is a nucleic acid (e.g. DNA). Assays of the invention are used to identify compounds that interfere with nucleic acid binding activity of NF-HEV, comprising the steps of: contacting a NF-HEV protein or a portion thereof comprising the DNA-binding domain immobilized on a solid support with both a test compound and polynucleotide fragments, or contacting a polynucleotide fragment immobilized on a solid support with both a test compound and a NF-HEV protein. The binding between the DNA and the NF-HEV-protein or portion thereof is detected, wherein a decrease in DNA binding when compared to polynucleotide binding in the absence of the test compound indicates that the test compound is an inhibitor of DNA binding activity, and an increase in DNA binding when compared to DNA binding in the absence of the test compound indicates that the test compound is an inducer of or restores NF-HEV DNA binding activity. As discussed further, DNA fragments may be selected to be specific NF-HEV protein target DNA obtained for example as described in Example 8, or may be non-specific NF-HEV target DNA. Methods for detecting protein-DNA interactions are well known in the art, including most commonly used electrophoretic mobility shift assays (EMSAs) or by filter binding (Zabel et al, (1991) J. Biol. Chem., 266:252; and Okamoto and Beach, (1994) Embo J. 13: 4816). Other assays are available which are amenable for high throughput detection and quantification of specific and nonspecific DNA binding



(Amersham, N.J.; and Gal S. et al, 6<sup>th</sup> Ann. Conf. Soc. Biomol. Screening, 6-9 Sept 2000, Vancouver, B.C.)

In a first aspect, a screening assay involves identifying compounds which interfere with NF-HEV DNA binding activity without prior knowledge about specific NF-HEV binding sequences. For example, a NF-HEV protein is contacted with both a test compound and a library of oligonucleotides or a sample of DNA fragments not selected based on specific DNA sequences. Preferably the NF-HEV protein is immobilized on a solid support (such as an array or a column). Unbound DNA is separated from DNA which is bound to the NF-HEV-family protein, and the DNA which is bound to NF-HEV protein is detected and can be quantitated by any means known in the art. For example, the DNA fragment is labelled with a detectable moiety, such as a radioactive moiety, a colorimetric moiety or a fluorescent moiety. Techniques for so labelling DNA are well known in the art.

The DNA which is bound to the NF-HEV protein or a portion thereof is separated from unbound DNA by immunoprecipitation with antibodies which are specific for the NF-HEV protein or a portion thereof. Use of two different monoclonal anti-NF-HEV antibodies may result in more complete immunoprecipitation than either one alone. The amount of DNA which is in the immunoprecipitate can be quantitated by any means known in the art. NF-HEV proteins or portions thereof which bind to the DNA can also be detected by gel shift assays (Tan, Cell, 62:367, 1990), nuclease protection assays, or methylase interference assays.

It is still another object of the invention to provide methods for identifying compounds which restore or the ability of mutant NF-HEV proteins or portions thereof or increase the ability of wild-type NF-HEV proteins to bind to DNA sequences. In one embodiment a method of screening agents for use in therapy is provided comprising: measuring the amount of binding of a NF-HEV protein or a portion thereof which is encoded by a mutant gene found in cells of a patient to DNA molecules, preferably random oligonucleotides or DNA fragments from a nucleic acid library; measuring the amount of binding of said NF-HEV protein or a portion thereof to said nucleic acid molecules in the presence of a test substance; and comparing the amount of binding of the NF-HEV protein or a portion thereof in the presence of said test substance to the amount of binding of the NF-

HEV protein in the absence of said test substance, a test substance which increases the amount of binding being a candidate for use in therapy. In another embodiment of the invention, oligonucleotides can be isolated which restore or increase to NF-HEV proteins or portions thereof the ability to bind to a consensus binding sequence or conforming sequences.

5 NF-HEV protein or a portion thereof and random oligonucleotides are added to a solid support on which NF-HEV-specific DNA fragments are immobilized. Oligonucleotides which bind to the solid support are recovered and analyzed. Those whose binding to the solid support is dependent on the presence of the NF-HEV protein are presumptively binding the support by binding to and restoring the conformation of the mutant protein.

10 If desired, specific binding can be distinguished from non-specific binding by any means known in the art. For example, specific binding interactions are stronger than non-specific binding interactions. Thus the incubation mixture can be subjected to any agent or condition which destabilizes protein/DNA interactions such that the specific binding reaction is the predominant one detected. Alternatively, as taught more specifically below, a non-  
15 specific competitor, such as dI-dC, can be added to the incubation mixture. If the DNA containing the specific binding sites is labelled and the competitor is unlabeled, then the specific binding reactions will be the ones predominantly detected upon measuring labelled DNA.

According to another embodiment of the invention, after incubation of NF-HEV  
20 protein or a portion thereof with specific DNA fragments all components of the cell lysate which do not bind to the DNA fragments are removed. This can be accomplished, among other ways, by employing DNA fragments which are attached to an insoluble polymeric support such as agarose, cellulose and the like. After binding, all non-binding components can be washed away, leaving NF-HEV protein or a portion thereof bound to the DNA/solid  
25 support. The NF-HEV protein or a portion thereof can be quantitated by any means known in the art. It can be determined using an immunological assay, such as an ELISA, RIA or Western blotting.

In another embodiment of the invention a method is provided for identifying compounds which specifically bind to NF-HEV-specific-DNA sequences, comprising the  
30 steps of: contacting a NF-HEV-specific DNA fragment immobilized on a solid support with

both a test compound and wild-type NF-HEV protein or a portion thereof to bind the wild-type NF-HEV protein or a portion thereof to the DNA fragment; determining the amount of wild-type NF-HEV protein which is bound to the DNA fragment, inhibition of binding of wild-type NF-HEV protein by the test compound with respect to a control lacking the test compound suggesting binding of the test compound to the NF-HEV-specific DNA binding sequences.

It is still another object of the invention to provide methods for identifying compounds which restore the ability of mutant NF-HEV proteins or portions thereof to bind to specific DNA binding sequences. In one embodiment a method of screening agents for use in therapy is provided comprising: measuring the amount of binding of a NF-HEV protein or a portion thereof which is encoded by a mutant gene found in cells of a patient to a DNA molecule which comprises more than one monomer of a specific NF-HEV target nucleotide sequence; measuring the amount of binding of said NF-HEV protein to said nucleic acid molecule in the presence of a test substance; and comparing the amount of binding of the NF-HEV protein in the presence of said test substance to the amount of binding of the NF-HEV protein or a portion thereof in the absence of said test substance, a test substance which increases the amount of binding being a candidate for use in therapy.

In another embodiment of the invention a method is provided for screening agents for use in therapy comprising: contacting a transfected cell with a test substance, said transfected cell containing a NF-HEV protein or a portion thereof which is encoded by a mutant gene found in cells of a patient and a reporter gene construct comprising a reporter gene which encodes an assayable product and a sequence which conforms to a NF-HEV DNA binding site, wherein said sequence is upstream from and adjacent to said reporter gene; and determining whether the amount of expression of said reporter gene is altered by the test substance, a test substance which alters the amount of expression of said reporter gene being a candidate for use in therapy.

In still another embodiment a method of screening agents for use in therapy is provided comprising: adding RNA polymerase ribonucleotides and a NF-HEV protein or a portion thereof to a transcription construct, said transcription construct comprising a reporter gene which encodes an assayable product and a sequence which conforms to a NF-HEV

consensus binding site, said sequence being upstream from and adjacent to said reporter gene, said step of adding being effected in the presence and absence of a test substance; determining whether the amount of transcription of said reporter gene is altered by the presence of said test substance, a test substance which alters the amount of transcription of said reporter gene being a candidate for use in therapy.

According to the present invention compounds which have NF-HEV activity are those which specifically complex with a NF-HEV-specific DNA binding site. Oligonucleotides and oligonucleotide containing nucleotide analogs are also contemplated among those compounds which are able to complex with a NF-HEV-specific DNA binding site.

In still yet other embodiments, one would look at the effect of a candidate substance on the expression of NF-HEV. This can be done by examining mRNA expression, although alterations in mRNA stability and translation would not be accounted for. A more direct way of assessing expression is by directly examining protein levels, for example, through Western blot or ELISA.

Preferably, modulators of NF-HEV expression are identified in a method wherein a cell is contacted with a candidate compound and the expression of NF-HEV mRNA or protein in the cell is determined. The level of expression of NF-HEV mRNA or protein in the presence of the candidate compound is compared to the level of expression of NF-HEV mRNA or protein in the absence of the candidate compound. The candidate compound can then be identified as a modulator of NF-HEV expression based on this comparison. For example, when expression of NF-HEV mRNA or protein is greater (statistically significantly greater) in the presence of the candidate compound than in its absence, the candidate compound is identified as a stimulator of NF-HEV mRNA or protein expression. Alternatively, when expression of NF-HEV mRNA or protein is less (statistically significantly less) in the presence of the candidate compound than in its absence, the candidate compound is identified as an inhibitor of NF-HEV mRNA or protein expression. The level of NF-HEV mRNA or protein expression can be determined by methods described herein for detecting NF-HEV mRNA or protein.

Another subject of the present invention is therefore a method for screening molecules that modulate the expression of the NF-HEV protein. Such a screening method

comprises the steps of: (a) cultivating a prokaryotic or an eukaryotic cell that has been transfected with a nucleotide sequence encoding the NF-HEV protein or a variant or a fragment thereof, placed under the control of its own promoter; (b) bringing into contact the cultivated cell with a molecule to be tested; and (c) quantifying the expression of the NF-HEV protein or a variant or a fragment thereof.

Using DNA recombination techniques well known by the one-skill in the art, the NF-HEV protein encoding DNA sequence is inserted into an expression vector, downstream from its promoter sequence. As an illustrative example, the promoter sequence of the NF-HEV gene is contained in the nucleic acid of the 5' regulatory region.

The quantification of the expression of the NF-HEV protein may be realized either at the mRNA level or at the protein level. In the latter case, polyclonal or monoclonal antibodies may be used to quantify the amounts of the NF-HEV protein that have been produced, for example in an ELISA or a RIA assay. In a preferred embodiment, the quantification of the NF-HEV mRNA is realized by a quantitative PCR amplification of the cDNA obtained by a reverse transcription of the total mRNA of the cultivated NF-HEV - transfected host cell, using a pair of primers specific for NF-HEV.

The present invention also concerns a method for screening substances or molecules that are able to increase, or in contrast to decrease, the level of expression of the NF-HEV gene.

Thus, also part of the present invention is a method for screening of a candidate substance or molecule that modulated the expression of the NF-HEV gene, this method comprises the following steps: providing a recombinant cell host containing a nucleic acid, wherein said nucleic acid comprises a nucleotide sequence of the 5' regulatory region or a biologically active fragment or variant thereof located upstream a polynucleotide encoding a detectable protein; obtaining a candidate substance; and determining the ability of the candidate substance to modulate the expression levels of the polynucleotide encoding the detectable protein.

In a further embodiment, the nucleic acid comprising the nucleotide sequence of the 5' regulatory region or a biologically active fragment or variant thereof also includes a

5'UTR region of the NF-HEV cDNA, or one of its biologically active fragments or variants thereof.

Among the preferred polynucleotides encoding a detectable protein, there may be cited polynucleotides encoding beta galactosidase, green fluorescent protein (GFP) and chloramphenicol acetyl transferase (CAT).

The invention also pertains to kits useful for performing the herein described screening method. Preferably, such kits comprise a recombinant vector that allows the expression of a nucleotide sequence of the 5' regulatory region or a biologically active fragment or variant thereof located upstream and operably linked to a polynucleotide encoding a detectable protein or the NF-HEV protein or a fragment or a variant thereof.

In another embodiment of a method for the screening of a candidate substance or molecule that modulates the expression of the NF-HEV gene, wherein said method comprises the following steps: (a) providing a recombinant host cell containing a nucleic acid, wherein said nucleic acid comprises a 5'UTR sequence of the NF-HEV cDNA, or one of its biologically active fragments or variants, the 5'UTR sequence or its biologically active fragment or variant being operably linked to a polynucleotide encoding a detectable protein; (b) obtaining a candidate substance; and (c) determining the ability of the candidate substance to modulate the expression levels of the polynucleotide encoding the detectable protein.

In a specific embodiment of the above screening method, the nucleic acid that comprises a nucleotide sequence selected from the group consisting of the 5'UTR sequence of the NF-HEV cDNA or one of its biologically active fragments or variants, includes a promoter sequence which is endogenous with respect to the NF-HEV 5'UTR sequence. In another specific embodiment of the above screening method, the nucleic acid that comprises a nucleotide sequence selected from the group consisting of the 5'UTR sequence of the NF-HEV cDNA or one of its biologically active fragments or variants, includes a promoter sequence which is exogenous with respect to the NF-HEV 5'UTR sequence defined therein.

The invention further comprises with a kit for the screening of a candidate substance modulating the expression of the NF-HEV gene, wherein said kit comprises a recombinant vector that comprises a nucleic acid including a 5'UTR sequence of the NF-HEV cDNA, or one of their biologically active fragments or variants, the 5'UTR sequence or its biologically

active fragment or variant being operably linked to a polynucleotide encoding a detectable protein.

For the design of suitable recombinant vectors useful for performing the screening methods described above, it will be referred to the section of the present specification wherein the preferred recombinant vectors of the invention are detailed.

Expression levels and patterns of NF-HEV may be analyzed by solution hybridization with long probes as described in International Patent Application No. WO 97/05277, the entire contents of which are incorporated herein by reference. Briefly, a NF-HEV cDNA or NF-HEV genomic DNA, or a fragment thereof, is inserted at a cloning site immediately downstream of a bacteriophage (T3, T7 or SP6) RNA polymerase promoter to produce antisense RNA. Preferably, the NF-HEV insert comprises at least 100 or more consecutive nucleotides of the genomic DNA sequence or the cDNA sequences. The plasmid is linearized and transcribed in the presence of ribonucleotides comprising modified ribonucleotides (i.e. biotin-UTP and DIG-UTP). An excess of this doubly labeled RNA is hybridized in solution with mRNA isolated from cells or tissues of interest. The hybridization is performed under standard stringent conditions (40-50°C for 16 hours in an 80% formamide, 0.4 M NaCl buffer, pH 7-8). The unhybridized probe is removed by digestion with ribonucleases specific for single-stranded RNA (i.e. RNases CL3, T1, Phy M, U2 or A). The presence of the biotin-UTP modification enables capture of the hybrid on a microtitration plate coated with streptavidin. The presence of the DIG modification enables the hybrid to be detected and quantified by ELISA using an anti-DIG antibody coupled to alkaline phosphatase.

Quantitative analysis of NF-HEV gene expression may also be performed using arrays. As used herein, the term array means a one dimensional, two dimensional, or multidimensional arrangement of a plurality of nucleic acids of sufficient length to permit specific detection of expression of mRNAs capable of hybridizing thereto. For example, the arrays may contain a plurality of nucleic acids derived from genes whose expression levels are to be assessed. The arrays may include the NF-HEV genomic DNA, the NF-HEV cDNA sequences or the sequences complementary thereto or fragments thereof. In some embodiments, the fragments are at least 50 nucleotides in length. More preferably, the

fragments are at least 100 nucleotides in length. In another preferred embodiment, the fragments are more than 100 nucleotides in length. In some embodiments the fragments may be more than 500 nucleotides in length.

For example, quantitative analysis of NF-HEV gene expression may be performed with a complementary DNA microarray as described by [Schena et al.(1995 and 1996)]. Full length NF-HEV cDNAs or fragments thereof are amplified by PCR and arrayed from a 96-well microtiter plate onto silylated microscope slides using high-speed robotics. Printed arrays are incubated in a humid chamber to allow rehydration of the array elements and rinsed, once in 0.2% SDS for 1 min, twice in water for 1 min and once for 5 min in sodium borohydride solution. The arrays are submerged in water for 2 min at 95°C, transferred into 0.2% SDS for 1 min, rinsed twice with water, air dried and stored in the dark at 25°C.

Cell or tissue mRNA is isolated or commercially obtained and probes are prepared by a single round of reverse transcription. Probes are hybridized to 1 cm<sup>2</sup> microarrays under a 14 x 14 mm glass coverslip for 6-12 hours at 60°C. Arrays are washed for 5 min at 25°C in low stringency wash buffer (1 x SSC/0.2% SDS), then for 10 min at room temperature in high stringency wash buffer (0.1 x SSC/0.2% SDS). Arrays are scanned in 0.1 x SSC using a fluorescence laser scanning device fitted with a custom filter set. Accurate differential expression measurements are obtained by taking the average of the ratios of two independent hybridizations.

Quantitative analysis of NF-HEV gene expression may also be performed with full length NF-HEV cDNAs or fragments thereof in complementary DNA arrays as described by Pietu et al.(1996). The full length NF-HEV cDNA or fragments thereof is PCR amplified and spotted on membranes. Then, mRNAs originating from various tissues or cells are labeled with radioactive nucleotides. After hybridization and washing in controlled conditions, the hybridized mRNAs are detected by phospho-imaging or autoradiography. Duplicate experiments are performed and a quantitative analysis of differentially expressed mRNAs is then performed.

Alternatively, expression analysis using the NF-HEV genomic DNA, the NF-HEV cDNA, or fragments thereof can be done through high density nucleotide arrays as described by Lockhart et al.(1996) and [Sosnowsky et al.(1997)]. Oligonucleotides of 15-50



nucleotides from the sequences of the NF-HEV DNA are synthesized directly on the chip (Lockhart et al., supra) or synthesized and then addressed to the chip (Sosnowski et al., supra). Preferably, the oligonucleotides are about 20 nucleotides in length.

5 NF-HEV cDNA probes labeled with an appropriate compound, such as biotin, digoxigenin or fluorescent dye, are synthesized from the appropriate mRNA population and then randomly fragmented to an average size of 50 to 100 nucleotides. The said probes are then hybridized to the chip. After washing as described in Lockhart et al., supra and application of different electric fields (Sosnowsky et al., 1997), the dyes or labeling compounds are detected and quantified. Duplicate hybridizations are performed.

10 Comparative analysis of the intensity of the signal originating from cDNA probes on the same target oligonucleotide in different cDNA samples indicates a differential expression of NF-HEV mRNA.

#### *Test Compounds*

15 This invention further pertains to novel agents identified by the above-described screening assays and to processes for producing such agents by use of these assays. Accordingly, in one embodiment, the present invention includes a compound or agent obtainable by a method comprising the steps of any one of the aforementioned screening assays (e.g., cell-based assays or cell-free assays). For example, in one embodiment,

20 the invention includes a compound or agent obtainable by a method comprising contacting a cell which expresses a NF-HEV target molecule with a test compound and the determining the ability of the test compound to bind to, or modulate the activity of, the NF-HEV target molecule. In another embodiment, the invention includes a compound or agent obtainable by a method comprising contacting a cell which expresses a NF-HEV target molecule with a

25 NF-HEV protein or biologically-active portion thereof, to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with, or modulate the activity of, the NF-HEV target molecule. In another embodiment, the invention includes a compound or agent obtainable by a method comprising contacting a NF-HEV protein or biologically active portion thereof with a test compound and

30 determining the ability of the test compound to bind to, or modulate (e.g., stimulate or

inhibit) the activity of, the NF-HEV protein or biologically active portion thereof. In yet another embodiment, the present invention included a compound or agent obtainable by a method comprising contacting a NF-HEV protein or biologically active portion thereof with a known compound which binds the NF-HEV protein to form an assay mixture, contacting the  
5 assay mixture with a test compound, and determining the ability of the test compound to interact with, or modulate the activity of the NF-HEV protein.

Accordingly, it is within the scope of this invention to further use an agent identified as described herein in an appropriate animal model. For example, an agent identified as described herein (e.g., a NF-HEV modulating agent, an antisense NF-HEV nucleic acid  
10 molecule, a NF-HEV-specific antibody, or a NF-HEV-binding partner) can be used in an animal model to determine the efficacy, toxicity, or side effects of treatment with such an agent. Alternatively, an agent identified as described herein can be used in an animal model to determine the mechanism of action of such an agent. Furthermore, this invention pertains to uses of novel agents identified by the above-described screening assays for treatments as  
15 described herein.

The present invention also pertains to uses of novel agents identified by the above-described screening assays for diagnoses, prognoses, and treatments as described herein. Accordingly, it is within the scope of the present invention to use such agents in the design, formulation, synthesis, manufacture, and/or production of a drug or pharmaceutical  
20 composition for use in diagnosis, prognosis, or treatment, as described herein. For example, in one embodiment, the present invention includes a method of synthesizing or producing a drug or pharmaceutical composition by reference to the structure and/or properties of a compound obtainable by one of the above-described screening assays. For example, a drug or pharmaceutical composition can be synthesized based on the structure and/or properties of a  
25 compound obtained by a method in which a cell which expresses a NF-HEV target molecule is contacted with a test compound and the ability of the test compound to bind to, or modulate the activity of, the NF-HEV target molecule is determined. In another exemplary embodiment, the present invention includes a method of synthesizing or producing a drug or pharmaceutical composition based on the structure and/or properties of a compound  
30 obtainable by a method in which a NF-HEV protein or biologically active portion thereof is

contacted with a test compound and the ability of the test compound to bind to, or modulate (e.g., stimulate or inhibit) the activity of, the NF-HEV protein or biologically active portion thereof is determined.

5 An inhibitor according to the present invention may be one which exerts an inhibitory effect on the expression or function of NF-HEV. By the same token, an activator according to the present invention may be one which exerts a stimulatory effect on the expression or function of NF-HEV. As used herein, the term "candidate substance", "candidate compound" or "test compound" refers to any molecule that may potentially modulate NF-HEV expression or function. The candidate substance may be a protein or fragment thereof, a small  
10 molecule inhibitor, or even a nucleic acid molecule. It may prove to be the case that the most useful pharmacological compounds will be compounds that are structurally related to compounds which interact naturally with NF-HEV. Creating and examining the action of such molecules is known as "rational drug design," and include making predictions relating to the structure of target molecules.

15 The goal of rational drug design is to produce structural analogs of biologically active polypeptides or target compounds. By creating such analogs, it is possible to fashion drugs which are more active or stable than the natural molecules, which have different susceptibility to, alteration or which may affect the function of various other molecules. In one approach, one would generate a three-dimensional structure for a molecule like NF-HEV, and then design a molecule for its ability to interact with NF-HEV. Alternatively, one could  
20 design a partially functional fragment of NF-HEV (binding, but no activity), thereby creating a competitive inhibitor. This could be accomplished by x-ray crystallography, computer modelling or by a combination of both approaches.

It also is possible to use antibodies to ascertain the structure of a target compound or  
25 inhibitor. In principle, this approach yields a pharmacore upon which subsequent drug design can be based. It is possible to bypass protein crystallography altogether by generating anti-idiotypic antibodies to a functional, pharmacologically active antibody. As a mirror image of a mirror image, the binding site of anti-idiotypic. On the other hand, one may simply acquire, from various commercial sources, small molecule libraries that are believed to meet the basic  
30 criteria for useful drugs in an effort to "brute force" the identification of useful compounds.

Screening of such libraries, including combinatorially generated libraries (e.g., peptide libraries), is a rapid and efficient way to screen large number of related (and unrelated) compounds for activity. Combinatorial approaches also lend themselves to rapid evolution of potential drugs by the creation of second, third and fourth generation compounds modelled of active, but otherwise undesirable compounds.

Candidate compounds may include fragments or parts of naturally-occurring compounds or may be found as active combinations of known compounds which are otherwise inactive. It is proposed that compounds isolated from natural sources, such as animals, bacteria, fungi, plant sources, including leaves and bark, and marine samples may be assayed as candidates for the presence of potentially useful pharmaceutical agents. It will be understood that the pharmaceutical agents to be screened could also be derived or synthesized from chemical compositions or manmade compounds. Thus, it is understood that the candidate substance identified by the present invention may be polypeptide, polynucleotide, small molecule inhibitors or any other compounds that may be designed through rational drug design starting from known inhibitors of NF-HEV.

The test compounds of the present invention can be obtained using any of the numerous approaches in combinatorial library methods known in the art, including: biological libraries; spatially addressable parallel solid phase or solution phase libraries; synthetic library methods requiring deconvolution; the 'one-bead one-compound' library method; and synthetic library methods using affinity chromatography selection. The biological library approach is used with peptide libraries, while the other four approaches are applicable to peptide, non-peptide oligomer or small molecule libraries of compounds (Lam, K. S. (1997) Anticancer Drug Des. 12:145, the disclosure of which is incorporated herein by reference in its entirety).

Examples of methods for the synthesis of molecular libraries can be found in the art, for example in: DeWitt et al. (1993) Proc. Natl. Acad. Sci. U.S.A. 90:6909; Erb et al. (1994) Proc. Natl. Acad. Sci. USA 91:11422; Zuckermann et al. (1994). J. Med. Chem. 37:2678; Cho et al. (1993) Science 261:1303; Carrell et al. (1994) Angew. Chem. Int. Ed. Engl. 33:2059; Carell et al. (1994) Angew. Chem. Int. Ed. Engl. 33:2061; and in Gallop et al.

(1994) J. Med. Chem. 37:1233, the disclosures of which are incorporated herein by reference in their entireties.

Libraries of compounds may be presented in solution (e.g., Houghten (1992) Biotechniques 13:412-421), or on beads (Lam (1991) Nature 354:82-84), chips (Fodor (1993) Nature 364:555-556), bacteria (Ladner U.S. Pat. No. 5,223,409), spores (Ladner U.S. Pat. No. '409), plasmids (Cull et al. (1992) Proc Natl Acad Sci USA 89:1865-1869) or on phage (Scott and Smith (1990) Science 249:386-390); (Devin (1990) Science 249:404-406); (Cwirla et al. (1990) Proc. Natl. Acad. Sci. 87:6378-6382); (Felici (1991) J. Mol. Biol. 222:301-310); (Ladner supra.), the disclosures of which are incorporated herein by reference in their entireties.

#### *Methods of Treatment*

NF-HEV inhibitors identified according to the methods in the section titled "Drug Screening Assays" can be further tested for their ability to ameliorate or prevent inflammation, preferably chronic inflammation and autoimmune disorders in a suitable animal model of disease. Examples of animal models for rheumatoid arthritis include collagen-induced arthritis in mice (Gerlag et al. (2001) Arthritis Research 3:357-361; Bullard et al. (1996) J Immunol 157:3153-3158), adjuvant-induced arthritis in rats (Spargo et al., (1996) J Immunol 157:5198-5207), the rheumatoid arthritis transgenic mouse model (Kouskoff et al. (1996) Cell 87:811-822), the disclosures of which are incorporated herein by reference in their entireties. Examples of animal models for Crohn's and inflammatory bowel diseases include several 'gene knockout' mice with inactivated IL2 (Sadlack et al. (1993) Cell 75:253-261), IL10 (Kuhn et al. (1993) Cell 75:263-274) or T cell receptor (Mombaerts et al. (1993) Cell 75:275-282; Mizoguchi et al. (1996) J Exp Med 184:707-715) genes, the T-cell-mediated colitis model in SCID mice (Picarella et al. (1997) J Immunol 158:2099-2106), the cotton-top tamarin chronic colitis model (Podolsky et al. (1993) J Clin Invest 92: 272; Hesterberg et al. (1996) Gastroenterology 111:1373), the disclosures of which are incorporated herein by reference in their entireties.

In one aspect, compounds capable of modulating NF-HEV may function by modulating the expression of a proinflammatory protein, particularly a protein involved in a

proinflammatory signalling pathway. In another aspect, compounds capable of modulating NF-HEV may inhibit or prevent the development of HEV-like vessels. Since endothelial cells and particularly HEV-like vessels have several functions related to leukocyte adherence and extravasation, inflammation, and coagulation, compounds that interfere with HEV-like vessel development or maintenance can be used to modulate the pathological consequences of these events. Moreover, HEV-like vessels are known to develop at sites of inflammation resulting in further exacerbation of the inflammatory symptoms. Targeting HEV-like vessels for therapy has demonstrated that substantial decreases in lymphocyte migration can be achieved. For example functional inactivation of L-selectin by blocking antibodies (Gallatin et al, (1983) Nature 304: 30-34; Hamann et al, (1994) J. Immunol. 152: 3283-3293) or by gene knockout (Arbones et al, (1994) Immunity 1: 247-260) results in a 99% decrease of lymphocyte migration to peripheral lymph nodes (PLNs) and a 50% reduction of lymphocyte emigration in PP HEVs. The inhibitors therefore may be administered locally or systemically to control tissue damage associated with such injuries. Moreover, because of the specificity of such inhibitors for sites of inflammation, these compositions will be more effective and less likely to cause complications when compared to traditional anti-inflammatory agents.

NF-HEV inhibitors are expected to be particularly useful in the treatment of chronic inflammatory disorders. A review of disorders is provided in Girard and Springer, (1995) Immunology Today 16(9): 449-457, the disclosure of which is incorporated herein by reference in its entirety. An inflammatory response can cause damage to the host if unchecked, because leukocytes release many toxic molecules that can damage normal tissues including proteolytic enzymes and free radicals. Vessels with HEV characteristics appear in human tissue in association with long-standing chronic inflammation. Such vessels exhibit plump endothelial cells, take up and incorporate high levels of  $^{35}\text{SO}_4$ , contain many luminal and intramural lymphocytes (presumably in the process of extravasating) and mediate in vitro lymphocyte adhesion (Freemont (1998) J. Pathol. 155: 225-230, the disclosure of which is incorporated herein by reference in its entirety).

The methods and compositions of the invention may be useful in the treatment of rheumatoid arthritis. Rheumatoid arthritis is characterized by symmetric, polyarticular inflammation of synovial-lined joints, and may involve extraarticular tissues, such as the

pericardium, lung, and blood vessels. Adhesion molecules appear to play an important role (Postigo et al., *Autoimmunity* 16:69, 1993, the disclosure of which is incorporated herein by reference in its entirety). Soluble selectins are present in the synovial fluid and blood of affected patients, correlating with elevated ESR and synovial PMN count (Carson CW et al. J. Rheumatol. 21:605, 1994, the disclosure of which is incorporated herein by reference in its entirety). Conventional antirheumatic therapy may modify synovial inflammation by altering leukocyte adhesion. Corticosteroids, gold compounds, and colchicine downregulate endothelial expression of selectins (Corkill et al., *J. Rheumatol.* 18:1453, 1991; Molad et al., *Arthritis Rheum.* 35:S35, 1992, the disclosures of which are incorporated herein by reference in their entireties).

In rheumatoid arthritis, it has been observed that the level of sulfate incorporation as well as the 'plumpness' (or 'fullness') of the endothelium in areas of lymphocyte infiltration in the synovial membrane are closely related to the concentration of the lymphocytes in the perivascular infiltrates (Freemont, (1987) *Ann. Rheum. Dis.* 46: 924-928, the disclosure of which is incorporated herein by reference in its entirety). Similarly, expression of MECA-79 and HECA-452 on these vessels is most pronounced in association with extensive lymphoid infiltrates (Michie et al, (1993) *Am. J. Pathol.* 143: 1688-1698; van Dinther-Janssen et al, (1990) *J. Rheumatol.* 17:11-17, the disclosures of which are incorporated herein by reference in their entireties). Therefore, the development of bona fide HEVs in the synovial membrane of patients with rheumatoid arthritis is likely to facilitate large-scale influx of lymphocytes, leading to amplification and maintenance of chronic inflammation. Inhibition of HEVEC differentiation and HEV-like vessel development would therefore be useful for the treatment of rheumatoid arthritis.

The development of HEV-like vessels after prolonged inflammatory stimulus is not restricted to the diseased synovium, but can also occur in other tissues, particularly the gut and thyroid. During chronic inflammation of the gut in inflammatory bowel diseases (Crohn's disease and ulcerative colitis), or the thyroid in autoimmune thyroiditis (Graves' disease and Hashimoto's thyroiditis), areas of dense lymphocytic infiltration contain HEV-like vessels with plump endothelium expressing MECA-79 and HECA-452 (Michie et al, supra; Duljvestijn et al., (1988) *Am. J. Pathol.* 130: 147-155; Kabel et al., J. (1989) *Clin.*

Endocrinol. Metab. 68: 744-751; and Salmi et al. (1994) Gastroenterology 106: 595-605, the disclosures of which are incorporated herein by reference in their entireties). These observations suggest that HEV-like vessels could play an important rôle in the pathogenesis of these diseases by mediating abnormal lymphocyte recruitment to the gut or the thyroid.

5 MECA-79+ HEV-like venules with plump endothelium have also been detected in other sites of chronic inflammation, including many cutaneous inflammatory lesions (Michie et al, supra).

NF-HEV inhibitors may also be useful in the treatment of disorders characterized by extralymphoid sites of chronic inflammation. In one example, NF-HEV inhibitors may be

10 useful for the treatment or prevention of diabetes mellitus. In the nonobese diabetic (NOD) mouse model of human insulin-dependent diabetes mellitus (IDDM), vessels with HEV characteristics (e.g. plump endothelial cells, numerous lymphocytes in the vessel walls) are observed during inflammation of the pancreas. Expression of MECA-79 and MECA-367 (MAdCAM-1) is induced on these HEV-like vessels (Hanninen et al., (1993) J. Clin. Invest.

15 92: 2509-2515; Favreuw et al., (1994) J. Immunol. 152: 5969-5978, the disclosures of which are incorporated herein by reference in their entireties) during the development of insulinitis, whereby lymphocytes infiltrate the pancreatic islets. Staining with MECA-79 is consistent with the induction of functional L-selectin ligands, CD34, MAdCAM-1 and GlyCAM-1 (Baumhueter et al, (1994) Blood 84: 2554-2565, the disclosure of which is incorporated

20 herein by reference in its entirety). The induction of GlyCAM-1 in the inflamed pancreas of NOD mice is particularly striking since GlyCAM-1 expression in mice had previously been shown to be restricted to PLN and mesenteric lymph node (MLN) HEVs (Lasky et al., (1992) Cell 69: 927-938, the disclosure of which is incorporated herein by reference in its entirety). Together these results indicate that HEV-like vessels induced by chronic inflammation in

25 extralymphoid sites appear to be phenotypically similar to HEVs from lymphoid tissues. The induction of MECA-79 and MAdCAM-1 on the endothelium correlates with the expression of their counter-receptors L-selectin and alpha4-beta7 on cells infiltrating the islets (Hanninen et al., supra, the disclosure of which is incorporated herein by reference in its entirety). In vivo studies have revealed that these two receptor-counter receptor pairs,

30 alpha4-beta7 -MAdCAM-1 and L-selectin-MECA-79, play a major role in the recruitment of



lymphocytes from blood into the inflamed pancreas (Yang et al., (1993) PNAS USA 90: 10494-10498, the disclosure of which is incorporated herein by reference in its entirety). Treatment of NOD mice with function-blocking monoclonal antibodies specific for L-selectin and alpha-4 integrins resulted in the inhibition of insulitis and the prevention of autoimmune diabetes.

In other examples, a NF-HEV inhibitor may be used for the treatment or prevention of graft rejection. L-selectin dependent lymphocyte extravasation as occurs through HEVs is a hallmark of acute heart allograft rejection in rates. Evidence further demonstrates a complete correlation between the level of expression of the sulfated sialyl Lewis-x decorated L-selectin ligands and the histological severity of heart allograft rejection (Toppila et al., (1999) Am. J. Pathol. 155:1013-1020, the disclosure of which is incorporated herein by reference in its entirety), suggesting that NF-HEV inhibitors capable of blocking sulfation of L-selectin ligands may be capable of preventing lymphocyte extravasation into human heart allografts at the onset and during acute rejection episodes. In particular, Toppila et al showed that non-rejecting heart endothelium did not express, or expressed only weakly, sulfated and or sialyl Lewis-x decorations of L-selectin ligands, while said epitopes were readily detectable on endothelium of capillaries and venules at the onset and during acute rejection episodes. Molecules capable of preventing or reducing the formation of HEV-like vessels would thus reduce the sites available for lymphocyte extravasation.

Thus, the invention includes in preferred embodiments methods of inhibiting inflammation or more preferably chronic inflammation, as well as methods of modulating the expression of a proinflammatory protein, particularly a protein involved in a proinflammatory signalling pathway, methods of inhibiting leukocyte adhesion or migration, and yet more particularly methods of inhibiting development of HEV-like vessels or inhibiting differentiation of endothelial or HEVEC cells, the methods comprising administering a NF-HEV inhibitor.

Activators of NF-HEV activity may be used to treat conditions in which it is desired to obtain increased development of HEVECs or HEV-like vessels, particularly where it is desired to obtain increased lymphocyte infiltration (Schrama et al. (2001) Immunity 14:111-121, the disclosure of which is incorporated herein by reference in its entirety) For example,

NF-HEV activators may be used to enhance the infiltration of lymphocytes into solid tumors, such as melanoma and colon or breast carcinoma.

An "individual" treated by the methods of this invention is a vertebrate, particularly a mammal (including model animals of human disease), and typically a human.

5 As used herein, "treatment" refers to clinical intervention in an attempt to alter the natural course of the individual being treated, and may be performed either for prophylaxis or during the course of clinical pathology. Desirable effects include preventing occurrence or recurrence of disease, alleviation of symptoms, diminishment of any direct or indirect pathological consequences of the disease, such as hyperresponsiveness, inflammation, or  
10 necrosis, lowering the rate of disease progression, amelioration or palliation of the disease state, and remission or improved prognosis. The "pathology" associated with a disease condition is anything that compromises the well-being, normal physiology, or quality of life of the affected individual.

Treatment is performed by administering an effective amount of a NF-HEV inhibitor  
15 or activator. An "effective amount" is an amount sufficient to effect a beneficial or desired clinical result, and can be administered in one or more doses.

The criteria for assessing response to therapeutic modalities employing the lipid compositions of this invention are dictated by the specific condition, measured according to standard medical procedures appropriate for the condition.

20

#### *Pharmaceutical Compositions*

Compounds capable of inhibiting NF-HEV activity, preferably small molecules but also including peptides, NF-HEV nucleic acid molecules, NF-HEV proteins, and anti-NF-HEV antibodies (also referred to herein as "active compounds") of the invention can be  
25 incorporated into pharmaceutical compositions suitable for administration. Such compositions typically comprise a pharmaceutically acceptable carrier. As used herein the language "pharmaceutically acceptable carrier" is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. The use of such  
30 media and agents for pharmaceutically active substances is well known in the art. Except

insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions.

A pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (topical), transmucosal, and rectal administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.

Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL™ (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents,

for example, sugars, polyalcohols such as manitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.

5       Where the active compound is a protein, peptide or anti-NF-HEV antibody, sterile injectable solutions can be prepared by incorporating the active compound in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle which contains a basic dispersion  
10       medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

15       Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. For administration by inhalation, the compounds are delivered in the form of an aerosol spray from pressured container or dispenser which  
20       contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer. Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal  
25       administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art. Most preferably, active compound is delivered to a subject by intravenous injection.

30       In one embodiment, the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release

formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be  
5 obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Pat. No. 4,522,811, the disclosure of which is incorporated herein by reference in its  
10 entirety.

It is especially advantageous to formulate oral or preferably parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to  
15 produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the invention are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an active compound for the treatment of individuals.

20 Toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD50/ED50. Compounds which  
25 exhibit large therapeutic indices are preferred. While compounds that exhibit toxic side effects may be used, care should be taken to design a delivery system that targets such compounds to the site of affected tissue in order to minimize potential damage to uninfected cells and, thereby, reduce side effects.

The data obtained from the cell culture assays and animal studies can be used in  
30 formulating a range of dosage for use in humans. The dosage of such compounds lies

preferably within a range of circulating concentrations that include the ED50 with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. For any compound used in the method of the invention, the therapeutically effective dose can be estimated initially from cell culture assays. A dose may be formulated in animal models to achieve a circulating plasma concentration range that includes the IC50 (i.e., the concentration of the test compound which achieves a half-maximal inhibition of symptoms) as determined in cell culture. Such information can be used to more accurately determine useful doses in humans. Levels in plasma may be measured, for example, by high performance liquid chromatography.

10 The pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration.

#### *Diagnostics and Identification of HEVECs and HEV-Like Vessels*

15 The nucleic acid molecules, proteins, protein homologues, and antibodies described herein can be of particular benefit in the identification of endothelial cells, HEVEC and HEV-like vessels involved in inflammation, preferably chronic inflammation. The compositions will also be useful in diagnostic assays, prognostic assays, monitoring clinical trials, and pharmacogenetics related to inflammatory disorders as further described herein.

20 According to the present invention, a NF-HEV protein, a NF-HEV-specific antibody, or a NF-HEV nucleic acid is used to distinguish endothelial cells, HEVECs or HEV-like vessels involved in inflammation from endothelial cells, or vessels that are not involved in inflammation or have decreased inflammatory potential. This is particularly useful in research and development, where there is a need for means that are capable of distinguishing endothelial cells from inflamed samples from other endothelial cells. In other aspects, the levels of NF-HEV expression in HEVEC cells indicates that NF-HEV can also be used to distinguish HEVECs from non-HEVEC cells.

25 The invention also involves methods of use (e.g., a diagnostic assay, prognostic assay, or a prophylactic/therapeutic method of treatment) wherein a NF-HEV protein, NF-HEV nucleic acid, or most preferably a NF-HEV inhibitor or activator, is used, for example, to diagnose, prognose and/or treat an inflammatory disorder, most preferably a chronic

inflammatory disorder. In another embodiment, the methods of use (e.g., diagnostic assays, prognostic assays, or prophylactic/therapeutic methods of treatment) involve administering to a human subject a NF-HEV inhibitor or activator.

For example, the invention encompasses a method of determining whether NF-HEV  
5 is expressed within a biological sample comprising: a) contacting said biological sample with: ii) a polynucleotide that hybridizes under stringent conditions to a NF-HEV nucleic acid; or iii) a detectable polypeptide that selectively binds to a NF-HEV polypeptide; and b) detecting the presence or absence of hybridization between said polynucleotide and an RNA species within said sample, or the presence or absence of binding of said detectable  
10 polypeptide to a polypeptide within said sample. A detection of said hybridization or of said binding indicates that said NF-HEV is expressed within said sample and that the sample comprises nucleic acids or protein derived from an inflamed tissue, or more preferably from an endothelial cell involved in inflammation or having inflammatory potential. Preferably, the polynucleotide is a primer, and wherein said hybridization is detected by detecting the  
15 presence of an amplification product comprising said primer sequence, or the detectable polypeptide is an antibody,

Also envisioned is a method of determining whether a cell expresses a NF-HEV nucleic acid or polypeptide, comprising: a) providing a biological sample (e.g. sample of cells or sample from a mammal); and b) preferably comparing the amount of a NF-HEV  
20 polypeptide or of a NF-HEV RNA species encoding a NF-HEV polypeptide within said biological sample with a level detected in or expected from a control sample. Expression of said NF-HEV polypeptide or said NF-HEV RNA species within said biological sample indicates that the sample comprises nucleic acids or protein derived from an inflamed tissue, or more preferably from an endothelial cell involved in inflammation or having inflammatory  
25 potential. Also encompassed is a method of determining whether a cell or mammal, preferably human, has an elevated or reduced level of NF-HEV expression, comprising: a) providing a biological sample (e.g. sample of cells or sample from said mammal; and b) comparing the amount of a NF-HEV polypeptide or of a NF-HEV RNA species encoding a NF-HEV polypeptide within said biological sample with a level detected in or expected from  
30 a control sample. An increased amount of said NF-HEV polypeptide or said NF-HEV RNA

species within said biological sample compared to said level detected in or expected from said control sample indicates that said mammal has an elevated level of NF-HEV expression, and wherein a decreased amount of said NF-HEV polypeptide or said NF-HEV RNA species within said biological sample compared to said level detected in or expected from said control sample indicates that said mammal has a reduced level of NF-HEV expression. As discussed, NF-HEV expression may be useful for identifying a HEVEC or HEV-like vessel involved in inflammation or having inflammatory potential as well as for identifying subjects suffering from or susceptible to suffering from chronic inflammatory conditions.

An exemplary method for detecting the presence or absence of NF-HEV protein or nucleic acid in a biological sample involves obtaining a biological sample from a test subject, for example by conducting a biopsy at a site of inflammation or suspected inflammation, and contacting the biological sample with a compound or an agent capable of detecting NF-HEV protein or nucleic acid (e.g., mRNA, genomic DNA) that encodes NF-HEV protein such that the presence of NF-HEV protein or nucleic acid is detected in the biological sample. A preferred agent for detecting NF-HEV mRNA or genomic DNA is a labeled nucleic acid probe capable of hybridizing to NF-HEV mRNA or genomic DNA. The nucleic acid probe can be, for example, a full-length NF-HEV nucleic acid, such as a nucleic acid of sequences of SEQ ID NOS 1, 2 or 3 such as a nucleic acid of at least 15, 30, 50, 100, 250, 400, 500 or 1000 nucleotides in length and sufficient to specifically hybridize under stringent conditions to NF-HEV mRNA or genomic DNA. Other suitable probes for use in the diagnostic assays of the invention are described herein.

A preferred agent for detecting NF-HEV protein is an antibody capable of binding to NF-HEV protein, preferably an antibody with a detectable label. Antibodies can be polyclonal, or more preferably, monoclonal. An intact antibody, or a fragment thereof (e.g., Fab or F(ab')<sub>2</sub>), can be used. The term "labeled", with regard to the probe or antibody, is intended to encompass direct labeling of the probe or antibody by coupling (i.e., physically linking) a detectable substance to the probe or antibody, as well as indirect labeling of the probe or antibody by reactivity with another reagent that is directly labeled. Examples of indirect labeling include detection of a primary antibody using a fluorescently labeled secondary antibody and end-labeling of a DNA probe with biotin such that it can be detected



with fluorescently labeled streptavidin. The term "biological sample" is intended to include tissues, cells and biological fluids isolated from a subject, as well as tissues, cells and fluids present within a subject. That is, the detection method of the invention can be used to detect NF-HEV mRNA, protein, or genomic DNA in a biological sample in vitro as well as in vivo.

5 For example, in vitro techniques for detection of NF-HEV mRNA include Northern hybridizations and in situ hybridizations. In vitro techniques for detection of NF-HEV protein include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations and immunofluorescence. In vitro techniques for detection of NF-HEV genomic DNA include Southern hybridizations. Furthermore, in vivo techniques for detection

10 of NF-HEV protein include introducing into a subject a labeled anti-NF-HEV antibody. For example, the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques.

In one embodiment, the biological sample contains protein molecules from the test subject or test composition (e.g. composition of cells). Alternatively, the biological sample

15 can contain mRNA molecules from the test subject or genomic DNA molecules from the test subject or test composition. In another embodiment, the methods further involve obtaining a control biological sample from a control subject, contacting the control sample with a compound or agent capable of detecting NF-HEV protein, mRNA, or genomic DNA, such that the presence of NF-HEV protein, mRNA or genomic DNA is detected in the biological

20 sample, and comparing the presence of NF-HEV protein, mRNA or genomic DNA in the control sample with the presence of NF-HEV protein, mRNA or genomic DNA in the test sample. The invention also encompasses kits for detecting the presence of NF-HEV in a biological sample. For example, the kit can comprise a labeled compound or agent capable of detecting NF-HEV protein or mRNA in a biological sample; means for determining the

25 amount of NF-HEV in the sample; and means for comparing the amount of NF-HEV in the sample with a standard. The compound or agent can be packaged in a suitable container. The kit can further comprise instructions for using the kit to detect NF-HEV protein or nucleic acid.

In certain embodiments, detection involves the use of a probe/primer in a polymerase

30 chain reaction (PCR) (see, e.g., U.S. Pat. Nos. 4,683,195 and 4,683,202, the disclosures of

which are incorporated herein by reference in their entireties), such as anchor PCR or RACE PCR, or, alternatively, in a ligation chain reaction (LCR) (see, e.g., Landegran et al. (1988) Science 241:1077-1080; and Nakazawa et al. (1994) PNAS 91:360-364, the disclosures of which are incorporated herein by reference in their entireties), the latter of which can be particularly useful for detecting point mutations in the NF-HEV-gene (see Abravaya et al. (1995) Nucleic Acids Res. 23:675-682, the disclosure of which is incorporated herein by reference in its entirety). This method can include the steps of collecting a sample of cells from a patient, isolating nucleic acid (e.g., genomic, mRNA or both) from the cells of the sample, contacting the nucleic acid sample with one or more primers which specifically hybridize to a NF-HEV gene under conditions such that hybridization and amplification of the NF-HEV-gene (if present) occurs, and detecting the presence or absence of an amplification product, or detecting the size of the amplification product and comparing the length to a control sample. It is anticipated that PCR and/or LCR may be desirable to use as a preliminary amplification step in conjunction with any of the techniques used for detecting mutations described herein.

Genotyping assays for diagnostics can also be carried out. Genotyping assays may be useful, for example, to detect alleles associated with inflammatory disorders. Genotyping assays generally require the previous amplification of the DNA region carrying the allele of interest. However, ultrasensitive detection methods which do not require amplification are also available. Methods well-known to those skilled in the art that can be used to detect polymorphisms include methods such as, conventional dot blot analyzes, single strand conformational polymorphism analysis (SSCP) described by Orita et al. PNAS 86 : 2766-2770 (1989), the disclosure of which is incorporated herein by reference in its entirety, denaturing gradient gel electrophoresis (DGGE), heteroduplex analysis, mismatch cleavage detection, and other conventional techniques as described in Sheffield et al. (1991), White et al. (1992), and Grompe et al. (1989 and 1993) (Sheffield, V.C. et al, Proc. Natl. Acad. Sci. U.S.A 49:699-706 (1991); White, M.B. et al., Genomics 12:301-306 (1992); Grompe, M. et al., Proc. Natl. Acad. Sci. U.S.A 86:5855-5892 (1989); and Grompe, M. Nature Genetics 5:111-117 (1993), the disclosures of which are incorporated herein by reference in their entireties). Another method for determining the identity of the nucleotide present at a

particular polymorphic site employs a specialized exonuclease-resistant nucleotide derivative as described in U.S. patent 4,656,127, the disclosure of which is incorporated herein by reference in its entirety. Further methods are described as follows. Other methods include microsequencing methods, in which the nucleotide at a polymorphic site in a target DNA is  
5 detected by a single nucleotide primer extension reaction. A homogeneous phase microsequencing-based detection method based on fluorescence resonance energy transfer has been described by Chen and Kwok (1997) and Chen et al. (1997) Chen and Kwok (*Nucleic Acids Research* 25:347-353 1997) and Chen et al. (*Proc. Natl. Acad. Sci. USA* 94/20 10756-10761,1997), the disclosures of which are incorporated herein by reference in their  
10 entireties).

Having generally described this invention, a further understanding can be obtained by reference to certain specific examples which are provided herein for purposes of illustration only, and are not intended to be limiting unless otherwise specified.

## 15 EXAMPLES

### EXAMPLE 1

#### Suppression Subtractive Hybridization (SSH)

SSH was performed as described (Girard et al. (1999) *Am J Pathol* 155:2043-55.) with some modifications. Total RNA was isolated from highly purified HEVECs  
20 (Baekkevold et al. (1999) *Lab Invest* 79:327-36) cultured for 2 days with an RNeasy kit (Qiagen). PMECs were prepared from nasal polyps as described (Jahnsen et al. (1997) *Am J Pathol* 150:2113-23.), stained with anti-CD34-FITC (Diatec), and purified by cell sorting (FACSVantage, Becton Dickinson). PMEC mRNA was isolated by  $\mu$ MACS mRNA isolation kit (Miltenyi Biotech). To obtain sufficient amounts of double-stranded (ds) cDNA for  
25 subtraction, both PMEC and HEVEC cDNAs were preamplified with the SMART PCR cDNA synthesis kit (Clontech). cDNAs synthesized from 1  $\mu$ g of total RNA (HEVECs) or 0.15  $\mu$ g mRNA (PMECs) with Advantage KlenTaq polymerase (22 cycles, Clontech) were used with the PCR Select cDNA subtraction kit (Clontech). Briefly, PCR-generated HEVEC and PMEC cDNAs were digested with RsaI (New England Biolabs) and ligated to ds cDNA  
30 adaptors. For the first hybridization, the mixtures of HEVEC and PMEC cDNAs were

incubated for 8 hours at 68°C. For the second hybridization, excess PMEC cDNA was added and incubated for 22 hours at 68°C. Differentially expressed cDNAs were then selectively amplified by two successive PCR (27 cycles) and nested PCR (10 cycles) reactions.

T/A cloning libraries of the subtracted cDNAs were prepared as described (von Stein et al. (1997) Nucleic Acids Res 25:2598-602.). Briefly, the HEVEC<sub>-PMEC</sub> and PMEC<sub>-HEVEC</sub> subtracted mixtures (200 ng) were cloned directly into pCR2.1-TOPO (TA Cloning kit, Invitrogen) and introduced into One Shot Competent TOP10 cells (Invitrogen) according to the manufacturer. The bacteria were plated on agar plates containing 100 µg/ml ampicillin, 100 µM isopropyl-β-D-thiogalactoside (IPTG) and 50 µg/ml X-Gal, and then grown until  
10 blue/white colonies appeared.

## EXAMPLE 2

### Differential Hybridization Screening with Subtracted probes

A total of 960 individual recombinant (white) colonies were picked and used to  
15 inoculate ten 96-well micotitre plates with LB medium and 100 µg/ml ampicillin, which was incubated overnight and diluted 1/4 with H<sub>2</sub>O. This diluted bacterial culture (1 µl) was used to PCR amplify cloned inserts in 25 µl reactions with M13rev and M13for (-20) primers flanking the vector cloning site under the following conditions: 95°C, 5 min; 30 cycles each at 94°C for 30 sec, 55°C for 30 sec, and 72°C for 1 min. The PCR reaction products (12 µl)  
20 were then loaded onto duplicate agarose gels (1.6% w/v), denatured, and blotted onto nylon membranes. The filters were hybridized with equivalent amounts of <sup>32</sup>P-labeled cDNA of similar specific activity derived from HEVEC and PMEC total RNA as described (Girard et al. (1999) Am J Pathol 155:2043-55.). Miniprep DNA of the differentially hybridizing clones was prepared and sequenced at Medigenomix (Martinsried, Germany) with the plasmid-specific TOPO1 and TOPO2 oligonucleotides.  
25

## EXAMPLE 3

### Virtual Northern Blot Analysis

SMART PCR generated cDNAs from HEVECs, PMECs, first passage HUVECs and  
30 placenta total RNA (0.5 µg per lane) were electrophoresed on 1.6% agarose gels, transferred

onto nylon filters and hybridized as described (Girard et al. (1999) Am J Pathol 155:2043-55.) with a <sup>32</sup>P-labeled cDNA probe corresponding to the coding region of NF-HEV.

#### EXAMPLE 4

##### In situ hybridization

*In situ* mRNA hybridization was performed as described (Hashimoto et al. (2000) Blood 96:2206-14.). Briefly, digoxigenin-labeled riboprobes were generated from the NF-HEV cDNA with the DIG RNA labeling kit according to the manufacturer's directions (Boehringer Mannheim, Mannheim, Germany). Frozen sections (8 µm) from human palatine tonsils, Peyer's patches and mesenteric lymph nodes were fixed in 4% paraformaldehyde (PFA)/DEPC-treated PBS and subsequently washed in PBS containing 0.1% active DEPC (Sigma). After equilibration in 5x SSC, sections were prehybridized (2 h, 59°C) in hybridization solution (50% formamide, 5x SSC, 50 µg/ml yeast tRNA, 100 µg/ml heparin, 1x Denhardt solution, 0.1% Tween 20, 0.1% CHAPS, and 5 mM EDTA). Sections were subsequently hybridized overnight at 59°C with 250 ng/ml of riboprobe in hybridization solution. High stringency wash was performed, and the sections were next incubated (45 min) with horseradish peroxidase (HRP)-conjugated rabbit anti-DIG (1/50; DAKO, Glostrup, Denmark) in blocking buffer (0.1% Boehringer Blocking Agent dissolved in Tris-HCl 100 mM, NaCl 150 mM, pH 7.5), followed by signal amplification with biotin-tyramide deposition (GenPoint kit; DAKO). Subsequently, sections were incubated (20 min) with HRP-conjugated rabbit anti-biotin (1/50 in blocking buffer; DAKO), followed by an additional cycle of biotin-tyramide deposition. Signal was detected by incubation (20 min) with alkaline phosphatase (AP)-conjugated rabbit anti-biotin (1/50 in blocking buffer; DAKO), followed by the AP substrate Fast Red (Ventana Medical Systems, Tucson, AZ). Finally, the sections were counterstained with hematoxylin.

#### EXAMPLE 5

##### Epitope tagging

The coding region of NF-HEV was cloned into the pCDNA3.1A /myc-his (Invitrogen) by PCR amplification of the NF-HEV open reading frame with primers 5'-GAATTCTGAAAAATGAAGCCTAAAATGAAGTATTCAAC-3' and 5'-

GGGCCAGTTTCAGAGAGCTTAAACAAGATATTTTCAG-3', digested with EcoRI and  
 ApaI, and cloned in frame with the myc tag of the PCDNA3.1A.

#### EXAMPLE 6

##### 5. Cell culture, transfection, and immunofluorescence studies

HUVECs were grown in ECGM medium (Promocell), and were transfected in RPMI  
 medium. HeLa cells were grown in Dulbecco's Modified Eagle's Medium supplemented  
 with 10% fetal calf serum and 1% penicillin-streptomycin (all from Gibco-BRL). HUVECs  
 were plated on coverslips and transiently transfected with 0.7 µg PCDNA3.1A-NF-HEV-  
 10 myc-his expression vector and Genejammer transfection reagent according to the  
 manufacturer's instructions (Stratagene). HeLa cells were plated on coverslips and transiently  
 transfected with 2 µg PCDNA3.1A-NF-HEV-myc-his expression vector, with the calcium  
 phosphate method. After medium change, transfected cells were incubated for 48 h to allow  
 gene expression and then washed twice with PBS, fixed for 15 min at room temperature in  
 15 PBS containing 3.7% PFA, and washed again with PBS prior to neutralization with 50mM  
 NH<sub>4</sub>Cl in PBS for 5 min at room temperature. Cells were permeabilized for 5 min at room  
 temperature in PBS containing 0.1% Triton-X100, and washed twice with PBS.  
 Permeabilized cells were then incubated for 2 hr at room temperature with an anti-myc  
 monoclonal antibody (IgG, 7 µg/ml, Clontech) in PBS with 1% (w/v) bovine serum albumin  
 20 (BSA). Cells were then washed three times 5 min at room temperature in PBS-BSA, and  
 incubated for 1 hr with FITC-labeled rabbit anti-mouse IgG (1/40, Amersham Pharmacia  
 Biotech). After extensive washing in PBS, samples were air dried and mounted in Mowiol  
 (Hoechst Pharmaceuticals). Fluorescence of fixed immunostained cells was viewed with a  
 Leica confocal laser-scanning microscope.

25

#### EXAMPLE 7

##### Antibody production, immunohistochemistry, and Western blotting

Rabbit polyclonal antibodies were raised against the peptides  
 MKPKMKYSTNKISTAC and CYFRRETTKRPSLKTG, corresponding to amino acids 1-15  
 30 and 58-73 of the human NF-HEV sequence, respectively, using multiple antigen peptides

technology (Eurogentec). The antisera were applied in immunohistochemistry as previously described (Girard et al. (1999) Am J Pathol 155:2043-55.). In brief, acetone-fixed sections (4  $\mu$ m) of human palatine tonsils were first incubated with a mixture of mAb MECA-79 (rat IgM, 1/30; courtesy of E.C. Butcher, Stanford, CA) and anti-NF-HEV rabbit antiserum (1/1000), followed by a mixture of Cy3-conjugated goat anti-rat IgM (1/200; Jackson ImmunoResearch) and Alexa Fluor 488-conjugated goat anti-rabbit IgG (Molecular Probes). The sections were mounted with 4',6-diamidino-2-phenylindole (DAPI)-containing Vectashield (Vector). Negative controls were tissue sections incubated with concentration-matched irrelevant rat IgM and preimmune rabbit serum. Lysates from purified HEVECs and primary cultures of PMECs and HUVECs (each corresponding to  $\sim 10^5$  cells) were fractionated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) (10%). Detection was performed with rabbit antiserum to NF-HEV (1/500), followed by HRP-conjugated donkey anti-rabbit Ig (1/1000; Amersham), and finally an enhanced chemiluminescence kit (Pierce).

#### EXAMPLE 8

##### Threading and molecular modeling analyses

We used the *InsightII*, *SeqFold*, *Homology* and *Discover* modules from the *Accelrys* (San Diego, CA) molecular modeling software (version 98), run on a Silicon Graphics O2 workstation. Structural homologs of human NF-HEV were searched with the *SeqFold* threading program (Olszewski (1999) Theor. Chem. Acc. 101:57-61), which combines sequence and secondary structure alignment. Optimal secondary structure prediction of the query protein domains was ensured by the DSC method (King and Sternberg (1996) Protein Sci 5:2298-310.) within *SeqFold*. The *engrailed* homeodomain (PDB code: 1DU0) was identified as the best structural template of the NF-HEV amino-terminal domain (NF-HEV aa 1-65). We used the threading-derived secondary structure alignments as input for homology-modeling, which was performed according to a previously described protocol. (Manival et al. (2001) Nucleic Acids Res 29:2223-33.) The validity of the models was checked both by Ramachandran analysis and folding consistency verification as previously reported. (Manival et al. (2001) Nucleic Acids Res 29:2223-33.)

EXAMPLE 9RT-PCR analysis

5 For RT-PCR analysis, total RNA was purified from human tonsil HEVEC, Rheumatoid arthritis ECs, Crohn's disease ECs, Colon tumor ECs or Hela cells. Human tonsil HEVEC, Rheumatoid arthritis ECs, Crohn's disease ECs, Colon tumor ECs were purified from human tissues using a combination of mechanical and enzymatic procedures, immunomagnetic depletion and positive selection (Girard and Springer (1995) Immunity

10 2:113-123)(Baekkevold et al. (1999) Lab Invest 79:327-36). Fresh human tissues were minced finely with scissors on a steel screen, digested with collagenase/dispase enzyme mix and unwanted contaminating cells were then depleted using immunomagnetic depletion. ECs were then selected by immunomagnetic positive selection with magnetic beads conjugated to EC-specific antibody (Girard and Springer (1995) Immunity 2:113-123)(Baekkevold et al.

15 (1999) Lab Invest 79:327-36). 2 µg of human tonsil HEVEC, Rheumatoid arthritis ECs, Crohn's disease ECs, Colon tumor ECs or Hela cells total RNA was reverse transcribed using superscript<sup>TM</sup> first strand synthesis system from Invitrogen. 1/20 of reaction products were subjected to PCR amplification with 10 pmol of primers using Advantage2 polymerase mix according to the supplier's instructions in a 25 µl reaction volume with 30 cycles (94°C,

20 15''; 60°C, 20''; 72°C, 1'). The following *NF-HEV*- and *G3PDH*-gene specific primers were used: *NF-HEV*, NF-HEV-1: 5'- CACCCCTCAAATGAATCAGG 3' and NF-HEV-2: 5'- GGAGCTCCACAGAGTGTTC 3'; *G3PDH*, G3PDH-1: 5'- ACCACAGTCCATGCCATCAC 3' and G3PDH-2: 5'- TCCACCACCCTGTTGCTGTA 3'.

EXAMPLE 10In vitro assay to identify NF-HEV polypeptide DNA targets

DNA binding specificity of NF-HEV is determined using a random oligonucleotide selection method allowing unbiased analysis of binding sites selected by the NF-HEV protein from a random pool of possible sites. The method is carried out essentially as described in

30 Pollack and Treisman (1990), A sensitive method for the determination of protein-DNA binding specificities. Nuc. Acid Res. 18:6197-6204. Also, see (Blackwell and Weintraub,



(1990) Science 250: 1104-1110; Ko and Engel, (1993) Mol. Cell. Biol. 13:4011-4022; Merika and Orkin, (1993) Mol. Cell. Biol. 13: 3999-4010; and Krueger and Morimoto, (1994) Mol. Cell. Biol. 14:7592-7603), the disclosures of which are incorporated herein by reference in their entireties.

5

#### *Random Oligonucleotide Selection*

According to the protocol of Pollack and Treisman (1990), supra, a 77 bp oligonucleotide having sequences as follows is synthesized: 5'-CAGGTCAGTTCAGCGGATCCTGTCG-(N)27-

10 GAGGCGAATTCAGTGCAACTGCAGC-3', where N is any nucleotide, and primers complementary to each end. Primer P is: 5'-GCTGCAGTTGCACTGAATTCGCCTG-3', and primer R is 5'-CAGGTCAGTTCAGCGGATCCTGTCG-3'.

The 77-mer is purified on an 8% denaturing acrylamide gel and used to prepare a probe for gel shift analysis. The 77-mer oligonucleotide is labeled and made double stranded  
15 with Klenow fragment in the presence of [ $\alpha$ -<sup>12</sup>P]dCTP. Approximately 5ng of labeled probe and 1 $\mu$ g of poly(dI-dC) is mixed with 10nM NF-HEV protein or a portion thereof and incubated at 25C for 30 min. The extended binding reaction permits proteins to cycle through several association and dissociation events, leading to the isolation of higher-affinity selected sequences. The binding reaction mixture is then subjected to electrophoresis on a  
20 4% (40:1) acrylamide gel in 0.25x Tris-borate-EDTA buffer for 2h at 150V. The gel is dried and exposed to XAR-5 film at -70C overnight. The NF-HEV shifted DNA complexes are excised from the dried gel and incubated in 200 $\mu$ l of 10mM Tris-HCl, pH 8.0 for 3h at 37C. Ten microliters of the eluted DNA is used in a PCR to make probe for the next round of selection. PCR conditions are 10mM Tris-HCl, pH 8.8, 50mM KCl, 6mM MgCl<sub>2</sub>; 1mM  
25 dithiothreitol; 0.18 $\mu$ M primers P and R 10 $\mu$ Ci of [ $\alpha$ -<sup>12</sup>P]dCTP; 50 $\mu$ M each of dATP, dTTP and dGTP; and 20 $\mu$ M of dCTP. Final reaction volume is 100 $\mu$ l, and the parameters are 20 cycles at 94C for 1 min, 62C for 1 min and 72C for 1 min. In subsequent rounds, 1.5 nM protein is used. After five rounds of selection by NF-HEV, pools of amplified oligonucleotides are digested with BamHI and EcoRI and cloned into Bluescript KS-  
30 (Stratagene). The blue and white colony selection method is used to identify possible

recombinants, and the composition of the insert is determined by dideoxy sequencing of the denatured double-stranded templates.

#### EXAMPLE 11

5     High throughput in vitro assay to identify inhibitors of NF-HEV polypeptide or NF-HEV interactions with nonspecific DNA targets

High throughput assays for the detection and quantification of NF-HEV-nonspecific DNA binding is carried out using a scintillation proximity assay. Materials are available from Amersham (Piscataway, NJ) and assays can be carried out according to Gal S. et al, 6<sup>th</sup>  
10   Ann. Conf. Soc. Biomol. Screening, 6-9 Sept 2000, Vancouver, B.C.), the disclosure of which is incorporated herein by reference in its entirety.

Random double stranded DNA probes are prepared and labelled using [<sup>3</sup>H]TTP and terminal transferase to a suitable specific activity (e.g. approx. 420i/mmol). NF-HEV protein or a portion thereof is prepared and the quantity of NF-HEV protein or a portion thereof is  
15   determined via ELISA. For assay development purposes, electrophoretic mobility shift assays (EMSA) can be carried out to select suitable assay parameters. For the high throughput assay, <sup>3</sup>H labelled DNA, anti-NF-HEV monoclonal antibody and NF-HEV in binding buffer (Hepes, pH7.5; EDTA; DTT; 10mM ammonium sulfate; KCl and Tween-20) are combined. The assay is configured in a standard 96-well plate and incubated at room  
20   temperature for 5 to 30 minutes, followed by the addition of 0.5 to 2 mg of PVT protein A. SPA beads in 50-100 µl binding buffer. The radioactivity bound to the SPA beads is measured using a TopCount™ Microplate Counter (Packard Biosciences, Meriden, CT).

#### EXAMPLE 12

25     High throughput in vitro assay to identify inhibitors of NF-HEV polypeptide or NF-HEV interactions with specific DNA targets

High throughput assays for the detection and quantification of NF-HEV specific DNA binding is carried out using a scintillation proximity assay. Materials are available from Amersham (Piscataway, NJ) and assays can be carried out according to Gal S. et al, 6<sup>th</sup> Ann.  
30   Conf. Soc. Biomol. Screening, 6-9 Sept 2000, Vancouver, B.C.).

NF-HEV-specific double stranded DNA probes corresponding to NF-HEV DNA binding sequences obtained according to Example 20 are prepared. The probes are labelled using [ $^3\text{H}$ ]TTP and terminal transferase to a suitable specific activity (e.g. approx. 420i/mmol). NF-HEV protein or a portion thereof is prepared and the quantity of NF-HEV protein or a portion thereof is determined via ELISA. For assay development purposes, electrophoretic mobility shift assays (EMSA) can be carried out to select suitable assay parameters. For the high throughput assay,  $^3\text{H}$  labelled DNA, anti-NF-HEV monoclonal antibody, 1 $\mu\text{g}$  non-specific DNA (double or single stranded poly-dAdT) and NF-HEV protein or a portion thereof in binding buffer (Hepes, pH7.5; EDTA; DTT; 10mM ammonium sulfate; KCl and Tween-20) are combined. The assay is configured in a standard 96-well plate and incubated at room temperature for 5 to 30 minutes, followed by the addition of 0.5 to 2mg of PVT protein A SPA beads in 50-100 $\mu\text{l}$  binding buffer. The radioactivity bound to the SPA beads is measured using a TopCount<sup>TM</sup> Microplate Counter (Packard Biosciences, Meriden, CT).

### EXAMPLE 13

#### Preparation of antibody compositions

Substantially pure NF-HEV protein or a portion thereof is obtained. The concentration of protein in the final preparation is adjusted, for example, by concentration on an Amicon filter device, to the level of a few micrograms per ml. Monoclonal or polyclonal antibodies to the protein can then be prepared as follows: Monoclonal Antibody Production by Hybridoma Fusion Monoclonal antibody to epitopes in the NF-HEV protein or a portion thereof can be prepared from murine hybridomas according to the classical method of Kohler and Milstein (Nature, 256: 495, 1975) or derivative methods thereof (see Harlow and Lane, Antibodies A Laboratory Manual, Cold Spring Harbor Laboratory, pp. 53-242, 1988), the disclosure of which is incorporated herein by reference in its entirety.

Briefly, a mouse is repetitively inoculated with a few micrograms of the NF-HEV protein or a portion thereof over a period of a few weeks. The mouse is then sacrificed, and the antibody producing cells of the spleen isolated. The spleen cells are fused by means of polyethylene glycol with mouse myeloma cells, and the excess unfused cells destroyed by

growth of the system on selective media comprising aminopterin (HAT media). The successfully fused cells are diluted and aliquots of the dilution placed in wells of a microtiter plate where growth of the culture is continued. Antibody-producing clones are identified by detection of antibody in the supernatant fluid of the wells by immunoassay procedures, such as ELISA, as originally described by Engvall, E., Meth. Enzymol. 70: 419 (1980), the disclosure of which is incorporated herein by reference in its entirety. Selected positive clones can be expanded and their monoclonal antibody product harvested for use. Detailed procedures for monoclonal antibody production are described in Davis, L. et al. Basic Methods in Molecular Biology Elsevier, New York. Section 21-2, the disclosure of which is incorporated herein by reference in its entirety.

#### *Polyclonal Antibody Production by Immunization*

Polyclonal antiserum containing antibodies to heterogeneous epitopes in the NF-HEV protein or a portion thereof can be prepared by immunizing suitable non-human animal with the NF-HEV protein or a portion thereof, which can be unmodified or modified to enhance immunogenicity. A suitable nonhuman animal, preferably a non-human mammal, is selected. For example, the animal may be a mouse, rat, rabbit, goat, or horse. Alternatively, a crude protein preparation which, has been enriched for NF-HEV or a portion thereof can be used to generate antibodies. Such proteins, fragments or preparations are introduced into the non-human mammal in the presence of an appropriate adjuvant (e. g. aluminum hydroxide, RIBI, etc.) which is known in the art. In addition the protein, fragment or preparation can be pretreated with an agent which will increase antigenicity, such agents are known in the art and include, for example, methylated bovine serum albumin (mBSA), bovine serum albumin (BSA), Hepatitis B surface antigen, and keyhole limpet hemocyanin (KLH). Serum from the immunized animal is collected, treated and tested according to known procedures. If the serum contains polyclonal antibodies to undesired epitopes, the polyclonal antibodies can be purified by immunoaffinity chromatography.

Effective polyclonal antibody production is affected by many factors related both to the antigen and the host species. Also, host animals vary in response to site of inoculations and dose, with both inadequate or excessive doses of antigen resulting in low titer antisera.

Small doses (ng level) of antigen administered at multiple intradermal sites appears to be most reliable. Techniques for producing and processing polyclonal antisera are known in the art, see for example, Mayer and Walker (1987), the disclosure of which is incorporated herein by reference in its entirety. An effective immunization protocol for rabbits can be found in  
5 Vaitukaitis, J. et al. J. Clin. Endocrinol. Metab. 33: 988-991 (1971), the disclosure of which is incorporated herein by reference in its entirety. Booster injections can be given at regular intervals, and antiserum harvested when antibody titer thereof, as determined semi-quantitatively, for example, by double immunodiffusion in agar against known concentrations of the antigen, begins to fall. See, for example, Ouchterlony, O. et al., Chap. 19 in:  
10 Handbook of Experimental Immunology D. Wier (ed) Blackwell (1973). Plateau concentration of antibody is usually in the range of 0.1 to 0.2 mg/ml of serum (about 12: M). Affinity of the antisera for the antigen is determined by preparing competitive binding curves, as described, for example, by Fisher, D., Chap. 42 in: Manual of Clinical Immunology, 2d Ed. (Rose and Friedman, Eds.) Amer. Soc. For Microbiol., Washington, D.  
15 C. (1980).

Antibody preparations prepared according to either the monoclonal or the polyclonal protocol are useful in quantitative immunoassays which determine concentrations of antigen-bearing substances in biological samples; or they are also used semi-quantitatively or qualitatively to identify the presence of antigen in a biological sample. The antibodies may  
20 also be used in therapeutic compositions for killing cells expressing the protein or reducing the levels of the protein in the body.

Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it is readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes  
25 and modifications may be made thereto without departing from the spirit and scope of that which is described and claimed.

Numerous literature and patent references have been cited in the present application. All references cited are incorporated by reference herein in their entireties.

WHAT IS CLAIMED IS:

1. A method of reducing the symptoms of a condition associated with inflammation, said method comprising modulating the level of transcription of at least one promoter responsive to an NF-HEV polypeptide or biologically active portion thereof.
- 5 2. The method of Claim 1, wherein said NF-HEV polypeptide or biologically active fragment thereof comprises an amino acid sequence selected from the group consisting of amino acids 1-65 of SEQ ID NOs: 4-6.

**NF-HEV GENE, PROTEIN, ASSAYS FOR INHIBITORS OF HEV-LIKE VESSEL  
DEVELOPMENT IN CHRONIC INFLAMMATION**

Abstract of the Disclosure

5 The present invention relates to uses of NF-HEV nuclear factor polynucleotides and  
polypeptides expressed in endothelial cells from chronically inflamed tissues, particularly in  
high endothelial venules endothelial cells (HEVECs) and endothelial cells from HEV-like  
vessels and small blood vessels in rheumatoid arthritis and Crohn's disease. The invention  
also relates to drug screening assays for identifying compounds capable of modulating NF-  
HEV activity, which compounds may be used in inhibiting or preventing chronic  
10 inflammation.

S:\DOCS\VLH\VLH-1706.DOC  
121902


NF-HEV GENE, PROTEIN, ASSAYS FOR INHIBITORS OF HEV-LIKE  
VESSEL DEVELOPMENT IN CHRONIC INFLAMMATION

Girard et al.  
Appl. No.: Unknown Atty Docket: BIOBANK.01/PR



Girard et al., Fig 1




		Helix 1	Helix 2 - Turn - Helix 3
hNF-HEV	1	KKPKKKKYSTNHIISTKWKNTASKEELC--EKLGGKQQAEEVCPNYEHKLESGLMIKKERL	
caDVS27	1	---HKKYSTTKIPPAKHHSSEDEKLKSPKLRKQQAEEVCPNYEHKLESGLMIKKERL	
mNF-HEV	1	KKPKKKKYSTNHIISTKWKNTASKEELC--EKLGGKQQAEEVCPNYEHKLESGLMIKKERL	
		Bipartite NLS	
hNF-HEV	69	YERKEITKRPGLKTERHHKRLVLARCQQSTVRCFARGSSVQHYTRALHDSITGTS	
caDVS27	67	YERKEITKRPGLKTERHHKRLVLARCQQSTVRCFARGSSVQHYTRALHDSITGTS	
mNF-HEV	61	YERKEITKRPGLKTERHHKRLVLARCQQSTVRCFARGSSVQHYTRALHDSITGTS	
hNF-HEV	119	ITEYLLASLTYNQDSITFALEDESYEIVVEGLKEDKEDKEDVLLSYYESQHPSHESQDQVD	
caDVS27	111	IQEYSSALSTYNQDSITFALEDESYEIVVEGLKEDKEDKEDVLLSYYESQHPSHESQDQVD	
mNF-HEV	116	LTQSPASLTYNQDSVSEVLEHGCYVINVDLSGKEDQEQDQVLLRYYESPCASQSGDQVD	
hNF-HEV	179	GKMLKVVTLSP--KDFGLHANNHHEHVELKCEKPLPDQAEFFVLHNNH--CVFECKTDF	
caDVS27	171	GQTLLVNLSPTEKDELLHANNHHEHVELKCEKPLPDQAEFFVLHNNH--CVFECKTDF	
mNF-HEV	176	GKRVVNVHSPFKDTEIWLHANNHHEHVELKCEKPLPDQAEFFVLHNNH--CVFECKTDF	
hNF-HEV	237	GVEIGVKDNHLRLIKV--SSSEELCTENILEKLSPT	
caDVS27	231	GVEIGVKDNHLRLIKV--SSSEELCTENILEKLSPT	
mNF-HEV	236	GTVIGVKDNQLRLVLR--KDE--SCNNILEKLSKI	



Girard et al., Fig 2











## DNA sequences

## SEQ ID 1

➤ human NF-HEV cDNA - GenBank AB024518

CACAAGAATACTGAAAAATGAAGCCTAAATGAAGTATTCAACCAACAAAATTTCCACAGCAAAGTGGAAG  
GAACACAGCAAGCAAAGCCTTGTGTTTCAAGCTGGGAAAATCCCAACAGAAGGCCAAAGAAGTTTGCCCC  
ATGTACTTTATGAAGCTCCGCTCTGGCCTTATGATAAAAAAGGAGGCCTGTACTTTAGGAGAGAAACCA  
CCAAAAGGCCCTTCACTGAAAACAGGTAGAAAGCACAAAAGACATCTGGTACTCGCTGCCTGTCAACAGCA  
GTCTACTGTGGAGTGCTTTGCTTTGGTATATCAGGGGTCCAGAAATATACTAGAGCACTTCATGATTCA  
AGTATCACAGGAATTTACCTATTACAGAGTATCTTGCTTCTCTAAGCACATACAATGATCAATCCATTA  
CTTTTGCTTTGGAGGATGAAAGTTATGAGATATATGTTGAAGACTTGAAAAAAGATGAAAAGAAAGATAA  
GGTGTTTACTGAGTTACTATGAGTCTCAACACCCCTCAAATGAATCAGGTGACGGTGTGATGGTAAGATG  
TTAATGGTAACCTGAGTCTTACAAAAGACTTCTGGTTGCATGCCAACACAAGGAACACTCTGTGGAGC  
TCCATAAGTGTGAAAAACCACTGCCAGACCAGGCCTTCTTTGCTTTCATAATATGCACTCCAAGTGTGT  
TTCATTTGAAATGCAAGACTGATCCTGGAGTGTATATAGGTGTAAAGGATAATCATCTTGCTCTGATTAAA  
GTAGACTCTTCTGAGAAATTTGTGACTGAAAATATCTTGTTTAAGCTCTCTGAAACTTAGTTGATGGAAA  
CCTGTGAGTCTTGGGTTGAGTACCCAAATGCTACCACTGGAGAAGGAATGAGAGATAAAGAAAGAGACAG  
GTGACATCTAAGGGAAATGAAGAGTGCTTAGCATGTGTGGAATGTTTTCCATATTATGTATAAAAAATATT  
TTTTCTAATCCTCCAGTATTCTTTTATTTCCCTCTGTATAAAGTGCATCTTCAATACAAGTATCAGTATA  
TTAATATAGGGTATTGGTAAAGAAACGGTCAACATTTCTAAAGAGATACAGTCTGACCTTTACTTTTCTCTA  
GTTTCAGTCCAGAAAGAACTTCATATTTAGAGCTAAGGCCACTGAGGAAAGAGCCATAGCTTAAGTCTCT  
ATGTAGACAGGGATCCATTTTAAAGAGCTACTTAGAGAAATAATTTTCCACAGTTCCAAACGATAGGCTC  
AAACACTAGAGCTGCTAGTAAAAAGAAAGACCAGATGCTTCACAGAATTATCATTTTTTCAACTGGAATAA  
AACACCAGGTTTGTGTTGTAGATGCTTAGGCAACACTCAGAGCAGATCTCCCTTACTGTGAGGGGATATG  
GAACCTCAAAGGCCACATGGCAAGCCAGGTAACATAAATGTGTGAAAAAGTAAAGATAACTAAAAAATT  
TAGAAAAATAAATCCAGTATTTGTAAAGTGAATAAATCTCATTTCTAATTGTTTAATTTTTAAATTTCTGA  
TTTTTATATATTGAGTTTAAGCAAGGCATTCTTACACGAGGAAGTGAAGTAAATTTTAGTTTCAGACATAA  
AATTTCACTTATTAGGAATATGTAACATGCTAAACCTTTTTTTTTTTTAAAGAGTACTGAGTCACAACAT  
GTTTTAGAGCATCCAAGTACCATATAATCCAATATCATGGTAAAGCCAGAAATCTTCTAACCTACCAGA  
GCCTAGATGAGACACCGAATTAACATTAATAATTTTCACTAAGTACTGCTGCTCCCTCATGTCCATGGCCTACCA  
TCCCTTCTGACCCTGGCTTCCAGGGACCTATGCTTTTTAATACTCACTGTTCACATTGGGCAAAGTTGCTT  
CTAATCCTTATTTCCCATGTGCACAAGTCTTTTTGTATTCCAGCTTCTCTGATAACACTGCTTACTGTGGA  
ATATTCATTTGACATCTGTCTCTTTTCACTTCTTTTAACTACCATGCCCTTGATATATCTTTTGACCTG  
CTGAACCTTCACTTCTGTATCACCTGACCTCTGGATGCCAAAACGTTTATTCTGCTTTGTCTGTTGTAGAA  
TTTTAGATAAAGCTATTAATGGCAATATTTTTTTGCTAAACGTTTTTGTTTTTTACTGTCACTAGGGCAA  
TAAATTTTATACTCAACCATATAATAACATTTTTTAACTACATAAAGGAGTAGTTTTTATTPTAAAGTCT  
TAGCAATTTCTATTACAACCTTTTCTTAGACTTAACACTTATGATAAATGACTAACATAGTAACAGAATCT  
TTATGAAATATGACCTTTTCTGAAAATACATACTTTTACATTTCTACTTTATTGAGACCTATTAGATGTA  
AGTGCTAGTAGAATATAAGATAAAAGAGGCTGAGAATTTACCATAACAAGGGTATTACAACCTGTAACCAAT  
TTATCTTTGTTTCAATTGTTCTGTCAATAATTGTTTACCAAGAGATAAAAATAAAAAGCAGAAATGTATATCA  
TCCCATCTGAAAAACACTAATTATTGACATGTGCATCTGTACAATAAATTTAAATGATTATTAAATAAT  
CAAATATATCTACTACATTGTTTATATTATTGAATAAAGTATATTTTCCAAATGT

## SEQ ID 2

➤ mouse NF-HEV cDNA - GenBank XM\_123362

AAACCTGAAAAATGAGACCTAGAATGAAGTATTCCAACCTCCAAGATTTCCCCGGCAAAGTTCAGCAGCAC  
CGCAGGCGAAGCCCTGGTCCCGCCTTGCAAAATAAGAAGATCCCAACAGAAGACCAGAAGATTCCTGCCAT  
GTCTACTGCATGAGACTCCGTTCTGGCCTCACCATAGAAGAGAGACTAGTTATTTTAGGAAAGAACCCA  
CGAAAAGATATTTCACTAAAATCGGGTACCAAGCATGAAGAGAACTTCTCTGCCTATCCACGGGATTTCTAG  
GAAGAGATCCTTGCTTGGCAGTATCCAAGCATTGCTGCGTCTGTTGACACATTGAGCATCCAAGGAACCT  
TCACCTTTTAACACAGTCTCTGCTCCCTGAGTACATAAATGACCAATCTGTTAGTTTTGTTTGGAGA  
ATGGATGTTATGTGATCAATGTTGACGACTCTGGAAAAGACCAAGAGCAAGACCAGGTGCTACTACGCTA  
CTATGAGTCTCCCTGTCTGCAAGTCAATCAGGCGACGGTGTGGATGGGAAGAAGCTGATGGTGAACATG  
AGTCCCATCAAAGACACAGACATCTGGCTGCATGCCAACGACAAGGACTACTCCGTGGAGCTTCAAAGGG  
GTGACGCTCTCGCTCCGGAACAGGCCTTCTTCGTCTTCCAAAAAGTCTCGGACTTTGTTTCATTTGA

ATGCAAGAATCTTCCTGGCACCTACATAGGAGTAAAAAGATAACCAGCTGGCTCTAGTGGAGGAGAAAGAT  
 GAGAGCTGCAACAATATTATGTTTAAAGCTCTCGAAAATCTAATGCAGTAAAACGCCTGTGCGTTCTGGGT  
 TGAATGACTTAATGCTTCCAACCTGAAGAAAAGGGTAACAGAGAGAAAGAAAGCCATTCTTGGCTTACGATG  
 TTGTGGAATGTTATTATGTAGAAAACCTCTTTTATTTCTTTTCTTCAGCTACATGTTCAATAGACTCAC  
 AGATATATGACTTACGGCGTTGGTAAAGAACTGAAGGAGATTAGCCTTGCTCTTTCTTTCTCTGCTGCT  
 TTGAGTCTGTATGAAATCACACTCACGGACTTCAGAAGAGCAGGCACCAACAGTGCATGGTTTGGCTTTAG  
 AGAGGGTCCATTTCAAAAACCTTCATAAAAAAATGCAAAAACAAGAAAACAACCGAACAACCAAGGAGGAT  
 TATTTCTGGTTCATAAACAAATGATTGTAATACTAGAGCAGTTAGTGGGAGGACCAGCTAGGGGGAGGAT  
 CACCTAGGGGAGGACCAGCTAGGGGGAGGACCAGCTGCTGCAAAGACTGACTGTTTCTCACTTATAATAA  
 AATGCCAAATGCCTCCGCAGATGCCCCAGGCAACCCCTCAGATCAGCCCTTCTGTGAAGAGTGGCGTTAC  
 CTGTGCTTGTTCCTTCTTAACTTCCAATTTTTCTCTTTTAAACATTTAAACATTTAACTTTAAGCAAG  
 CCAGCTTACATTAGGAAGTGAAAGACATTTTAGTTCACCCCGTGATTGAAATCATTGACTATATCTAAC  
 AAGCTTAAAGTCTCCTGTAAGAACTGATCAGGATATACACTAGGACATGCCAATAGAATGGGATCTCATG  
 GTGCAGTCTGAAGCCCTCCAACCTGGAGAGACGCTAACATCATCCTTCTCGCTGATTTTCAAGGAGTATG  
 ACTTTGGATGCATGCATCTGCTTGGATGAGATGTCTCGGCTGCTTGCTTTCTTATGCACACGTTCTGTT  
 CAGCTTCACAGCAGCAATGCTCACGGTGAATAGCTTAGCTTAGCTTCTGCCCCTTCTTTGGTTCTTTTG  
 ACCACCATATCCGTAACGGCTCTCCTACTCCCTCAGCTTTCTTTCTTTGCTCTGACGCTATATGCCA  
 ACACACTTATTCCACTGTCTTACCCTGCACTGCAGAAATTTACATCTACCTACTGGTTACCAGGTTGTC  
 CCCTGAACAACCTTCCCTTTGTGTTTACTGTTTATTAAAGTAGTAATATTTGTATTCAACCATGTAGTAAT  
 ATTTTAAAGCCACTAAAGGAATAGTTTACTTATTAGACAACAGCAATTTCTACTACATTTTATAAGCT  
 TAAAACCTTACATGTTTTTAAACCTTAAACGATAAAGACAATAACAACATTGATGGAGTATGATGACAG  
 TTCAGAAAGGGTTAGCTCTTATCTTCCAGTGCAGGAAACCTATTGTATACAATAGCTGGAGGAATGTATG  
 ATCAAAGAGGCCGGGAACCGCGTGTAGGATCGTACGGCTGTAACAGGTATAATTGTTTCATTAATTTGT  
 CACAGTCTTACTGTAGAGGAATGTAAAGGCGGAATCTGCGTCATTCTCTGGAACACAGTGTGACTC  
 TGTGAATCTGTACGATATCTTTAAAGTAGTAACCTAGTAGTCAAATGTGTTCTTGACGTTGTTCACTA  
 TTGAATAAACCATTTTCAAAACCACGTGTGACCAC

SEQ ID 3

> canine NF-HEV cDNA - GenBank AB024517

TTCAGAGGAGAAAATCAAAAACAAGATTACACGAAGCTTCAACAACAAGGCTAAAATGAAGTATTCAACCA  
 CGAAAATCCCCCAGCAAGATGAACAGTTTCCAGCAGACAAGGCTTTGGTAAAATCTCCTAAGCTGAGAAA  
 ATCCCAACAGAAGCCTGAAGGAGTTTGCCAGATGTACTTTATGCAACTGCGTTCTGGCCTTATCATAGAA  
 AAGACATCCTGTACTTTAGGAAAGAAATCACCAAAAGGTATTCCCAAGAACAGCTGAAAAGTGCAGAA  
 AGCAATGTCTGGTATTCACTGCCTGTATCAGCAGCTGAACAAAGATTTACCTCTGATGTCCTTATGTT  
 ACAGAAATGTTTGGAGAGCTAATGTTCCAAGTATCCAAGAATATTCTGCTTCTCTGAGCACATACAAT  
 GATCAATCTATTACTTTCTGTTTTGAGGATGGAAGTTATGAGATCTATGTAGAAGACTTGAGAAAAGGCC  
 AAGAGAAAGATAAGGTGTTATCCGTTATTATGATTCCCAATCCCCCTCACATGAAACAGGTGATGATGT  
 TGATGGCCAGACGTTATTGGTAAACCTGAGTCTTACAAAAGATAAAGATTTTTGCTGTCATGCCAACAA  
 GAGGAACATTCTGTGGAGCTACAAAATGTGAAAACCAATTGCCAGACCAAGGCTTCTTCTCTCTCATA  
 GGAAGTCTTCTGAATGTGTTTCATTGCAATGTAAGAACAATCCTGGAGTGTTTATAGAGTAAAGGATAA  
 CCACCTTGCTTTAATTAAAGTAGGAGACCAAACTAAGGATTTCATATATAGAGAAAACCATATTTAAGCTC  
 TCTTAAATTTAATGGGATGAAAAAGTTGTCAATCCTGGGTTGGGTAGCCAGATAGCTACTGCTGAAGA  
 AAGAATAAGAGATAAAGAGATAGACAACATTTAAGGGAATAAAGAGTACTTAGTATGCTATGGAATGTT  
 TTTCTTATTATGTGTAAAATATATTTTTATAATCCTTCAGTTCTGTTTTTATTACCTTGTCTCACTAC  
 ATATTCAATAGTGTATTATTAAGGAGACCTCAGAAAATATACAACCTGACTTTTACTTTTTCTACTTGCT  
 GTCAAGAAAGAGCTTAATATCTAATTAAGCTCTGCTGAGACCTCTGGGGACAAGGAAGGCCCTTAATCCA  
 AGTTTTCATTTTAGACAAGGATTTCAAAAAGCCACATAGAGACATAATTTCCCTGGTTCCAAAACAAGTTC  
 AAACAGTAGAGCTGTTGGTGAAAAGACAATCAGCTCTACTTAGACTGAACATTTCAAAATGGAATAAAA  
 CACCAAAATTTGTTGAAGATTTCCAAAATTTAGATACCTTACACATGTAGGCAGATAATATAAATATGTG  
 AAATGACAGAGACAATTGAAAAAATTAAGAAAAATAAATCCTGTATTTGTAAAGTAAATAATTTTACCTC  
 TAATTGTTTCATTTTTTAAATGCTGATTTTTTATAGATGGAGTTAAATTTAGCAAGACATTCTTACATTAG  
 GAAGTAAATAAATTTTATCTCAGACATATAATTGAAATCATTTGGGAATATCTCAAAACTAAAACATTA  
 TTTTAAAGCACTGAGACACAACATACCTTAAGACATCAAAGTACCATGGGATCCAAGTACCATGGTGAGG  
 CCACAAGTTCCTTATCTACTAGAAGCTAGATTGGACACAGCATTAAACATTACAATTTTAAATACTGGCT  
 ATCCCTTATGTTTATTGTATACCTGCTTTCTGACTCTATGCTCCAGGGATCTGTAACCTTGATATACATGT  
 CACCTGCACAAAATTTCTTATAATCCTTTCTTACCATGTGTACAAGTGTTTTCTTGTCCACCTTCTGT  
 ATTAGTCTGTTTACTATGGAATATTTATTGACTTTTCTTCTTCAATTTCTTTTGACCAACTCTGTTCTTG

ATATACATTTTGTGCCCCGTGAGCTTCATTCCATATCACCTGACCTCTGGACACCAACATATTTTCTAT  
 TTGTCTCTCTGATGTAGAAATTTACATAAGCCTATTGATGGGAATATTTTATTAAACATCTTTGTAT  
 TTTACATTACTAAGGTAGTAAAATTTATTCTCAACGATATATGATTTTCAACTACTAAAGGAATAATTT  
 TTGCTTATTTTAAAGTCTTAAATTTCTACTATAAATTTTTCATAGGCTTAACATTGACAATAAGTGATAAAC  
 TAGTAACAGAATACTTATGAAATACAACCTGTTTCTGAAAGTGTGGCTTTTAAATTTCTAATTTGTTGAGA  
 TCTATTGGATATAATGATGGTGGAACATAAGATTAGAAAGGCTGAGAATTACTGAGTGAGGGTAACAAT  
 TGTAAACAACATAGCTTTTCATTACATTGTCAGTTTTATTATGAAGACAAAAATAAAAGCAGAAATATATAT  
 CATCTTCTCTGAAAAACACTAAATGTTGACCATATGCATCTGTATGATATACTCGAAATGATTTGTTTTA  
 AGTAACTAAATATATTAATTACATTAAATTTCTCAAGTTGTATTTTTTAAAGTATGTGAGGCCATGATGA  
 TTTTATCATAAAATAACTATTCTGAAATTTTAAAGTCAAAGCAATCTTACCTTAATCCACTGATGTTGGT  
 ATCTGGGGTAGGTCATTTGTCTGGTGATTCAAACTAAATAAGATATTCAAAG

## SEQ ID 4

> human NF-HEV protein

MKPCKMYSTNKISTAKWKNTASKALCFKLGKSQOKAKEVCPMYFMKLRSGLMIKKEACYFRRETTKRPSL  
 KTGRKHKRHLVLAACQQQSTVECFAGFISGVQKYTRALHDSSITGISPITEYLASLSTYNDQSITFALED  
 ESYEIYVEDLKKDEKKDKVLLSYYESQHPSNESGDGVDGKMLMVTLSPTKDFWLHANNKEHVELHKCEK  
 PLPDQAFVFLHNMHSNCVSFECKTDPGVFIGVKDNHLALIKVDSSENLCTENILFKLSET

## SEQ ID 5

> mouse NF-HEV protein

MRPRMKYSNSKISPAKFSSTAGEALVPPCKIRRSQOKTKEFCHVYCMRLRSGLTIRKETSIFRKEPTKRY  
 SLKSGTKHEENFSAYPRDSRKRSLLSIQAFASVDTLISIQGTSLLTQSPASLSTYNDQSVSFVLENGCY  
 VINVDDSGKQEQDQVLLRYYESPCPASQSGDVGDKKLMVNMSPIKDTDIWLHANDKDYSVELQRGDVS  
 PPEQAFVFLHKKSSDFVSFECKNLPPTYIGVKDNQLALVEEKDESCNNIMFKLSKI

## SEQ ID 6

> canine NF-HEV protein

MKYSTTKIPPAKMNSSADKALVKSPKLRSQOKPEGVCQMYFMQLRSGLIIEKTSCYFRKEITKRYSPRT  
 AEKCRKQCLVFTACHQQLNKDFTSDVPMLQKCFGRANVPSIQEYSASLSTYNDQSITFVFEDGSYEIYVE  
 DLRKGQEKDKVLFYRYSQSPSHETGDDVDGQTLNLVNLSPTKDKDFLLHANNNEHVELQKCENQLPDQA  
 FFLHHRKSSECVSFECKNPNPGVFIGVKDNHLALIKVGDTKDSYIEKTIFKLS

## SEQ ID 7

> human NF-HEV genomic DNA sequence - GenBank NT\_008413 16301 bp DNA linear

DEFINITION Homo sapiens chromosome 9 reference genomic contig.  
 ACCESSION NT\_008413 REGION: 6102429..6118729  
 VERSION NT\_008413.12 GI:22047017

Human NF-HEV mRNA join(1..104,8793..8918,9459..9584,11185..11310,  
 11871..11921,12781..12872,14287..16301)

Human NF-HEV coding sequence  
 join(14..104,8793..8918,9459..9584,11185..11310,  
 11871..11921,12781..12872,14287..14487)

variation 9009 / allele="A" /allele="T" /db\_xref="dbSNP:885090"  
 variation 9331 / allele="C" /allele="A" /db\_xref="dbSNP:1317230"  
 variation 9774 / allele="T" /allele="C" /db\_xref="dbSNP:1854709"



variation 9826 / allele="T" / allele="G" / db\_xref="dbSNP:1330383"  
 variation 9907 / allele="T" / allele="C" / db\_xref="dbSNP:1929992"  
 STS 10121..10293 / standard\_name="RH46528" / db\_xref="UniSTS:9396"  
 variation 10305 / allele="G" / allele="A" / db\_xref="dbSNP:1330382"  
 variation 11505 / allele="G" / allele="C" / db\_xref="dbSNP:995919"  
 variation 13329 / allele="C" / allele="A" / db\_xref="dbSNP:1412421"  
 variation 13471 / allele="G" / allele="A" / db\_xref="dbSNP:1412420"  
 variation 14200 / allele="T" / allele="G" / db\_xref="dbSNP:1332290"  
 variation 14611 / allele="A" / allele="G" / db\_xref="dbSNP:1048274"  
 variation 14848 / allele="A" / allele="C" / db\_xref="dbSNP:1048279"  
 STS 16054..16185 / standard\_name="D9S2078" / db\_xref="UniSTS:25864"  
 STS 16065..16220 / standard\_name="RH47407" / db\_xref="UniSTS:79761"  
 variation 16217 / allele="G" / allele="A" / db\_xref="dbSNP:8172"  
 variation 16258..16260 / allele="-" / allele="ACT" / db\_xref="dbSNP:3069904"

```

agaatactga aaaaatgaagc ctaaaatgaa gtattcaacc aacaaaattt ccacagcaaa 61
gtggaagaac acagcaagca aagccttggtg tttcaagctg ggaagtaagg acttaagtta 121
tctctgaatg ttttacgcac tttttttatc tggtatcaaa tttttatact ccaatgttta 181
tacatgctat cttatcaaaa tctactaaga ataagaagac taaaataaaa agagatggca 241
cataagggta taatacagca gactgggttt gaaccaacca tatatagcca actttggcat 301
atttgatata tcaccaggca ggaatagctg agataatctg aacctgtgaa tagtgataaa 361
cttaattata gcctttttata tcaaccactt tttgctccac acacctcctg ctgccaaacc 421
cccaaaacct tttccctgat aaactagcaa acttttaagc aggtccactt ttattcaaca 481
aatattcatt aagacctttg gtggtatcag gcatgtggtc ttaacttgcy actactgatg 541
aagaagagaa taacagatga agatatttga ataactatct tagtcaattt gtgttaccat 601
agaaatatac ctgaagctgg gtaatttaac cctttttcca tttagaaaaa aaagtgcagc 661
ttgctgccag cgcttattta atttttacata aacatctctt tgaggctgaa gcaaatctga 721
ttttcaatgc aaaaatagaa taaaaaaact gttcttggag ttattttctaa acagaactac 781
catcagcatt gtctattttca gaaaaaatga gattcaccaa atgaaacttc agcaagcaac 841
taactgttca agaagtgttc aagaatgtta acatcacatg taggaatgct acattttcca 901
ggatttgaca ttttcagcga tcaagaatta ctatatttta tcaatgaaaa taccactact 961
aaaaacataa atagaatgat gtcttttgggt tccaaagtgt atatactaga gagatgtaaa 1021
aataataata aaagcaagat ctttcgtggc aaagtatatc taaacactgc agaagcactg 1081
ccagtaatta ttctctgggc aaatgggaaa ggggttaaaaa caaaagaggt ttatttggtt 1141
tacagttctg caggctgtac aagaagcatg gtgctagcat ctgcttctgg tgagggcttc 1201
aggctatttc cactcatgat ggaaagggaa gggaaaccag tatgtgcaga ggtcacatag 1261
ggggagaaca gagggagaac agaagcagga gaaagaggag aggagggacc aacctttttt 1321
caacaacat cttgcaaaact aagagtgaat attcgctctt gtgagaatgg caccaagctg 1381
ttcatgagtg gtctgccccca tgatccaaat acctcccaca agggcccccacc tccaacaatg 1441
gggatcaaat ttcaacagga gacttggtgg gaccaaacca accaaagcca aaccatagaa 1501
ataaagcaga accaacaat gatgctcaag tctatctagc tgcaaaactca gagttttag 1561
taagacagaa ggtaagtaaa gtcagggtggc agctatagct ctgagattaa agggctgtat 1621
aaactcttga tctttaaact tatctgtcct aggaagaag catgcaaat tattttattta 1681
tttattttct gttgagacag tctcactttg tctcccaggc tgaagtgcag tggcaccatc 1741
tcatctcact aaaacctctg cctcctgggt caagcgatc tctgtctca gcctcccaag 1801
tagctggaat tacaggcaca caccaccata cctggctaat tttttgtatt tttagtagag 1861
atggggtttc accagggttg ccagggtgg cttgaactcc tggcctcaag tgatccacc 1921
gcctcagcct cccaaagtgc tgggatcaca ggcataaacc accgcacttg gccagaaagc 1981
atgcaatttt aggatctgtt tttcatatgg gagtagtaac acaaaagtaa gttaatggag 2041
ccttggtgaa caggaaagaa aatggaggat aaggaatgat ggtggggact ggcataacct 2101
tgtccttcat gtccttttcc atttctctgt acatctttta ggtagaaaa gaaagcagag 2161
ttaatatcat ttctgtctca ttctgtcttc cctgaggctg tggcccaccc acactgttct 2221
ttggtgacca gggaaagcac taatttgact gtggtttctg aacaaccagg aaatcacagc 2281
agaaccaatc cttttacttg tagctgagtc aaaatgctct ctgtagaaac agtgactcag 2341
tgactttgca tccctaaatt gcctctcata aaaagtacat tttctttgta cctcaggaag 2401
tatgggctct ttatagaaac tggaaatgagg gagtgggcta gagtttatgc cagagttggg 2461
ggtattgata caaaagttaa aatgtaacct ctcttttaag ggaacagtgg ccttaactac 2521
ttacctatac catttagagg acagtgataa aaataatctc aaactcatt gtatggcttt 2581
acaaatacat cacattattt taattggccc ttaacagatc tttctttcca ataatttg 2641
ctcagttaaa tattgtcttc cctctttatt tgcaggaaat atgtaccaag acaccaaca 2701

```

gatgcttaaa	acaatggata	gtaatgaacc	ctatatatac	tatgtttttt	cctacagata	2761
catacccatg	ataatgttta	atttataagt	taggcacaat	gagagattaa	caataaccaa	2821
caaaaaagt	gagcaattag	aacaacatac	tgtaatgaaa	ataatgtgaa	tgtctgctct	2881
ctctctcaaa	atatcttatt	gtatttcaat	gtgggtaact	gaaatcatgg	aaagtaaacc	2941
cacagatggg	ggcaagcagg	atagagttac	tgcactaaaa	ctgtgattat	ttaaacaatc	3001
ctggtgaaaa	atlttgacaga	tatctctggg	gtatgtgaca	gggtgaaact	gcttctcaac	3061
tcaaaatgca	agatatgtca	tatcttgttt	ttctaaataa	gctgctgctc	taagatgcca	3121
agacacaagg	caagaaagca	cattttaatc	cttctcttct	cttgagctac	caggatccaa	3181
cacaagccac	agttcacaat	gctacaaaa	ttagtagcca	accactgcag	gtgtccccc	3241
agtcagtccc	acattgtggg	caccacacag	gcattttgcc	tctaagcca	gcagggtaca	3301
ggacttcatg	acctggagga	aagcctctca	caacccttcc	cttccccgtt	tccaggaagc	3361
tacttcccta	cttcccagg	tcaggctttc	ctcttctcct	actttcttct	ccccacatcc	3421
atcaacactt	tctcttccct	aaaaatccag	cctgtctcat	tcattggatct	agccagaggt	3481
cacaatatgg	gagccttggg	atagatccat	ccagcaggag	tattttatta	ggattgaacg	3541
gtgttattga	tattttctaa	ttgagtcaat	ttttaaaaaa	taggatattt	ttaatgaaaa	3601
tctaaatgtg	tatagtttct	ctaaaaaaat	ccaaagatct	agaaacactg	ggtccatata	3661
ttgcatggca	atagttggct	agaactgagt	agagatcaac	cccttttagt	tgagtctatc	3721
catagaagat	ctgttacagt	aaaggagatt	tgactttatc	ctgtagacag	tagggaatca	3781
ttgaaaatgt	tgaactgagg	aatgataaaa	tatttttact	ttacagagat	cacattgggtg	3841
aagtgtgatg	atagtagtgt	gatgataaag	tgaggaggca	agagttagaaa	cagaaactgg	3901
ttagagggtc	actgcattaa	tctaagggac	taatgatgaa	ggtgtgacct	aagacaacag	3961
aatagagagg	acggactaga	tttcagatat	attcagaagg	tgaaatcaaa	aagacttaat	4021
gacagattga	atgaattgta	agaatggaaa	gaaggaaaaa	taaatgattc	tcagcttttt	4081
gatttaagaa	ttgggtagac	gccagggtgt	gtggctcaag	cctgtaatcc	cagaactttg	4141
ggaggctgag	gcgggcggt	catgaggtca	agagattgag	atcatcctgg	ttaacacggt	4201
gaaaccccg	ctctactaaa	aaatacaaaa	aattgcctgg	gcattggtgg	gggcgcctgt	4261
agtcacagcc	acttgggagg	ctgaggcagg	agaatggcat	gaactcggga	ggcagagctt	4321
gcagtgaagc	gagatcacgc	cactgcactc	cagcctgggt	gacagagcaa	gactctgtct	4381
ccaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaagaat	tgggtggata	atgatagata	4441
gttgactact	ttctcaagat	aggcaattca	ggagaaatat	attgggggca	gaaaaagata	4501
aagacatttt	ttattataag	gactgccatg	gtttgaatgt	cccctccaaa	actcatgttg	4561
aaatgtaatt	accattgcga	tagtattaa	agggtgaacc	ggctgggtgc	gggtggttat	4621
gcctgtaatc	ccagcacttt	gggaggccaa	gggtgggtgga	tcacgaggtc	aagagattaa	4681
gaccatcttt	gccaacatgg	tgaaaccccg	tctctactaa	aaatacaaaa	attagctggg	4741
caccgtggcg	cacgcctgta	gtcccagcta	ctcaggaagc	tgaggcagga	gaattgctgg	4801
aaccagggag	gcagagggtg	cagtgaacca	agattgcacc	actgcactcc	agcctgacaa	4861
cagagcagat	ctccatctca	aaaaaataaa	aataaaaaaa	aagagagggtg	ggacctttta	4921
gggggtgatta	ggtaataaa	gctctgccct	cattaatgga	ttaatgccat	tgctcatggga	4981
gtgggttagt	tattacagga	ttgggtttct	gataaaaaatg	atgaagtcca	gtccccatcc	5041
tttctttgcc	tcattgtcac	tctcaccatg	tgtgatgtct	tccaccatgt	gatgacacag	5101
caagaaggcc	ctcatcagct	acagcccctc	aatcctggac	ttctcaacct	ccagaaccag	5161
acaccaaata	aaactctttt	ctttataaat	caccagtcct	atggtatttt	gttatggcag	5221
cagaaaagag	actaagacca	gtgtacttta	gtttaaggta	gctgcagggtc	accaggttag	5281
agatatccag	aattcagaag	atatacacag	aaagagacag	ctatgcttca	aagtagctgg	5341
gtcaaaatga	cttgggggaga	aagaaaaaca	gatagaaagc	tcaggaaaaa	gaccaaagat	5401
agagttacag	tttgggggagt	catcagcctc	taaaaagggtg	attgaagtca	ttggagcaag	5461
catgattgcc	caggaagaaa	gtttaagagt	gagagaagaa	aaaaagtcaa	aaccctgagg	5521
aaaaccaaca	tttatgagca	gacagtagag	ggataactaa	caaagagaca	aggtgcagta	5581
gtcagagaga	aacaagaaga	acctaggga	actggtgaca	tggcataagg	aaagaggggt	5641
tcaaagaaag	aagtggctct	gagagtccaa	tgccacagac	aggtcaagggt	tagtaagcag	5701
ttaagaagac	accttggtaa	aatccgtgct	tggggaagaa	acgaaagacg	gagtgattca	5761
cctctgtggg	ttcctatcag	ccatagtcta	gttctctgag	tggcagaatt	atagaaagat	5821
ttccaggggc	cttctatatt	actcacaaga	aatccctgag	ggattcatgc	tgctgttatg	5881
attaaattag	ctatgggaat	tttcttaaaa	ttcatactaa	gccattgccc	tcagcgagca	5941
ggcaggatag	agacatggaa	agtggtaaca	gcccttatat	acatttgagc	tggctctttg	6001
acccagtggt	agtgtctctc	cctgcaaagt	ccacatgtcc	aggccagctt	tgacttttcc	6061
tctccagaac	acaacccctca	cacttttcagc	ttcccaaac	accaaagcat	atgtttcttca	6121
aaattctcct	gatgcaaaagt	gttttcaata	cttcaaatgt	agtaaccccc	atccttgaac	6181
tataaccagt	gcttgtctca	ctagatgcta	gccccagat	gtacatcttt	aactttcttca	6241
tctcctaaag	acttccacat	cttcagtact	tcctcagat	tgtgaccctc	actttttaact	6301



```

acccaagact gatatcctgt tccccccaga gtccacactc agtattaggc atgcctatca 6361
cgttcccatg tgatgctgac taaaatataa agaataaag gagtgagtgt tctttcagtt 6421
atcatattat gccttttagc tctgaaaaga caatgtgata tagttgctat ggtttgaatg 6481
tttccacca aactcatgct aaaatttaac caccattgta acagtgttga gaggtcagat 6541
ctttttttct tttcttttct tttttttttt ttgagacaga gtctcgctct 6601
gtcgccagac tggagtgcag tggcactatc tcagctcact gcaacctccg gagaggtcgg 6661
atctttaaga tgtaattagg tcatgagaac tccaccatca taaacagatt actgctgta 6721
tcatgggagt ggtttgggta tcaagagact gggtttggtta taaaagttag ttctccgga 6781
ttctctcttg acttactcac tgctgccttc caccatcaga tgatcctcac cagatgccag 6841
cataatatct ttggatttgc ctgcctctag aagtgtaga aataaatttc tatctttttt 6901
ttcttttttt agagacaggg tcgcactctg tcacccaggg tggagtgcag tggcatgatt 6961
atagctcact acagcctcaa actcccaggg tcaagcaatc ctttgggtctc agcctcccaa 7021
gttgctgaga ctacaggagc aggccaccat gccagctac tttttttttt taaatttttt 7081
gtagagacgg tcttactgtg ttgcccaggg tggctctgaa tgtctagcct caagcaattt 7141
tcttgccctc gcctcccaaa gtgctgggat tacaggtgtg agccacagca cctggccaac 7201
aaatttcttt gctttataaa ttaccaagtc tatgggtatc tgtgatagta gcagaaaatg 7261
aattaatata acagtcagta aagtattgta ttaaattact tgtcaggaga ataagtacaa 7321
tgctgggtct ggcactagtt ttctttatga attatctttg taagtgtaaa agcactaaaa 7381
tataaatata agataccacc gttgatattt ctgcattaa aatcaatggg agagagttct 7441
agagtgggtg tgaatataat taagtgggtc ccccttatta aatcagttga agatagttaa 7501
aggtaacctac tcatctgaat tgggaagcaag atgtggatta attcaaaata atagctaata 7561
aaagcttttc cacttatctt taaaaagcat tattttagga aggcaaattc actggagaat 7621
tttttttaact cataaaatga atcccagagt cacaaataat attttatttt ctgaattact 7681
gtgactaatt gaaatttgac ttcattgtat tgactcatgt aaattgcttg ataattcatt tactacataa 7741
tgtaaaaaat tgagatccta tgactcatgt gttacaattt tcttttctac ctgattctga 7801
aagacttttt atgattttcc aagtagcaaa ttaatttttc tttttgagac ttagattttt 7861
cttttagcaaa atgaaataat tactgaataa ttaacttttt tactttgact gatttaattt 7921
gaatttgcat tttgttagtc cctcaaattg tagttagca ttttcttaga tggcggtaag 7981
tggatgggtg tggaaagaat aggtttgatt ttaggcacac ttcagtcaca acttctcgcc 8041
agctctgtaa tcttgggcaa gtgtcatgac tcttgagagc ctgagattat catctgtaa 8101
atggggacaa taatgcccac cttgcaagat tattatgaag aattaaatgg agacatatgt 8161
aaaatcatta gcacagcgtt tagcactta cctccaaaat tattaaagt gttctagaca 8281
tatcagtaac cttttagac tttagcaatc tcatatgagt aaaagatacc cctcaattag gcaaagggtg 8341
aggagaaaaa gatacagggt cacactccct catatggaat ttgacagcaa aatatgacct aaactcattt 8461
atatatgttg taaagttttt cagaacttat cctgatgtga actaacataa ggtctttatt tcaactttgtg 8521
tctaaagacc taaagttttt taaataaata actaattttg attatggggf gctgccccca 8581
cttgttcaca tcaactaact taaataaata atgtgcacta tatgtctat attacaatcc taaaatctaa 8641
taaattttcc tatgtttcaa atgtgcacta acagctgagt taaggatttc tgataagata ctgtgaacct 8701
tctcttctgg ggtgctacat atgtgcacta tcatgcttat taaggatttc aggataaaga tgaatggaat 8761
aaaactccga attttgaaac acagctgagt tcaattgttt agaatcccaa cagaaggcca aagaagtttg 8821
gtacttgctt cacttggctg ctacactcag gattttaga gattatgata aaaaaggagg cctgttactt 8881
gaaacagtct cacaagtttt tcaattgttt ccttatgata gaaaacaggt cacttaccac atctaaatat 8941
ccccatgtac tttatgaagc tccgtctctg gaaacaggt cacttaccac atctaaatat atgaactggg 9061
taggagagaa accaccaaaa tgggttgcct tttggaaaat attaagaat agcatgagag aaatgattat gttataatgt 9121
tggcaatagt gataagtatc ttttgcctt ttttgcctt ttttgcctt ttttgcctt ttttgcctt ttttgcctt 9241
ttcctcactc caaggttcc ttttgcctt ttttgcctt ttttgcctt ttttgcctt ttttgcctt ttttgcctt 9301
ttttaaagg gcatataaag aattttcaat ataactatgt gtaaatatgt ttacaatatt ttttgcctt 9361
taagtgaaaa caaaagatac ggtttaagca ttaatagtgc ctctaattag tgtgcttcta ctggggaata 9421
tttttaattt aaaggaaata ctttgcctt ttttgcctt ttttgcctt ttttgcctt ttttgcctt ttttgcctt 9481
ctgtgggtga ctagttttct ttttgcctt ttttgcctt ttttgcctt ttttgcctt ttttgcctt ttttgcctt 9541
agtgtgcaa gaggtatcaa agcaagcagc tctatcccta atcccatccg gtctgcaggt agaaagcaca aaagacatct 9601
cactactctc agcaagcagc tctatcccta atcccatccg gtctgcaggt agaaagcaca aaagacatct 9661
ggattgatgg tctatcccta atcccatccg gtctgcaggt agaaagcaca aaagacatct 9721
ggtactcgct gcctgtcaac agcagtctac tgtggagtgc ttcaagtatc acaggtatga ctggttacag 9781
gggtccagaaa tatactagag cacttcatga ttcaagtatc acaggtatga ctggttacag 9841
gggtgatgtg ggagttagga ctttaagtgt gaaatacttg caatggattg gaatcccatg 9901
tagcagtcce aagtctgtgt caaagtaggt tttgggaaaa aaacacattt tcccccaaa
gtcattagtt ttgggtgaaa tatgttatct tttgggaaaa aaacacattt tcccccaaa

```

tttcaatatt	ttgaccatga	aagaaaagag	ctattatatt	tttaaataata	attctaacac	9961
tttatacatt	ttaagtagta	gttaagatgg	ttttaaat	tatcacttcc	ttgtataagg	10021
ttccaagttg	atgatgactt	caagaagtga	agagatcatc	attaaaaaaa	aaacttggcc	10081
aggtgtggtg	gctcacacct	gtaatcccag	cactttggga	ggccgaggtt	gatggatcac	10141
ctgaggtcag	gagttcaaca	ccagcctggc	caacatggcg	aaaccctgtc	tctactaaaa	10201
atacaaaaat	ctgttgggtg	tggtgatgtg	cacccgtaat	tccagctact	tgtgaggctg	10261
aggcacaaga	attgcttgaa	ccttgacaga	ggttgcagtg	agccgagatc	atgtcagggc	10321
actctcgctt	gggcaacaag	agcggctgtc	tcagaaaaaa	aacaaacaaa	caaacaaaaa	10381
aaaaccaaac	aaaaaacaaa	acaaaacaaa	aaaaccaact	ttacctggaa	attgcatttg	10441
ccatttcaag	cattattcct	gctataaatg	tcctaaattc	ccagaagcaa	cactgaagtt	10501
ttctcattaa	gtattttctaa	atcattttact	ttagaagttc	atgtacaaat	tcagtatgta	10561
acatttctct	taatattttg	tatactattt	ttttccaggc	cccatctgag	tagtccctaa	10621
atctgctcca	gtttacctca	gcaggctata	aaaatattat	cattttctat	gggtattttg	10681
acacttttta	aaagttggga	gcactgcact	aagtgtccct	gttatttagc	cagaggtagg	10741
aacagggtct	atatccgcat	tctccaggac	tgtcagaaac	ttctgggtaa	ctccatactt	10801
tatagatgaa	cattttattt	tccatgtcta	tcaaaataca	gtcccttctt	taccacagtc	10861
cccagaccga	gtgggtgcat	gaagtgaagg	tttctcaag	caatgtctgt	tgctttccat	10921
tttctttttc	cccaccaaac	cctcccataa	gcacactcac	atggcctccc	agggccttoa	10981
tgcaggacac	tagcaccttt	aatcccattc	aagggtcaca	tctcagcctt	ttagctatgt	11041
aaaacttgta	tcgaaggctt	taatctagcc	aacagtgaca	tacaaaatgc	aactcaaat	11101
gcaaaaatgt	tttttgaggg	agcatttttt	aaaaagggtg	ccaaaagaat	tgtgcctgac	11161
aaatttttga	attcttaaca	acaggaattt	cacctattac	agagtatctt	gcttctctaa	11221
gcacatacaa	tgatcaatcc	attacttttg	ccttgaggga	tgaaagttat	gagatatatg	11281
ttgaagactt	gaaaaaagat	gaaaagaaag	gtagattatt	ttctttttct	ataataatgt	11341
aataatgact	aataaaaagta	aaacatttta	ataaacttac	caaactttaa	acaatggatt	11401
aacttagaca	tggcaaacag	gtcatgctgt	gtgctaactc	taatgcattg	gcagtgggtg	11461
cctgaatcca	cttctatgtc	aagatggatt	cagaagcttt	gtcacgttca	tcagagaaga	11521
atgctgacat	tgaaatgcag	tatctgttgt	gaaagatgga	aagagggggc	acatgtattt	11581
gctatctcta	aattatccac	cagatctttc	tagccctatt	agtatcacca	aagtacaacc	11641
tttatgccac	tgctatgaaa	aatattttta	atattttta	aacaactata	ttggagaatt	11701
catcagagca	tattcgtgca	tttttgagac	ccttctcaaa	accacaaaag	atttgttttt	11761
attgatatat	aataaaaagg	gaggatattt	tctgatgta	tgtgtgtgtt	ggaactgaaa	11821
acttaacaaa	attgtgtctc	accagaggga	tttcttgc	tctctttcag	ataaggtgtt	11881
actgagttac	tatgagtctc	aacacccctc	aatgaatca	ggtaatttgg	agggctgggt	11941
agctgtagtg	cctgaattct	taagtatggg	gtaaagataa	atccaaaaaa	atcctttttg	12001
ccccatagga	aaaaagatag	tctcagaagg	ttatctccaa	cccaagctca	tggtaaaacc	12061
ttagattctc	agaggatgca	ttctcatcca	ttttacagct	taatcgtag	gataaagttt	12121
tggctacact	taatacagat	ccaaaacaag	agtggtttat	gctagataaaa	actttctgtc	12181
ttagccaggg	ctgcaatggc	tcaacaagtt	gtccagggaa	cccatctcct	tctatcttgt	12241
ggttctgcca	acatctacat	ggttcaagag	tacttgggag	catgacaatg	cctgggtcagc	12301
aggacacaga	aaaacagatg	tatgcattct	atttcccttt	aagggtacaa	cctagaagtt	12361
gcacctaaaca	cttctcttta	tctcacattg	gtcagaactc	agttgtatta	ctacacttag	12421
ccataagaag	gcaagctggg	gaatgttcta	ttactatccc	aaaagaggaa	tgaatattgg	12481
gtgacactat	gagtggtctt	acatgcagac	aggaaagctg	atgccccgag	aagtaaccat	12541
tagggtcaca	actctccaat	taaaaagcat	ataagaaaac	taatttctct	ccgggttata	12601
agtaccctct	acttatcagt	gcctcttgaa	cctgggtaca	aatacttcta	agatacctgt	12661
tagtgaatga	agtaattatt	ttatgtaaca	tcttagactt	tttctctggg	tgttgaattc	12721
atttaaataa	agatgagtta	cagttcttaa	ccttatcatt	tatactttct	taattgtaag	12781
gtgacgggtg	tgatggtaag	atgttaatgg	taaccctgag	tctacaaaaa	gacttctggg	12841
tgcattgcaa	caacaaggaa	cactctgtgg	aggtaaaaaa	aaaaaattta	tctatatcta	12901
tatatatgat	tacagaactg	tcatgaatga	ctccaccaac	ttgtgtagat	ttgggtgttg	12961
gggtattttg	cagaaggatt	tttttggtgt	ctattgtata	taaagcacaa	tcacttacta	13021
caaagactt	gcttctagag	taaggaaagg	aggaaagtg	catgtatggc	tttgcatttg	13081
aaagtctgct	ctctgccagc	agcagagcat	cactgtggag	cctgttagaa	atgcaggatt	13141
ctaagccccc	cagaaataaa	tcagaatcag	catattttta	taaatctcca	ggaaattcat	13201
atgtgcctta	aagtttgaga	agcactgtta	catagaatga	tctcaaatcc	tttctgtttg	13261
gcttttaggaa	ctactatgtt	cctctaggaa	acgtttcttt	gtataaatatc	attttcttaa	13321
acaaatacaa	aaaaaatctc	cattctgagc	ctgcttaagg	gagagtcata	agcgtttcca	13381
tgtgccaaga	tttataaata	acctaacatc	tacattctga	acatagaatt	aattgcatat	13441
tcttcttttag	ttagcaaatg	gcattattac	attggctcatg	atgtgtaatt	ataactattt	13501

```

tgacaaacaa gccaaaggta gaggcacgga agaaaacaga agagagcata atatagaaga 13561
taaattatac aaacacagaa aaatataaag ctaactaaca cagccatgta aggccttatt 13621
aacataaata gtggatagta accagcatct tcctaagcaa aacattccta aacatatata 13681
atctagtgtt tggcatgtat aactactcaa aatattatct tcttagactg agctctatta 13741
tatagcaagc actgggctaa atgtttttaca aatattatct tcttagactg agctctatta 13801
tctacaatgg agttgttgta ttgggtcaact gttgctatgt aacaaacat cccaaaactt 13861
agtgcctcaa aataataatc atttatattt actcatgtct gtagatattt tgaggattga 13921
ctgatctaga aaactgggta gactaaaaaa aatgaggctt gagagataaa gcaacatccc 13981
caagatctca gagatagtag atgtcaaaaag aagggtacaa atccagaact gttgcatcca 14041
gatccaatca ccctaatacca tactgcctct ctatgttgac tatcagtga tcaaatcaaa 14101
tccacccaact acccctctgg cctctactct acttctcccc ctcttccctc cacaactcac 14161
taagcaagct tgctagaaat atcaagtcac aaataagtat tccccttag tttccaatac 14221
aggcaggtaa agttgactct gaacttcccc ttacatatg gattgctttc tctctgtttt 14281
cctcagctcc ataagtgtag aaaaccactg ccagaccagg ccttctttgt ccttcataat 14341
atgcactcca actgtgtttc atttgaatgc aagactgatc ctggagtgtt tatagggtga 14401
aaggataatc atcttgctct gattaaagta gactcttctg agaatttggtg tactgaaaat 14461
atcttggtta agctctctga aacttagttg atggaaacct gtgagtcttg ggttgagtac 14521
ccaaatgcta ccactggaga aggaatgaga gataaagaaa gagacagggtg acatctaagg 14581
gaaatgaaga gtgcttagca tgtgtggaat gttttccata ttatgtataa aaatatTTTT 14641
tctaatactc cagttattct tttatttccc tctgtataac tgcactctca atacaagtat 14701
cagtatatta aatagggtat tggtaaagaa acgggtcaaca ttctaaagag atacagtctg 14761
acctttactt ttctctagtt tcagtccaga aagaacttca tatttagagc taaggccact 14821
gaggaaagag ccataagcta agtctctatg tagacaggga tccattttaa agagctactt 14881
agagaaataa ttttccacag ttccaaacga taggtcaaaa cactagagct gctagtataa 14941
agaagaccag atgttccaca gaattatcat tttttcaact ggaataaaac accaggtttg 15001
tttgtagatg tcttaggcaa cactcagagc agatctccct tactgtcagg ggatatggaa 15061
cttcaaaggc ccacatggca agccaggtaa cataaatgtg tgaaaaagta aagataacta 15121
aaaaatttag aaaaataaat ccagtatttg taaagtgaat aacttcattt ctaattgttt 15181
aatttttaa attctgattt ttatatattg agtttaagca aggcattctt acacgaggaa 15241
gtgaagtaaa ttttagttca gacataaat ttacttattt aggaatatgt aacatgctaa 15301
aacttttttt tttttaaaga gtactgagtc acaacatggt ttagagcatc caagtaccat 15361
ataatccaac tatcatggta aggccagaaa tcttctaacc taccagagcc tagatgagac 15421
accgaattaa cattaaaatt tcagtaactg actgtccctc atgtccatgg cctaccatcc 15481
cttctgaccc tggcttccag ggacctatgt cttttaatac tcaactgtac attgggcaaa 15541
gttgcttcta atccttattt ccatgtgca caagtctttt tgtattccag ctctctgata 15601
acactgtcta ctgtggaata ttcatattgac atctgtctct tttcatttct tttactacc 15661
atgcccttga tatatctttt gcacctgtg aacttcattt ctgtatcacc tgacctctgg 15721
atgccaaaac gtttattctg ctttgtctgt tgtagaattt tagataaagc tattaatggc 15781
aatatttttt tgctaaacgt ttttgtttt tactgtcact agggcaataa aatttatact 15841
caaccatata ataactttt ttaactacta aaggagtagt ttttatttta agtcttagc 15901
aatttctatt acaactttt ttagacttaa cacttatgat aaatgactaa catagtaaca 15961
gaatctttat gaaatatgac cttttctgaa aatacatact tttacatttc tactttattg 16021
agacctatta gatgtaagtg ctagtagaat ataagataaa agaggctgag aattaccata 16081
caagggtatt acaactgtaa aacaatttat ctttgtttca ttgttctgtc aataattgtt 16141
accaaagaga taaaaataaa agcagaatgt atatcatccc atctgaaaaa cactaattat 16201
tgacatgtgc atctgtacaa taaacttaaa atgattatta aataatcaaa tatatctact 16261
acattgttta tattattgaa taaagtatat tttccaaatg t

```

SEQ ID 8

> mouse NF-HEV genomic DNA sequence - GenBank NW\_000143 11104 bp DNA linear

DEFINITION Mus musculus (strain="C57BL/6J") WGS supercontig  
Mm19\_WIFeb01\_319.

ACCESSION NW\_000143 REGION: 20687801..20698904  
VERSION NW\_000143.1 GI:20887994

Mouse NF-HEV mRNA join(<1..108,2317..2442,3071..3181,4887..5012,  
5545..5595,7290..7387,9239..11104)

## Mouse NF-HEV coding sequence

join(12..108,2317..2442,3071..3181,4887..5012,5545..5595,  
7290..7387,9239..9430)

STS 10959..11097 / standard\_name="AV028447" /db\_xref="UniSTS:166143"

```

aaacctgaaa aatgagacct agaatgaagt attccaactc caagatttcc cgggdaaagt 61
tcagcagcac cgcaggcgaa gccctgggtcc cgccttgcaa aataagaagt aagagcgctc 121
tctttaacca ctattaaatc tattatcaaa ttttggttat ttcaacatga agacgggcca 181
ccttaccaaa aactctcaag tatacaagag ctgaaaagaa agagagacag cttgttggtt 241
tcttaaacag acttcacagc atcaccggtg ttatttggta caacatagga cagttgacca 301
cttattcttg gactagtaac aagaagggtg gcagagctct ggtggacaga acggaagtta 361
gaggggtgat ggaaaggaaa gcgatgtccc cttctgccct tcccagggtg ctggactgct 421
cacacacttc tttcaaagcc aggatttaaa agaaaaaaa ttgacagtgg tttctgaatg 481
gccagaaaaa aatcacagtt aaattaatcc tttcatttgc agttatgtca taatgctctg 541
tgcagatata atgactcagt gcaagtgact cgggtgttccc aagtttcttc ctattaaaga 601
atgcaactgt ttcagatcca agaaaacgag gccctttatc ggcactgcct tgtggagtag 661
acatgccaga atgcctgaca ttgggtgccc cgcttgcttc gaatactgag atcttacaat 721
tcacatgttc tagttttcat ctccatctca ccctggaata ctatttacga tgtccagaac 781
acaatggact tttctgcatg ggacttaaat ttttcttggg ctaagtaaaa tgagaattaa 841
caaataacte gttaatcttt ttagttccgt tgccctgaatt tgcatttgac tgctccctca 901
gatggcagtg ctcaacttat tcttccccta ccaaataaga ctctgtgtag ctcaactga 961
tctggaaact cgcaaccctc ctgcttttagc ctcttgggta ctgggactag aggcacgacc 1021
acatctggcc agtggctcct ttctttgatg gaggtagagt ctaatgagta gctttgatat 1081
taaagatatt gcattaatta attttacacc gctatggcca aatacccagc agaagcaaca 1141
taaaggcttc atagcttaga agatacaggc cattaggata cagcagggat ggtggctgaa 1201
ccagtttgat ctctggtagc cttagcttcc agggagtctt catatggcac cgcccaagag 1261
tgggagatga aggaccaggc tataatctga gactgtcccc cacggtctag gtatatcagc 1321
aaggcccaaa aagtttcaca atctcccaaa gagtttcaat agtttgggac caagtgtcta 1381
aggacaagat tctgtgggaa catttaactt taacacactt cttagcaca ctctgagcta 1441
tgtaattttg ggcagtgcc aagcctcgaa ttatcattgt aaaactaaga 1501
taaaactttg caagataatc atgaatggct aagttaaaag acacataaaa gtaattagca 1561
gagtgttttg cctcgttttt atatgcagtc aatggcagtt ctttttagtat caataacctt 1621
tatggcttac agccatcctc caaaaattat gacgagcaga aatctcctat ggatgttaac 1681
gtgccctca gttaggcaaa gattggtcca tactgaatgt agacttggtc cttcaaatgg 1741
aattatgaaa acaaaacacc aaaaaaaaaa aaacccaaaa aaaaacaaaa aaccccaaat 1801
ttctaaagac ctaatgtctt tagaccatgt ggcagcaaaa tgcaactcca gcctcttgct 1861
tatcaaatcc caaggtcttg aacggctcat tttaaaggc aaattgattg aattcagaac 1921
cactcaaggc attcgtgagg catgtcttta ggtatgtgtc tatgacagca ttctctggaa 1981
aggattggct tagaccacc ctgaaaatga gtagctgcga catccctgg gctggatcca 2041
gaactaatta aggagaatac ggatatagac acaccttccc tccataaaga acctgagaca 2101
caagcaaaac taatcccttt ctcttttaag ttgctgcttg tcaaagactt ggtcacagta 2161
aggagaaaag actatttcat ttgcatatc ctatctgtgg cttgctgtaa aattaatgaa 2221
gttaactaag tagtgctgtt ccagcctctg ttggaggcac gtgtatatta taggatatga 2281
cctacataaa tctacctctt tttttcctat tgttaggata ccaacagaag accaaagaat 2341
tctgccatgt ctactgcatg agactccgtt ctggcctcac cataagaaaag gagactagtt 2401
attttaggaa agaaccacag aaaagatatt cactaaaatc gggtaagtac atttctggaa 2461
agactgatgg gcatctattt gcttttactt tccatacaca cacacacaac acacacacac 2521
acacacacac acacacacac acacacacac gcacacacac acacaattgt ttttcttacc 2581
taaatctctc ttgaggaaaa gaatacagat gataatgtgt tggccatttt agaaagggtt 2641
tttctatttt agaatttcta aataaatatt caaaaagtct attctagaat ccactttaga 2701
aatggataca ctgggtgagta aaaacagaag acacaagatt atgtgtaaat atgtaatcat 2761
gtgggtgatg attttgtaat atagaggaaa caaactaaat ggttcatagt ggctgctttg 2821
gaaggcagta actgtgggtg gtggctttct gtttatttgt ttgtttgttt cttcctttgg 2881
tgtgctctac tggagtgcac atggtcttca ctttacgtca ttattaagga ggaattgatc 2941
ccattagacc attgggtggc cacagcccta ggatcactta ccaccgtcgc catattggcc 3001
atcaaaaaag atagcatatt ggcacaatga agattgtctg ctacagccca gccccactac 3061
tgtcttgtag gtaccaagca tgaagagaac ttctctgctc atccacggga ttctaggaag 3121
agatccttgc ttggcagtat ccaagcattt gctgcgtctg ttgacacatt gagcatccaa 3181

```

```

ggatgactg gtcataagggg atgtgtgggg tgagggtggga gatagcacat ggggcotttg 3241
caagggtat tgcataagagc aaactcagga gtatgtcttc atatgtatta gaaacgtttg 3301
tttcctgctt gggtagcagt tcagtgggta tccaaatttg gtgtgggtgga gctgtgccta 3361
tttaattctat ggtagcatt ccacttggtat ttgaaatac ttgctatagg ttgggagcat 3421
gtcttcatca gtcctgataa atgtaatatc cttggagaga ggaaaaaac aaagcaccag 3481
tccccacatt tcaaaatgtt caccatgaaa gaaaataaag gaactatctt ttaaaataac 3541
atgatgtggc ttgaagagta gtttaaagtt ttgaccatt ttgctgcgt tctaagtaaa 3601
atggtaatta tcaagaagtg aagagaaccc agggcggtgta gttcagtggt agaacatttg 3661
cctcatgtgc caggctctgc atgtagtctc tatcaatgtg ggaaaaatc aaagtgaggg 3721
ttgggcataa tggcatataa tctccatccc agaattggggg aggcaggtga attccttggg 3781
ttcaggtctg cctgggtctac acagtggagc ccagaacagt tagagttata tagtgagaaa 3841
ctgtctcaaa gacaaacaaa aggccaaatt aaataattaa caaattagca gccccatcac 3901
taaggaaatcg tgattaagaa tcacatattg ccattctaaa tatatattat ttttatgt 3961
gatcttaata taaaacaagc ttagaatgta tttatgtata gtgtgtatat atattatata 4021
tatatatata taatatatac ttagtatatg tttaatataa atacattaac ctccctgggtca 4081
atattcagtt tctcacaac tggaattaaa ttacttttaga tgtttagatg ttttagatgtt 4141
tagatgttta gatgttcaca tgcgaattct ttctattttg tacagtaaat ttgaatgtag 4201
gacctcaga tgggtccaag tctgcttcag tttaccata tatgctttta aaatgttatc 4261
aagtgtctctg tatgtgtttc gattgtccgg gcaaaagcag aactagttta catctgcac 4321
cccctagacc agtgactcaa tcttcctaaa tgctgtaacc ctttaacata gttctgcacg 4381
ctgtgggtgac cccaaccata accttactct tggtgtaca tcataactgc aactttgtca 4441
ctgttatgaa tctaattgca aatatctggt accaccaggt tgagaaacac tgccctagag 4501
aggggatcat ttaaccaca tcatgcttta taaaggggaa tacattcacc tatgtcttcc 4561
tggtggaaat ctctaagtga agctgtcccc tagactgtgg gaaggtaaga aaaggagcta 4621
aaaacatgac cattctttgc actgtgcagg aaggtaacac ctttaatccc accctgggtat 4681
ccctcctcgt cctcaccca acttagcttt tgctatggt acaatgacaa agtagagctc acactaaaga 4741
cagctatggt tcagaggaag taattcatat aaataaccaa gagaacggtt catagaatcc 4801
ccaaaactct ttttcttaa tgacaggaac ttcactttta acacagctc ctgctccct 4861
gagtacatac aatgaccaat ctgttagttt tgttttggag aatggatgtt atgtgatcaa 4921
tggtgacgac tctggaaaag accaagagca aggtagagta tctcctcag tctatactta 4981
gtaatgactg gcaaggttta aaaaaaaa atctaccaag ttatcaacag tggattaact 5041
gagctattca acagcagcaa gtttcacat ctttggtaat tttagtcctt cctatgtcaa 5101
gaagggtctca gtgtagtcac attcttcagg gaataaatca gacattgaga aatacctatt 5161
gagaaatata gaaagagggg ctacatgtat ctacaaatgc tgaataataa gatcttgttc 5221
accttttcag tgcctccaaa gcatagtctt ttgtgaaaga ttatcccttt gtcataaaca 5281
ataccacctg catattgggg aatccatcag agcagaatat attttaagat ctttctaaga 5341
atcactaaag ttccgctttt gatggaaccg acaaaaggag agggagtttg tgttccccgc 5401
ccagcccagc cccaggacgg gatggaaccg aaaccttttg atcgttccct ctgtcaccca 5461
gtgacacca atgttgtctt tcagaccagg tgctactacg ctactatgag tctccctgtc 5521
ctgcaagtca atcaggtaat gtagaggcag ggggaggggg tgggtgttgc attctcatcc 5581
agaacaaagc tgaatctgaa gtagcccggt gttatcatga ggttcagaag gttatcttca 5641
acccacact cattgtaaaa ccttacctca tctacttctg aattagtagg agaaaagcct 5701
agctgcactt ataatagtac agccataata gtacagccca tctcagccaa gactcaaaag 5761
attctgtctca aaggttgccc agaagcagtt ccttctacat catcagttca tccatgcata 5821
atggctcacc actatggcca gtcagcaaga gacaggaagg caggtgaata catatgtctt 5881
ccgcttcagg gcacaattgt gtaccacgtg tctgcttate caggtgaata catatgtctt 5941
tctgagagca acaggaggag aaaagttcta tttatctgtta ttcagttggt cagaacttag 6001
agcagcttcc catgaacaga ggggaagcag tgaccaaaag agtatccatt ggcacagatt 6061
gaattacaaa agatcagaac aacaacagaa agtaaaaact aaaacctctc ctgagaaaga 6121
tttagaaaga ctcttgggct ggccttggtg gtgcacatct ttaatcccag cactcaggag 6181
gccaaggcaa gcagatctct gagttcaaag ccagctgac ctacagagtg agtttcagga 6241
cagatagggc cacacaaaga aaccctatct tgggggaagg aagaaataaa annnnnnnnn 6301
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 6361
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 6421
gagggaggaa ggggaaggagg aaagaaggaa gagaggagg aaagaaggaa ggaaggagg 6481
aaggaaggaa gtaaggagg aaggaaggaa ggaaggagg actacctggt atttgggtgc 6541
aaatactttt aaatggatta gtgagctatt ttcatttgca actgaaattc tttgagttaa 6601
gttaagatga gttacaagac ttagaatttt tgatttgtaa tttctttgtc ttacttttaa 6661
ttgataggta aaattgtatt aatcatgaac cacagtgat ttttgcttg gagcaagcga 6721

```

tatttttttt	aaaaagattt	tattttctatt	taatgggtat	gaatgttttg	cttgcattgca	6841
tgtaagcgct	tgagatgctt	atagttgtgt	agaaagctag	aagacagcac	tggatgtcct	6901
gtaacttatg	ggctctggga	actgaatgca	ggctctcttg	caagggcatc	aagtgtcat	6961
gacgaaggaa	gtatctctct	agtcccatag	caggagtttt	tttttttttt	aaagatttat	7021
ttattgatta	tatgtaagta	cactgtagct	gtcttcagac	actccagaag	agggcatcag	7081
atttcattag	ggatgggttg	gagccaccat	gtgggtgctg	ggatttgaac	tctggacctt	7141
cagaagagca	atcgggtgct	cttaccacct	gagccatctc	accagcccat	agcaggagtt	7201
ttgaggatc	tattgtctct	gtctaataga	gagatcaaat	gaggccaagt	ggcagctgta	7261
tcacctcacc	ttataatttt	cattttaagg	cgacgggtg	gatgggaaga	agctgatggt	7321
gaacatgagt	cccatcaaag	acacagacat	ctggctgcat	gccaacgaca	aggactactc	7381
cgtggaggta	acagaaatat	gacctatga	cggccacact	tggttctacc	tgttaacgta	7441
aaatagatgt	tagatgtag	ggcaattttg	aaggcagaag	tacacactgt	tgaaaaataaa	7501
ctacagtcag	tcacttctaa	tgacttgctt	gggagtaggg	aagggaagaga	agtgtggtct	7561
tgttgctaca	agtctggtct	ccagcaacaa	cacagaatca	ctggagaact	tgtcagaaag	7621
caggatttcc	ggctcccccc	acatccgaat	cagatctaaa	gtctccagga	caggaacttc	7681
atcccttcac	cacagtttga	gaggcacttc	tgcacagagt	gagtcacagc	ctttccattt	7741
ggctatgttc	ttccagaatt	gttttaggat	tatttatatt	atgcatatga	atgtactgtc	7801
actgtgttcg	gtcacaccag	aagagggcat	cagatcccat	tacagatggt	tgtgagccac	7861
catgtgggtg	ctgggaattg	agctgaggac	ctctggaaga	gcagttgggt	ctcttaaccg	7921
ctgagccatc	tctccagccc	tggagatata	tagtttctga	ctccaagtct	gtcaagggtc	7981
aggcagcaaa	tgtgtccata	catcagcagt	ttggggcagc	attacattct	acatctgggt	8041
cgttcttgct	cagcaaacag	caggtgtaca	tcagccagga	cgaaaaaaaa	aattctgatc	8101
atgtaaagaa	caaacaggcc	agagtgaaga	ggaaggaagg	aagggaaggaa	ggacatggga	8161
gaacataata	acgaagatga	tttctataaa	tatataccat	ttcaaagcaa	tccagccaca	8221
taagacatca	acacaaacag	tccacaaaga	ccagcactct	tctcaggaga	atactctcag	8281
gtgtacatga	tgcaaaatct	agcagaaaga	aagcctcaaa	agtaacagtg	ggctgccatg	8341
gcacatcaag	ttcttgctta	ccatttccta	agccctgtct	ctttaatcct	cacagcaaat	8401
ttatatggaa	aaattgcctt	ggtcagctat	tgtgcaacaa	actatcacaa	aactcattgg	8461
attaaaaata	taatcacata	taggtcctca	gcaactgaga	gctcattccg	acgacctgag	8521
ttggctcccc	agtattcatt	ggcaggcgac	tcacaacacc	tgtagctctc	gctccaagac	8581
agtcagggtg	ctctggcctc	catagacatc	tacacttatg	tgcacacact	cagacatagc	8641
cacatacaca	taatttaaaa	taaattctta	aaaataaacac	aaattaaaaa	caataatctg	8701
tatttaaatg	agcttaattt	aattgaacaa	cttagtttaa	caatcaactt	aattaaaaata	8761
tgtctgtatt	taaactgaca	atgaacgaac	ctagagggcg	tgtccacaga	gagttctggc	8821
ttaactgaaa	agtccagggt	tactagatac	atactagaca	gacatgttct	catggcaaaa	8881
acagagggga	acaaatctgg	atgttttgcg	gtagtttggt	gcacagaagc	tgaccaagggt	8941
aattattcca	tataaacttg	ctgtgtgaat	taaagagatg	gggtttgtga	cgatgaagg	9001
aaattgacct	ggtcagctct	tgccaagctg	cttatccact	ctccacaaat	cgctttcacc	9061
tcttccatgc	agcctctcta	ttocctccac	tgctcatttc	tccctcctcg	actcagtaca	9121
aacttcctag	aaagtccaag	ctataagtga	tcagtccccc	catggatgct	gaccagggaa	9181
ggcaatggta	gctctggact	ccccattcac	accttgggtt	cttctcttct	tccctcagct	9241
tcaaaggggt	gacgtctcgc	ctccggaaca	ggccttcttc	gtccttcaca	aaaagtcctc	9301
ggactttggt	tcatttgaat	gcaagaatct	tccctggcact	tacataggag	taaaagataa	9361
ccagctggct	ctagtggagg	agaaagatga	gagctgcaac	aatattatgt	ttaagctctc	9421
gaaaatctaa	tgcagtaaaa	cgcctgtgcg	ttctgggttg	aatgacttaa	tgcttccaac	9481
tgaagaaagg	gtaacagaga	gaaagaaagc	cattcttggc	ttacgatgtt	gtggaatggt	9541
attatgtaga	aaacttcttt	tatttccttt	tcttcagcta	catgttcaat	agactcacag	9601
atatatgact	tacggcggtg	gtaaagaaac	tgaaggagat	tcagccttgc	tctttccttt	9661
tctctgcctt	gagtctgtga	tgaatcaca	ctcacggact	tcagaagagc	aggcaccaca	9721
gtgcatgggt	tgcttttagag	agggtccatt	tcaaaaacct	tcataaaaaa	aatgcaaaac	9781
aagaaaacaa	ccgaacaaaa	aaaccaccta	tttccctggt	ctaaacaaat	gattgtaata	9841
ctagagcagt	tagtggggagg	accagctagg	gggaggatca	cctagggggag	gaccagctag	9901
ggggaggacc	agctgctgca	aagactgact	gtttctcact	tataataaaa	tgccaaatgc	9961
ctccgcagat	gccccaggca	accctcagat	cagccctttc	tgtgaagagt	ggcgtaacct	10021
gtgcttggtt	ccttcttaaa	cttccaattt	ttctctttta	acacatttaa	catttaacct	10081
taagcaagcc	agcttacatt	aggaagtga	agacatttta	gttccacccc	gtgattgaaa	10141
tcattgacta	tatctaacaa	gcttaaagtc	tcctgtaaga	actgatcagg	atatacacta	10201
ggacatgcca	atagaatggg	atctcatggt	gcagctctgaa	gccctccaac	tggagagacg	10261
ctaacatcat	ccttctcgct	gatttccaag	gagctatgac	tttgatgca	tgcattctgt	10321
tggatgagat	gtctcggctg	cttgctttcc	ttatgcacac	gttctgttca	gcttcacagc	10381



```

agcaatgctc acggtggaat agcttagctt agcttctgcc cttcttttgg ttcttttgac 10441
caccatatcc gtaacggctc tctactccc tcagctttct ttctctttgc tctgacgtct 10501
atatgccaac acacttatcc cactgtcttt accctgcact gcagaatttt acatctacct 10561
actggttacc aggttggtccc ctgaacaacc ttcttttggt ttttactggt attaaagtag 10621
taatatttgt attcaaccat gtagtaatat ttaagccac taaaggaata gttttactta 10681
tttagacaac agcaatttct actacatttt tataagctta aaacttacat gttttaaaac 10741
ttaaaccgat aaagacaata acaacattga tggagtatga tatgacagtt cagaaagggg 10801
tagctcttat cttccagtcg aggaaaccta ttgtatacaa tagctggagg aatgtatgat 10861
caaagaggcc gggaaccgcc gtgtaggac gtacggctgt aacagggtata attgtttcat 10921
taatttgtca cagtcttact gtagaggaat gtaaaggcgg aatctgcgtc attcctctgg 10981
aaaccacagt gttgactctg tgaatctgta cgatatcttt aaagtagtaa ctacgtagtc 11041
aaatgtgttc ttgacgttgt tcataacttt gaataaacca tttttcaaaa ccacgtgtga 11101
ccac

```